PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22800197-11	2012	In LS174T/R cells, GW4064 induced the expression of FGF19, SHP, OSTalpha/beta, but not MRP2 and BCRP, although the sensitivity of these cells to cisplatin was further reduced.	GW 4064	19-25	fibroblast growth factor 19	Homo sapiens	52-57
22800197-11	2012	In LS174T/R cells, GW4064 induced the expression of FGF19, SHP, OSTalpha/beta, but not MRP2 and BCRP, although the sensitivity of these cells to cisplatin was further reduced.	GW 4064	19-25	nuclear receptor subfamily 0 group B member 2	Homo sapiens	59-62
22800197-11	2012	In LS174T/R cells, GW4064 induced the expression of FGF19, SHP, OSTalpha/beta, but not MRP2 and BCRP, although the sensitivity of these cells to cisplatin was further reduced.	GW 4064	19-25	solute carrier family 51 subunit alpha	Homo sapiens	64-77
22800197-12	2012	In LS174T cells, GW4064-induced chemoresistance was seen only after being transfected with FXR+RXR, when BCRP, but not MRP2, was up-regulated.	GW 4064	17-23	nuclear receptor subfamily 1 group H member 4	Homo sapiens	91-94
22800197-12	2012	In LS174T cells, GW4064-induced chemoresistance was seen only after being transfected with FXR+RXR, when BCRP, but not MRP2, was up-regulated.	GW 4064	17-23	retinoid X receptor alpha	Homo sapiens	95-98
22800197-12	2012	In LS174T cells, GW4064-induced chemoresistance was seen only after being transfected with FXR+RXR, when BCRP, but not MRP2, was up-regulated.	GW 4064	17-23	BCR pseudogene 1	Homo sapiens	105-109
22800197-12	2012	In LS174T cells, GW4064-induced chemoresistance was seen only after being transfected with FXR+RXR, when BCRP, but not MRP2, was up-regulated.	GW 4064	17-23	ATP binding cassette subfamily C member 2	Homo sapiens	119-123
22732083-9	2012	While a synthetic ligand for farnesoid X receptor (FXR), GW4064, did not increase the transcriptional activation in HrRXR- or HrRXR/HrFXR-transfected HEK-293 cells, the ligand showed weak but significant activity for a single amino acid mutant of HrRXR ((Phe)231(Cys)) and HrFXR cotransfected cells.	GW 4064	57-63	nuclear receptor subfamily 1 group H member 4	Homo sapiens	51-54
22560881-6	2012	Moreover we observed both natural ligand CDCA and synthetic ligand GW4064 could upregulate SOCS 3 expression by enhancing the promoter activity in hepatocytes.	GW 4064	67-73	suppressor of cytokine signaling 3	Homo sapiens	91-97
22583617-3	2012	We previously found that compounds based on GW4064, a representative farnesoid X receptor (FXR) agonist, enhanced E297G BSEP transport activity.	GW 4064	44-50	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	79-89
22661717-3	2012	In addition, we discovered that natural (i.e. bile acids) and synthetic (i.e. GW4064) activators of the farnesoid X receptor (FXR) increased FGF21 gene expression and secretion.	GW 4064	78-84	nuclear receptor subfamily 1, group H, member 4	Mus musculus	104-124
22661717-3	2012	In addition, we discovered that natural (i.e. bile acids) and synthetic (i.e. GW4064) activators of the farnesoid X receptor (FXR) increased FGF21 gene expression and secretion.	GW 4064	78-84	nuclear receptor subfamily 1, group H, member 4	Mus musculus	126-129
22661717-3	2012	In addition, we discovered that natural (i.e. bile acids) and synthetic (i.e. GW4064) activators of the farnesoid X receptor (FXR) increased FGF21 gene expression and secretion.	GW 4064	78-84	fibroblast growth factor 21	Mus musculus	141-146
22278336-4	2012	A total of 15,263 and 5,272 FXR binding sites were identified in livers of healthy and obese mice, respectively, after a short 1-hour treatment with the synthetic FXR agonist, GW4064.	GW 4064	176-182	nuclear receptor subfamily 1, group H, member 4	Mus musculus	28-31
22278336-4	2012	A total of 15,263 and 5,272 FXR binding sites were identified in livers of healthy and obese mice, respectively, after a short 1-hour treatment with the synthetic FXR agonist, GW4064.	GW 4064	176-182	nuclear receptor subfamily 1, group H, member 4	Mus musculus	163-166
22583617-3	2012	We previously found that compounds based on GW4064, a representative farnesoid X receptor (FXR) agonist, enhanced E297G BSEP transport activity.	GW 4064	44-50	nuclear receptor subfamily 1 group H member 4	Homo sapiens	91-94
22583617-3	2012	We previously found that compounds based on GW4064, a representative farnesoid X receptor (FXR) agonist, enhanced E297G BSEP transport activity.	GW 4064	44-50	ATP binding cassette subfamily B member 11	Homo sapiens	120-124
22583617-4	2012	Here, we conducted a structure-activity relationship analysis of GW4064 derivatives aimed at separating E297G BSEP-function-promoting activity and FXR-agonistic activity.	GW 4064	65-71	ATP binding cassette subfamily B member 11	Homo sapiens	110-114
22583617-4	2012	Here, we conducted a structure-activity relationship analysis of GW4064 derivatives aimed at separating E297G BSEP-function-promoting activity and FXR-agonistic activity.	GW 4064	65-71	nuclear receptor subfamily 1 group H member 4	Homo sapiens	147-150
22583617-5	2012	Among newly synthesized reversed-amide derivatives of previously reported GW4064 analogs 2a-2f, we identified 7c as a selective BSEP function enhancer.	GW 4064	74-80	ATP binding cassette subfamily B member 11	Homo sapiens	128-132
22492528-5	2012	This effect was mimicked by the FXR agonist GW4064 and suppressed by the FXR antagonist guggulsterone.	GW 4064	44-50	nuclear receptor subfamily 1, group H, member 4	Mus musculus	32-35
22583617-0	2012	E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity.	GW 4064	75-81	ATP binding cassette subfamily B member 11	Homo sapiens	14-35
22583617-0	2012	E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity.	GW 4064	75-81	ATP binding cassette subfamily B member 11	Homo sapiens	37-41
23119029-5	2012	In contrast, FXR overexpression and activation with GW4064 attenuated cell proliferation by down-regulating EGFR (Tyr845) phosphorylation and ERK activation.	GW 4064	52-58	nuclear receptor subfamily 1 group H member 4	Homo sapiens	13-16
22178739-7	2012	In addition, EGCG suppressed FXR target gene expression induced by either GW4064 or chenodeoxycholic acid in vitro.	GW 4064	74-80	nuclear receptor subfamily 1, group H, member 4	Mus musculus	29-32
22197325-5	2012	Accordingly, pharmacological activation of Fxr with GW4064 overcomes the BA imbalance, restoring hepatic and plasma TG levels of FoxO1-deficient mice to normal levels.	GW 4064	52-58	nuclear receptor subfamily 1, group H, member 4	Mus musculus	43-46
22197325-5	2012	Accordingly, pharmacological activation of Fxr with GW4064 overcomes the BA imbalance, restoring hepatic and plasma TG levels of FoxO1-deficient mice to normal levels.	GW 4064	52-58	glucosidase beta 2	Mus musculus	73-75
22197325-5	2012	Accordingly, pharmacological activation of Fxr with GW4064 overcomes the BA imbalance, restoring hepatic and plasma TG levels of FoxO1-deficient mice to normal levels.	GW 4064	52-58	forkhead box O1	Mus musculus	129-134
23119029-5	2012	In contrast, FXR overexpression and activation with GW4064 attenuated cell proliferation by down-regulating EGFR (Tyr845) phosphorylation and ERK activation.	GW 4064	52-58	epidermal growth factor receptor	Homo sapiens	108-112
23119029-5	2012	In contrast, FXR overexpression and activation with GW4064 attenuated cell proliferation by down-regulating EGFR (Tyr845) phosphorylation and ERK activation.	GW 4064	52-58	mitogen-activated protein kinase 1	Homo sapiens	142-145
23119029-6	2012	Treatment with guggulsterone and GW4064 also caused dose-dependent changes in Src (Tyr416) phosphorylation.	GW 4064	33-39	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	78-81
21660973-0	2011	A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys.	GW 4064	89-95	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	69-79
21564085-6	2011	FXR were activated by giving mice natural (chenodeoxycholic acid; CDCA) or synthetic (GW4064) FXR agonists.	GW 4064	86-92	nuclear receptor subfamily 1, group H, member 4	Mus musculus	0-3
21564085-6	2011	FXR were activated by giving mice natural (chenodeoxycholic acid; CDCA) or synthetic (GW4064) FXR agonists.	GW 4064	86-92	nuclear receptor subfamily 1, group H, member 4	Mus musculus	94-97
21564085-11	2011	FXR activation by GW4064 rescued mice from intestinal injury caused by naproxen.	GW 4064	18-24	nuclear receptor subfamily 1, group H, member 4	Mus musculus	0-3
22952826-9	2012	However, wild-type mice treated with GW4064, a synthetic FXR ligand, showed that FXR activation induced mRNA and protein expression of Sqstm1/p62 in ileum, but not in liver.	GW 4064	37-43	nuclear receptor subfamily 1, group H, member 4	Mus musculus	57-60
22952826-9	2012	However, wild-type mice treated with GW4064, a synthetic FXR ligand, showed that FXR activation induced mRNA and protein expression of Sqstm1/p62 in ileum, but not in liver.	GW 4064	37-43	nuclear receptor subfamily 1, group H, member 4	Mus musculus	81-84
22952826-9	2012	However, wild-type mice treated with GW4064, a synthetic FXR ligand, showed that FXR activation induced mRNA and protein expression of Sqstm1/p62 in ileum, but not in liver.	GW 4064	37-43	sequestosome 1	Mus musculus	135-141
22952826-9	2012	However, wild-type mice treated with GW4064, a synthetic FXR ligand, showed that FXR activation induced mRNA and protein expression of Sqstm1/p62 in ileum, but not in liver.	GW 4064	37-43	sequestosome 1	Mus musculus	142-145
21957312-8	2011	Second, CDCA, deoxycholic acid (DCA), and other synthetic FXR agonists, such as GW4064, significantly reduced rotavirus replication in cell culture in a dose-dependent manner.	GW 4064	80-86	nuclear receptor subfamily 1 group H member 4	Homo sapiens	58-61
21988803-6	2011	The FXR effect has been illustrated with the use of the FXR agonist GW4064 and the FXR antagonist GS.	GW 4064	68-74	nuclear receptor subfamily 1 group H member 4	Homo sapiens	4-7
21988803-6	2011	The FXR effect has been illustrated with the use of the FXR agonist GW4064 and the FXR antagonist GS.	GW 4064	68-74	nuclear receptor subfamily 1 group H member 4	Homo sapiens	56-59
21988803-6	2011	The FXR effect has been illustrated with the use of the FXR agonist GW4064 and the FXR antagonist GS.	GW 4064	68-74	nuclear receptor subfamily 1 group H member 4	Homo sapiens	56-59
21988803-7	2011	More specifically, when the use of free bile acids combined with FXR agonist GW4064, the tumor cell inhibitory effect was even more pronounced.	GW 4064	77-83	nuclear receptor subfamily 1 group H member 4	Homo sapiens	65-68
21988803-13	2011	We also found that FXR agonist GW4064 effectively blocked the stimulatory effect of GDCA on tumor growth.	GW 4064	31-37	nuclear receptor subfamily 1 group H member 4	Homo sapiens	19-22
21988803-13	2011	We also found that FXR agonist GW4064 effectively blocked the stimulatory effect of GDCA on tumor growth.	GW 4064	31-37	G protein subunit alpha transducin 3	Homo sapiens	84-88
21660973-5	2011	We used a commercially available FXR agonist, GW4064, as a model compound to assess preclinical efficacy in two species (hamster and cynomolgus monkey).	GW 4064	46-52	nuclear receptor subfamily 1 group H member 4	Homo sapiens	33-36
21632533-1	2011	We evaluated the metabolic impact of farnesoid X receptor (FXR) activation by administering a synthetic FXR agonist (GW4064) to mice in which obesity was induced by a high fat diet.	GW 4064	117-123	nuclear receptor subfamily 1, group H, member 4	Mus musculus	59-62
21499302-4	2011	In this study, we show that activation of farnesoid X receptor (FXR), by the primary bile acid chenodeoxycholic acid (CDCA) or the synthetic agonist GW4064, inhibited growth of Tam-resistant breast cancer cells (termed MCF-7 TR1), which was used as an in vitro model of acquired Tam resistance.	GW 4064	149-155	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	52-62
21499302-4	2011	In this study, we show that activation of farnesoid X receptor (FXR), by the primary bile acid chenodeoxycholic acid (CDCA) or the synthetic agonist GW4064, inhibited growth of Tam-resistant breast cancer cells (termed MCF-7 TR1), which was used as an in vitro model of acquired Tam resistance.	GW 4064	149-155	nuclear receptor subfamily 1 group H member 4	Homo sapiens	64-67
21596890-6	2011	3-(2,6-Dichlorophenyl)-4-(3"-carboxy-2-chlorostilben-4-yl-)oxymethyl-5-isopropyl-isoxazole (GW4064), a synthetic FXR ligand, had similar effects.	GW 4064	92-98	nuclear receptor subfamily 1 group H member 4	Homo sapiens	113-116
21632533-1	2011	We evaluated the metabolic impact of farnesoid X receptor (FXR) activation by administering a synthetic FXR agonist (GW4064) to mice in which obesity was induced by a high fat diet.	GW 4064	117-123	nuclear receptor subfamily 1, group H, member 4	Mus musculus	104-107
21493670-8	2011	Using FXR-null [FXR knockout (FXRKO)] mice, we determined that GW4064 induction of PGC-1alpha expression is not affected in oxidative soleus muscles of FXRKO mice but is compromised in the FXRKO liver.	GW 4064	63-69	nuclear receptor subfamily 1, group H, member 4	Mus musculus	16-19
21291553-6	2011	RESULTS: Tetraodon FXR has a ligand selectivity profile very similar to human FXR, with strong activation by the synthetic ligand GW4064 and by the primary bile acid chenodeoxycholic acid.	GW 4064	130-136	nuclear receptor subfamily 1 group H member 4	Homo sapiens	19-22
21493670-8	2011	Using FXR-null [FXR knockout (FXRKO)] mice, we determined that GW4064 induction of PGC-1alpha expression is not affected in oxidative soleus muscles of FXRKO mice but is compromised in the FXRKO liver.	GW 4064	63-69	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	83-93
21319191-8	2011	Treatment of mouse or human hepatocytes with a farnesoid X receptor (FXR) agonist GW4064 or bile acids induced hepatic Abcg5/g8 expression.	GW 4064	82-88	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	57-67
21319191-8	2011	Treatment of mouse or human hepatocytes with a farnesoid X receptor (FXR) agonist GW4064 or bile acids induced hepatic Abcg5/g8 expression.	GW 4064	82-88	nuclear receptor subfamily 1 group H member 4	Homo sapiens	69-72
21319191-8	2011	Treatment of mouse or human hepatocytes with a farnesoid X receptor (FXR) agonist GW4064 or bile acids induced hepatic Abcg5/g8 expression.	GW 4064	82-88	ATP binding cassette subfamily G member 5	Homo sapiens	119-124
21291553-6	2011	RESULTS: Tetraodon FXR has a ligand selectivity profile very similar to human FXR, with strong activation by the synthetic ligand GW4064 and by the primary bile acid chenodeoxycholic acid.	GW 4064	130-136	nuclear receptor subfamily 1 group H member 4	Homo sapiens	78-81
21493670-0	2011	Bile acid receptor agonist GW4064 regulates PPARgamma coactivator-1alpha expression through estrogen receptor-related receptor alpha.	GW 4064	27-33	nuclear receptor subfamily 1, group H, member 4	Mus musculus	0-18
21493670-0	2011	Bile acid receptor agonist GW4064 regulates PPARgamma coactivator-1alpha expression through estrogen receptor-related receptor alpha.	GW 4064	27-33	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	44-72
21493670-3	2011	In our effort to identify new regulators of PGC-1alpha expression, we found that GW4064, a widely used synthetic agonist for the nuclear bile acid receptor [farnesoid X receptor (FXR)] strongly enhances PGC-1alpha promoter reporter activity, mRNA, and protein expression.	GW 4064	81-87	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	44-54
21493670-3	2011	In our effort to identify new regulators of PGC-1alpha expression, we found that GW4064, a widely used synthetic agonist for the nuclear bile acid receptor [farnesoid X receptor (FXR)] strongly enhances PGC-1alpha promoter reporter activity, mRNA, and protein expression.	GW 4064	81-87	nuclear receptor subfamily 1, group H, member 4	Mus musculus	137-155
21493670-3	2011	In our effort to identify new regulators of PGC-1alpha expression, we found that GW4064, a widely used synthetic agonist for the nuclear bile acid receptor [farnesoid X receptor (FXR)] strongly enhances PGC-1alpha promoter reporter activity, mRNA, and protein expression.	GW 4064	81-87	nuclear receptor subfamily 1, group H, member 4	Mus musculus	179-182
21493670-3	2011	In our effort to identify new regulators of PGC-1alpha expression, we found that GW4064, a widely used synthetic agonist for the nuclear bile acid receptor [farnesoid X receptor (FXR)] strongly enhances PGC-1alpha promoter reporter activity, mRNA, and protein expression.	GW 4064	81-87	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	203-213
21493670-5	2011	Using FXR-rich or FXR-nonexpressing cell lines and tissues, we found that this effect of GW4064 is not mediated directly by FXR but occurs via activation of estrogen receptor-related receptor alpha (ERRalpha).	GW 4064	89-95	nuclear receptor subfamily 1, group H, member 4	Mus musculus	6-9
21493670-5	2011	Using FXR-rich or FXR-nonexpressing cell lines and tissues, we found that this effect of GW4064 is not mediated directly by FXR but occurs via activation of estrogen receptor-related receptor alpha (ERRalpha).	GW 4064	89-95	nuclear receptor subfamily 1, group H, member 4	Mus musculus	18-21
21493670-5	2011	Using FXR-rich or FXR-nonexpressing cell lines and tissues, we found that this effect of GW4064 is not mediated directly by FXR but occurs via activation of estrogen receptor-related receptor alpha (ERRalpha).	GW 4064	89-95	nuclear receptor subfamily 1, group H, member 4	Mus musculus	18-21
21493670-5	2011	Using FXR-rich or FXR-nonexpressing cell lines and tissues, we found that this effect of GW4064 is not mediated directly by FXR but occurs via activation of estrogen receptor-related receptor alpha (ERRalpha).	GW 4064	89-95	estrogen related receptor, alpha	Mus musculus	199-207
21493670-6	2011	Cell-based, biochemical and biophysical assays indicate GW4064 as an agonist of ERR proteins.	GW 4064	56-62	solute carrier family 7 (cationic amino acid transporter, y+ system), member 1	Mus musculus	80-83
21493670-7	2011	Interestingly, FXR disruption alters GW4064 induction of PGC-1alpha mRNA in a tissue-dependent manner.	GW 4064	37-43	nuclear receptor subfamily 1, group H, member 4	Mus musculus	15-18
21493670-7	2011	Interestingly, FXR disruption alters GW4064 induction of PGC-1alpha mRNA in a tissue-dependent manner.	GW 4064	37-43	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	57-67
21493670-8	2011	Using FXR-null [FXR knockout (FXRKO)] mice, we determined that GW4064 induction of PGC-1alpha expression is not affected in oxidative soleus muscles of FXRKO mice but is compromised in the FXRKO liver.	GW 4064	63-69	nuclear receptor subfamily 1, group H, member 4	Mus musculus	6-9
21364590-6	2011	The function of FXR was studied by small interfering RNA and treatment with FXR antagonist guggulsterone and FXR agonist GW4064.	GW 4064	121-127	nuclear receptor subfamily 1 group H member 4	Homo sapiens	16-19
21364590-10	2011	Moreover, GW4064-mediated FXR activation increased cell migration and invasion.	GW 4064	10-16	nuclear receptor subfamily 1 group H member 4	Homo sapiens	26-29
20185821-4	2010	Activation of FXR by the synthetic agonist GW4064 decreases hepatic miR-34a levels in normal mice, and consistently, hepatic miR-34a levels are elevated in FXR-null mice.	GW 4064	43-49	nuclear receptor subfamily 1, group H, member 4	Mus musculus	14-17
21085652-5	2010	We report in this study that treatment of quiescent HSCs with GW4064, a synthetic FXR agonist, significantly inhibited the HSC transdifferentiation, which was associated with an inhibition of the upregulation of ET-1 expression.	GW 4064	62-68	nuclear receptor subfamily 1 group H member 4	Homo sapiens	82-85
21085652-5	2010	We report in this study that treatment of quiescent HSCs with GW4064, a synthetic FXR agonist, significantly inhibited the HSC transdifferentiation, which was associated with an inhibition of the upregulation of ET-1 expression.	GW 4064	62-68	endothelin 1	Homo sapiens	212-216
21085652-6	2010	These GW4064-treated cells also showed reduced contractile response to ET-1 in comparison to HSCs without GW4064 treatment.	GW 4064	6-12	endothelin 1	Homo sapiens	71-75
21085652-7	2010	We have further shown that GW4064 treatment inhibited the ET-1-mediated contraction in fully activated HSCs.	GW 4064	27-33	endothelin 1	Homo sapiens	58-62
21085652-8	2010	To elucidate the potential mechanism we showed that GW4064 inhibited ET-1-mediated activation of Rho/ROCK pathway in activated HSCs.	GW 4064	52-58	endothelin 1	Homo sapiens	69-73
20675645-5	2010	Treatment of DKO mice with the farnesoid X receptor (FXR) agonist GW4064 did not alter the intestinal cholesterol absorption, suggesting that the action of CA in this process is confined mainly to formation of intraluminal micelles and less to its ability to activate the nuclear receptor FXR.	GW 4064	66-72	nuclear receptor subfamily 1, group H, member 4	Mus musculus	53-56
20185821-4	2010	Activation of FXR by the synthetic agonist GW4064 decreases hepatic miR-34a levels in normal mice, and consistently, hepatic miR-34a levels are elevated in FXR-null mice.	GW 4064	43-49	microRNA 34a	Mus musculus	68-75
20104269-8	2010	The effects of CDCA and GW4064 on expression of Cdx2 and MUC2 were abolished by guggulsterone.	GW 4064	24-30	caudal type homeo box 2	Rattus norvegicus	48-52
20189675-10	2010	The FXR inducer GW4064 activated UGT1A3 transcription, and electrophoretic mobility shift assays identified UGT1A3 as a FXR target gene.	GW 4064	16-22	nuclear receptor subfamily 1 group H member 4	Homo sapiens	4-7
20189675-10	2010	The FXR inducer GW4064 activated UGT1A3 transcription, and electrophoretic mobility shift assays identified UGT1A3 as a FXR target gene.	GW 4064	16-22	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	33-39
20189675-10	2010	The FXR inducer GW4064 activated UGT1A3 transcription, and electrophoretic mobility shift assays identified UGT1A3 as a FXR target gene.	GW 4064	16-22	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	108-114
20189675-10	2010	The FXR inducer GW4064 activated UGT1A3 transcription, and electrophoretic mobility shift assays identified UGT1A3 as a FXR target gene.	GW 4064	16-22	nuclear receptor subfamily 1 group H member 4	Homo sapiens	120-123
20026603-5	2010	We found, in rat Leydig tumor cells, R2C, that FXR activation by the primary bile acid chenodeoxycholic acid (CDCA) or a synthetic agonist GW4064, through a SHP-independent mechanism, down-regulates aromatase expression in terms of mRNA, protein levels, and its enzymatic activity.	GW 4064	139-145	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	47-50
20091679-5	2010	This study analyzed genome-wide FXR binding in liver and intestine of mice treated with a synthetic FXR ligand (GW4064) by chromatin immunoprecipitation coupled to massively parallel sequencing (ChIP-seq).	GW 4064	112-118	nuclear receptor subfamily 1, group H, member 4	Mus musculus	32-35
20091679-5	2010	This study analyzed genome-wide FXR binding in liver and intestine of mice treated with a synthetic FXR ligand (GW4064) by chromatin immunoprecipitation coupled to massively parallel sequencing (ChIP-seq).	GW 4064	112-118	nuclear receptor subfamily 1, group H, member 4	Mus musculus	100-103
20104269-8	2010	The effects of CDCA and GW4064 on expression of Cdx2 and MUC2 were abolished by guggulsterone.	GW 4064	24-30	mucin 2, oligomeric mucus/gel-forming	Rattus norvegicus	57-61
19328688-0	2009	Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.	GW 4064	38-44	nuclear receptor subfamily 1 group H member 4	Homo sapiens	64-67
19605523-5	2009	We report here that treatment of mice with an FXR agonist 3-(2,6-dichlorophenyl)-4-(3"-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole; GW4064) led to increased expression of DDAH-1 and CAT-1 in both liver and kidney.	GW 4064	148-154	nuclear receptor subfamily 1, group H, member 4	Mus musculus	46-49
19605523-6	2009	In cultured human hepatocytes and kidney proximal tubular epithelial cells, GW4064 increased CAT-1 expression, and this was associated with a significant increase in the cellular uptake of ADMA.	GW 4064	76-82	solute carrier family 7 member 1	Homo sapiens	93-98
19608735-10	2009	In vitro experiments show reduced induction of mRNA expression of relevant genes upon chenodeoxycholic acid and a selective FXR agonist GW4064 stimulation in EFA-deficient Caco-2 cells.	GW 4064	136-142	nuclear receptor subfamily 1 group H member 4	Homo sapiens	124-127
19586769-1	2009	Two series of conformationally constrained analogs of the FXR agonist GW 4064 1 were prepared.	GW 4064	70-77	nuclear receptor subfamily 1 group H member 4	Homo sapiens	58-61
19410460-0	2009	Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.	GW 4064	68-74	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	43-53
19410460-0	2009	Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.	GW 4064	68-74	nuclear receptor subfamily 1 group H member 4	Homo sapiens	55-58
19228886-0	2009	Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.	GW 4064	134-140	ATPase phospholipid transporting 8B1	Homo sapiens	13-19
19228886-0	2009	Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.	GW 4064	134-140	nuclear receptor subfamily 1 group H member 4	Homo sapiens	122-125
19228886-9	2009	Treatment with the synthetic FXR agonist GW4064 was able to partially neutralize ATP8B1 siRNA-mediated FXR downregulation and fully counteract inhibition of FXR target genes.	GW 4064	41-47	nuclear receptor subfamily 1 group H member 4	Homo sapiens	29-32
19228886-9	2009	Treatment with the synthetic FXR agonist GW4064 was able to partially neutralize ATP8B1 siRNA-mediated FXR downregulation and fully counteract inhibition of FXR target genes.	GW 4064	41-47	ATPase phospholipid transporting 8B1	Homo sapiens	81-87
19228886-9	2009	Treatment with the synthetic FXR agonist GW4064 was able to partially neutralize ATP8B1 siRNA-mediated FXR downregulation and fully counteract inhibition of FXR target genes.	GW 4064	41-47	nuclear receptor subfamily 1 group H member 4	Homo sapiens	103-106
19228886-9	2009	Treatment with the synthetic FXR agonist GW4064 was able to partially neutralize ATP8B1 siRNA-mediated FXR downregulation and fully counteract inhibition of FXR target genes.	GW 4064	41-47	nuclear receptor subfamily 1 group H member 4	Homo sapiens	103-106
19328688-1	2009	According to the docking studies and the analysis of a co-crystal structure of GW4064 with FXR, a series of 3-aryl heterocyclic isoxazole analogs were designed and synthesized.	GW 4064	79-85	nuclear receptor subfamily 1 group H member 4	Homo sapiens	91-94
18436567-4	2008	Two FXR ligands, chenodeoxycholic acid (CDCA) and GW4064, rescued HepG2 cells from serum deprivation-induced apoptosis in a dose-dependent manner.	GW 4064	50-56	nuclear receptor subfamily 1 group H member 4	Homo sapiens	4-7
18755856-1	2008	The farnesoid X receptor (FXR, NR1H4) belongs to the nuclear receptor superfamily and is activated by bile acids such as chenodeoxycholic acid, or synthetic ligands such as GW4064.	GW 4064	173-179	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	14-24
18755856-1	2008	The farnesoid X receptor (FXR, NR1H4) belongs to the nuclear receptor superfamily and is activated by bile acids such as chenodeoxycholic acid, or synthetic ligands such as GW4064.	GW 4064	173-179	nuclear receptor subfamily 1 group H member 4	Homo sapiens	26-29
18755856-1	2008	The farnesoid X receptor (FXR, NR1H4) belongs to the nuclear receptor superfamily and is activated by bile acids such as chenodeoxycholic acid, or synthetic ligands such as GW4064.	GW 4064	173-179	nuclear receptor subfamily 1 group H member 4	Homo sapiens	31-36
19118524-3	2009	In this study, we report that two synthetic FXR agonists, WAY-362450 and GW4064, suppressed interleukin-6-induced CRP expression in human Hep3B hepatoma cells.	GW 4064	73-79	nuclear receptor subfamily 1 group H member 4	Homo sapiens	44-47
19118524-3	2009	In this study, we report that two synthetic FXR agonists, WAY-362450 and GW4064, suppressed interleukin-6-induced CRP expression in human Hep3B hepatoma cells.	GW 4064	73-79	interleukin 6	Homo sapiens	92-105
19118524-3	2009	In this study, we report that two synthetic FXR agonists, WAY-362450 and GW4064, suppressed interleukin-6-induced CRP expression in human Hep3B hepatoma cells.	GW 4064	73-79	C-reactive protein	Homo sapiens	114-117
19085950-3	2009	Chenodeoxycholic acid (CDCA) and the farnesoid X receptor (FXR)-specific agonist GW4064 strongly induced FGF19 but inhibited CYP7A1 messenger RNA (mRNA) levels in primary human hepatocytes.	GW 4064	81-87	nuclear receptor subfamily 1 group H member 4	Homo sapiens	37-57
19085950-3	2009	Chenodeoxycholic acid (CDCA) and the farnesoid X receptor (FXR)-specific agonist GW4064 strongly induced FGF19 but inhibited CYP7A1 messenger RNA (mRNA) levels in primary human hepatocytes.	GW 4064	81-87	nuclear receptor subfamily 1 group H member 4	Homo sapiens	59-62
19085950-3	2009	Chenodeoxycholic acid (CDCA) and the farnesoid X receptor (FXR)-specific agonist GW4064 strongly induced FGF19 but inhibited CYP7A1 messenger RNA (mRNA) levels in primary human hepatocytes.	GW 4064	81-87	fibroblast growth factor 19	Homo sapiens	105-110
19085950-3	2009	Chenodeoxycholic acid (CDCA) and the farnesoid X receptor (FXR)-specific agonist GW4064 strongly induced FGF19 but inhibited CYP7A1 messenger RNA (mRNA) levels in primary human hepatocytes.	GW 4064	81-87	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	125-131
19085950-8	2009	FGF19 antibody and siRNA specific to FGFR4 abrogated GW4064 inhibition of CYP7A1.	GW 4064	53-59	fibroblast growth factor 19	Homo sapiens	0-5
19085950-8	2009	FGF19 antibody and siRNA specific to FGFR4 abrogated GW4064 inhibition of CYP7A1.	GW 4064	53-59	fibroblast growth factor receptor 4	Homo sapiens	37-42
19085950-8	2009	FGF19 antibody and siRNA specific to FGFR4 abrogated GW4064 inhibition of CYP7A1.	GW 4064	53-59	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	74-80
18436567-6	2008	Similarly, the effects of both CDCA and GW4064 were abolished after inhibition of the MAPK pathway by a specific inhibitor of MAPK kinase 1/2.	GW 4064	40-46	mitogen-activated protein kinase 1	Mus musculus	86-90
18436567-7	2008	Immunoblotting results indicated that FXR activation by CDCA and GW4064 induced ERK1/2 phosphorylation, which was attenuated by serum deprivation.	GW 4064	65-71	nuclear receptor subfamily 1, group H, member 4	Mus musculus	38-41
18436567-7	2008	Immunoblotting results indicated that FXR activation by CDCA and GW4064 induced ERK1/2 phosphorylation, which was attenuated by serum deprivation.	GW 4064	65-71	mitogen-activated protein kinase 3	Mus musculus	80-86
18298956-4	2008	Moreover, activation of the BA-activated farnesoid X receptor (FXR) by its synthetic specific agonist GW4064 also decreased PCSK9 expression.	GW 4064	102-108	nuclear receptor subfamily 1 group H member 4	Homo sapiens	41-61
18385139-7	2008	Treatment of mice with GW4064, a synthetic agonist for farnesoid X receptor, induced SHP expression and decreased both the recruitment of PGC-1alpha to the Cyp7A1 promoter and the fasting-induced expression of CYP7A1 mRNA.	GW 4064	23-29	nuclear receptor subfamily 0, group B, member 2	Mus musculus	85-88
18385139-7	2008	Treatment of mice with GW4064, a synthetic agonist for farnesoid X receptor, induced SHP expression and decreased both the recruitment of PGC-1alpha to the Cyp7A1 promoter and the fasting-induced expression of CYP7A1 mRNA.	GW 4064	23-29	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	138-148
18385139-7	2008	Treatment of mice with GW4064, a synthetic agonist for farnesoid X receptor, induced SHP expression and decreased both the recruitment of PGC-1alpha to the Cyp7A1 promoter and the fasting-induced expression of CYP7A1 mRNA.	GW 4064	23-29	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	156-162
18385139-7	2008	Treatment of mice with GW4064, a synthetic agonist for farnesoid X receptor, induced SHP expression and decreased both the recruitment of PGC-1alpha to the Cyp7A1 promoter and the fasting-induced expression of CYP7A1 mRNA.	GW 4064	23-29	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	210-216
18298956-4	2008	Moreover, activation of the BA-activated farnesoid X receptor (FXR) by its synthetic specific agonist GW4064 also decreased PCSK9 expression.	GW 4064	102-108	nuclear receptor subfamily 1 group H member 4	Homo sapiens	63-66
18298956-4	2008	Moreover, activation of the BA-activated farnesoid X receptor (FXR) by its synthetic specific agonist GW4064 also decreased PCSK9 expression.	GW 4064	102-108	proprotein convertase subtilisin/kexin type 9	Homo sapiens	124-129
17988216-5	2008	In the present study, we report the expression of FXR in normal and cancer prostate epithelial cells, and we demonstrate that its activation by chenodeoxycholic acid or GW4064 negatively interferes with the levels of UGT2B15 and UGT2B17 mRNA and protein in prostate cancer LNCaP cells.	GW 4064	169-175	nuclear receptor subfamily 1 group H member 4	Homo sapiens	50-53
17988216-5	2008	In the present study, we report the expression of FXR in normal and cancer prostate epithelial cells, and we demonstrate that its activation by chenodeoxycholic acid or GW4064 negatively interferes with the levels of UGT2B15 and UGT2B17 mRNA and protein in prostate cancer LNCaP cells.	GW 4064	169-175	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	217-224
17988216-5	2008	In the present study, we report the expression of FXR in normal and cancer prostate epithelial cells, and we demonstrate that its activation by chenodeoxycholic acid or GW4064 negatively interferes with the levels of UGT2B15 and UGT2B17 mRNA and protein in prostate cancer LNCaP cells.	GW 4064	169-175	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	229-236
17047076-6	2006	At lower concentrations that had no direct effect on viability, the FXR agonist GW4064 induced expression of mRNA for the FXR target genes, small heterodimer partner (SHP), intestinal bile acid binding protein, and multidrug resistance-associated protein 2 (MRP-2), and repressed the expression of the SHP target gene aromatase.	GW 4064	80-86	nuclear receptor subfamily 1 group H member 4	Homo sapiens	68-71
17720959-4	2007	Treatment with the FXR-selective agonist GW4064 significantly repressed CYP7A1 in Fxr DeltaL mice but not Fxr DeltaIE mice, demonstrating that activation of FXR in intestine but not liver is required for short-term repression of CYP7A1 in liver.	GW 4064	41-47	nuclear receptor subfamily 1, group H, member 4	Mus musculus	19-22
17720959-4	2007	Treatment with the FXR-selective agonist GW4064 significantly repressed CYP7A1 in Fxr DeltaL mice but not Fxr DeltaIE mice, demonstrating that activation of FXR in intestine but not liver is required for short-term repression of CYP7A1 in liver.	GW 4064	41-47	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	72-78
17720959-4	2007	Treatment with the FXR-selective agonist GW4064 significantly repressed CYP7A1 in Fxr DeltaL mice but not Fxr DeltaIE mice, demonstrating that activation of FXR in intestine but not liver is required for short-term repression of CYP7A1 in liver.	GW 4064	41-47	nuclear receptor subfamily 1, group H, member 4	Mus musculus	82-85
17720959-4	2007	Treatment with the FXR-selective agonist GW4064 significantly repressed CYP7A1 in Fxr DeltaL mice but not Fxr DeltaIE mice, demonstrating that activation of FXR in intestine but not liver is required for short-term repression of CYP7A1 in liver.	GW 4064	41-47	nuclear receptor subfamily 1, group H, member 4	Mus musculus	157-160
17720959-4	2007	Treatment with the FXR-selective agonist GW4064 significantly repressed CYP7A1 in Fxr DeltaL mice but not Fxr DeltaIE mice, demonstrating that activation of FXR in intestine but not liver is required for short-term repression of CYP7A1 in liver.	GW 4064	41-47	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	229-235
17545158-5	2007	Treatment of wild-type mice with GW4064, a synthetic Fxralpha agonist, induced Slc13a1 mRNA in the intestine and kidney.	GW 4064	33-39	solute carrier family 13 (sodium/sulfate symporters), member 1	Mus musculus	79-86
18029909-4	2007	METHODS AND RESULTS: The FXR target gene, small heterodimer partner (SHP), was induced in vascular smooth muscle cells after treatment with synthetic FXR ligands, GW4064, or 6alpha-ethyl-chenodeoxycholic acid.	GW 4064	163-169	nuclear receptor subfamily 1 group H member 4	Homo sapiens	25-28
18029909-4	2007	METHODS AND RESULTS: The FXR target gene, small heterodimer partner (SHP), was induced in vascular smooth muscle cells after treatment with synthetic FXR ligands, GW4064, or 6alpha-ethyl-chenodeoxycholic acid.	GW 4064	163-169	nuclear receptor subfamily 0 group B member 2	Homo sapiens	42-67
18029909-4	2007	METHODS AND RESULTS: The FXR target gene, small heterodimer partner (SHP), was induced in vascular smooth muscle cells after treatment with synthetic FXR ligands, GW4064, or 6alpha-ethyl-chenodeoxycholic acid.	GW 4064	163-169	nuclear receptor subfamily 0 group B member 2	Homo sapiens	69-72
17975826-3	2007	Experiments in primary human hepatocytes and in human liver slices showed that ALAS1 messenger RNA (mRNA) and activity is increased upon exposure to chenodeoxycholic acid (CDCA), the most potent natural FXR ligand, or the synthetic FXR-specific agonist GW4064.	GW 4064	253-259	5'-aminolevulinate synthase 1	Homo sapiens	79-84
17660268-8	2007	In renal mesangial cells, overexpression of FXR or treatment with GW4064 also inhibited SREBP-1c and other lipogenic genes, transforming growth factor-beta, and interleukin-6, suggesting a direct role of FXR in modulating renal lipid metabolism and modulation of fibrosis and inflammation.	GW 4064	66-72	sterol regulatory element binding transcription factor 1	Mus musculus	88-96
17660268-8	2007	In renal mesangial cells, overexpression of FXR or treatment with GW4064 also inhibited SREBP-1c and other lipogenic genes, transforming growth factor-beta, and interleukin-6, suggesting a direct role of FXR in modulating renal lipid metabolism and modulation of fibrosis and inflammation.	GW 4064	66-72	interleukin 6	Mus musculus	161-174
17660268-8	2007	In renal mesangial cells, overexpression of FXR or treatment with GW4064 also inhibited SREBP-1c and other lipogenic genes, transforming growth factor-beta, and interleukin-6, suggesting a direct role of FXR in modulating renal lipid metabolism and modulation of fibrosis and inflammation.	GW 4064	66-72	nuclear receptor subfamily 1, group H, member 4	Mus musculus	204-207
17065154-2	2006	By microarray analysis of hepatic genes from female Zucker diabetic fatty (ZDF) rats treated with the FXR agonist GW4064, we have identified dimethylarginine dimethylaminohydrolase-1 (DDAH1) as an FXR target gene.	GW 4064	114-120	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	102-105
17065154-2	2006	By microarray analysis of hepatic genes from female Zucker diabetic fatty (ZDF) rats treated with the FXR agonist GW4064, we have identified dimethylarginine dimethylaminohydrolase-1 (DDAH1) as an FXR target gene.	GW 4064	114-120	dimethylarginine dimethylaminohydrolase 1	Rattus norvegicus	141-182
17065154-2	2006	By microarray analysis of hepatic genes from female Zucker diabetic fatty (ZDF) rats treated with the FXR agonist GW4064, we have identified dimethylarginine dimethylaminohydrolase-1 (DDAH1) as an FXR target gene.	GW 4064	114-120	dimethylarginine dimethylaminohydrolase 1	Rattus norvegicus	184-189
17065154-2	2006	By microarray analysis of hepatic genes from female Zucker diabetic fatty (ZDF) rats treated with the FXR agonist GW4064, we have identified dimethylarginine dimethylaminohydrolase-1 (DDAH1) as an FXR target gene.	GW 4064	114-120	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	197-200
17065154-5	2006	Functional analysis of the putative FXRE demonstrated GW4064 dose-dependent transcriptional activation from the element, and we have demonstrated that the FXRE sequence binds the FXR-RXR heterodimer.	GW 4064	54-60	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	36-39
17065154-6	2006	In vivo administration of GW4064 to female ZDF rats promoted a dose-dependent and >6-fold increase in hepatic DDAH1 gene expression.	GW 4064	26-32	dimethylarginine dimethylaminohydrolase 1	Rattus norvegicus	113-118
17047076-6	2006	At lower concentrations that had no direct effect on viability, the FXR agonist GW4064 induced expression of mRNA for the FXR target genes, small heterodimer partner (SHP), intestinal bile acid binding protein, and multidrug resistance-associated protein 2 (MRP-2), and repressed the expression of the SHP target gene aromatase.	GW 4064	80-86	nuclear receptor subfamily 1 group H member 4	Homo sapiens	122-125
17047076-6	2006	At lower concentrations that had no direct effect on viability, the FXR agonist GW4064 induced expression of mRNA for the FXR target genes, small heterodimer partner (SHP), intestinal bile acid binding protein, and multidrug resistance-associated protein 2 (MRP-2), and repressed the expression of the SHP target gene aromatase.	GW 4064	80-86	nuclear receptor subfamily 0 group B member 2	Homo sapiens	140-165
17047076-6	2006	At lower concentrations that had no direct effect on viability, the FXR agonist GW4064 induced expression of mRNA for the FXR target genes, small heterodimer partner (SHP), intestinal bile acid binding protein, and multidrug resistance-associated protein 2 (MRP-2), and repressed the expression of the SHP target gene aromatase.	GW 4064	80-86	nuclear receptor subfamily 0 group B member 2	Homo sapiens	167-170
17047076-6	2006	At lower concentrations that had no direct effect on viability, the FXR agonist GW4064 induced expression of mRNA for the FXR target genes, small heterodimer partner (SHP), intestinal bile acid binding protein, and multidrug resistance-associated protein 2 (MRP-2), and repressed the expression of the SHP target gene aromatase.	GW 4064	80-86	ATP binding cassette subfamily C member 2	Homo sapiens	215-256
17047076-6	2006	At lower concentrations that had no direct effect on viability, the FXR agonist GW4064 induced expression of mRNA for the FXR target genes, small heterodimer partner (SHP), intestinal bile acid binding protein, and multidrug resistance-associated protein 2 (MRP-2), and repressed the expression of the SHP target gene aromatase.	GW 4064	80-86	ATP binding cassette subfamily C member 2	Homo sapiens	258-263
17047076-6	2006	At lower concentrations that had no direct effect on viability, the FXR agonist GW4064 induced expression of mRNA for the FXR target genes, small heterodimer partner (SHP), intestinal bile acid binding protein, and multidrug resistance-associated protein 2 (MRP-2), and repressed the expression of the SHP target gene aromatase.	GW 4064	80-86	nuclear receptor subfamily 0 group B member 2	Homo sapiens	302-305
16946559-9	2006	Human SULT2A1 protein and mRNA levels were decreased in HepG2 cells treated with the FXR agonists, CDCA or GW4064 in dose-dependent manners, although SHP mRNA levels were increased.	GW 4064	107-113	sulfotransferase family 2A member 1	Homo sapiens	6-13
16946559-9	2006	Human SULT2A1 protein and mRNA levels were decreased in HepG2 cells treated with the FXR agonists, CDCA or GW4064 in dose-dependent manners, although SHP mRNA levels were increased.	GW 4064	107-113	nuclear receptor subfamily 1 group H member 4	Homo sapiens	85-88
16357058-8	2006	As predicted from the promoter analyses, ileal Ostalpha and Ostbeta mRNA expressions were increased in wild-type mice administered the FXR agonist GW4064 and decreased in FXR-null mice.	GW 4064	147-153	solute carrier family 51, alpha subunit	Mus musculus	47-55
16682417-5	2006	Feeding mice with cholic acid or the synthetic farnesoid X receptor (FXR) agonist GW4064 resulted in a robust PXR induction.	GW 4064	82-88	nuclear receptor subfamily 1, group H, member 4	Mus musculus	69-72
16682417-5	2006	Feeding mice with cholic acid or the synthetic farnesoid X receptor (FXR) agonist GW4064 resulted in a robust PXR induction.	GW 4064	82-88	nuclear receptor subfamily 1, group I, member 2	Mus musculus	110-113
16357058-8	2006	As predicted from the promoter analyses, ileal Ostalpha and Ostbeta mRNA expressions were increased in wild-type mice administered the FXR agonist GW4064 and decreased in FXR-null mice.	GW 4064	147-153	solute carrier family 51, beta subunit	Mus musculus	60-67
16357058-8	2006	As predicted from the promoter analyses, ileal Ostalpha and Ostbeta mRNA expressions were increased in wild-type mice administered the FXR agonist GW4064 and decreased in FXR-null mice.	GW 4064	147-153	nuclear receptor subfamily 1, group H, member 4	Mus musculus	135-138
16625821-3	2006	The C57L mouse is also susceptible to gallstone formation when fed a lithogenic diet, and in this model, the small-molecule FXR agonist GW-4064 prevents the precipitation of cholesterol.	GW 4064	136-143	nuclear receptor subfamily 1, group H, member 4	Mus musculus	124-127
16446356-9	2006	Treatment of differentiated 3T3-L1 adipocytes with the FXR-specific synthetic agonist GW4064 enhanced insulin signaling and insulin-stimulated glucose uptake.	GW 4064	86-92	nuclear receptor subfamily 1, group H, member 4	Mus musculus	55-58
16037943-7	2005	In these cells, the FXR pharmacological agonist GW4064 upregulated VPAC1 expression in a dose-dependent manner, and this effect was antagonized by the RXRalpha ligand, 9-cis retinoic acid.	GW 4064	48-54	nuclear receptor subfamily 1 group H member 4	Homo sapiens	20-23
16012168-4	2005	AlphaA-crystallin was identified in a microarray screen as one of the most highly induced genes after treatment of HepG2 cells with the synthetic FXR ligand GW4064.	GW 4064	157-163	nuclear receptor subfamily 1 group H member 4	Homo sapiens	146-149
16410358-3	2006	Activation of FXR by the synthetic agonist GW4064 or hepatic overexpression of constitutively active FXR by adenovirus-mediated gene transfer significantly lowered blood glucose levels in both diabetic db/db and wild-type mice.	GW 4064	43-49	nuclear receptor subfamily 1, group H, member 4	Mus musculus	14-17
16037943-7	2005	In these cells, the FXR pharmacological agonist GW4064 upregulated VPAC1 expression in a dose-dependent manner, and this effect was antagonized by the RXRalpha ligand, 9-cis retinoic acid.	GW 4064	48-54	vasoactive intestinal peptide receptor 1	Homo sapiens	67-72
16037943-7	2005	In these cells, the FXR pharmacological agonist GW4064 upregulated VPAC1 expression in a dose-dependent manner, and this effect was antagonized by the RXRalpha ligand, 9-cis retinoic acid.	GW 4064	48-54	retinoid X receptor alpha	Homo sapiens	151-159
15817812-5	2005	In addition, ICAM-1 and SHP mRNA levels were also induced in primary human hepatocytes when treated with chenodeoxycholic acid or GW4064, a FXR-selective agonist.	GW 4064	130-136	intercellular adhesion molecule 1	Homo sapiens	13-19
15817812-5	2005	In addition, ICAM-1 and SHP mRNA levels were also induced in primary human hepatocytes when treated with chenodeoxycholic acid or GW4064, a FXR-selective agonist.	GW 4064	130-136	nuclear receptor subfamily 0 group B member 2	Homo sapiens	24-27
15817812-5	2005	In addition, ICAM-1 and SHP mRNA levels were also induced in primary human hepatocytes when treated with chenodeoxycholic acid or GW4064, a FXR-selective agonist.	GW 4064	130-136	nuclear receptor subfamily 1 group H member 4	Homo sapiens	140-143
15817812-7	2005	Both ICAM-1 and SHP expression were induced in a dose- and time-dependent manner by treatment with the FXR-selective agonist GW4064.	GW 4064	125-131	intercellular adhesion molecule 1	Homo sapiens	5-11
15817812-7	2005	Both ICAM-1 and SHP expression were induced in a dose- and time-dependent manner by treatment with the FXR-selective agonist GW4064.	GW 4064	125-131	nuclear receptor subfamily 0 group B member 2	Homo sapiens	16-19
15817812-7	2005	Both ICAM-1 and SHP expression were induced in a dose- and time-dependent manner by treatment with the FXR-selective agonist GW4064.	GW 4064	125-131	nuclear receptor subfamily 1 group H member 4	Homo sapiens	103-106
15817812-8	2005	Moreover, the induction of ICAM-1 by GW4064 was inhibited by the FXR antagonist guggulsterone or with transfection of FXR siRNA.	GW 4064	37-43	intercellular adhesion molecule 1	Homo sapiens	27-33
15817812-8	2005	Moreover, the induction of ICAM-1 by GW4064 was inhibited by the FXR antagonist guggulsterone or with transfection of FXR siRNA.	GW 4064	37-43	nuclear receptor subfamily 1 group H member 4	Homo sapiens	65-68
15817812-8	2005	Moreover, the induction of ICAM-1 by GW4064 was inhibited by the FXR antagonist guggulsterone or with transfection of FXR siRNA.	GW 4064	37-43	nuclear receptor subfamily 1 group H member 4	Homo sapiens	118-121
15810635-6	2005	When the same experiment was performed in the presence of a synthetic FXR ligand (GW4064), cPLA2 expression and activity were reduced, although COX-2 expression was unchanged.	GW 4064	82-88	nuclear receptor subfamily 1, group H, member 4	Mus musculus	70-73
15692145-8	2005	Treatment of Huh7 cells with CDCA or the synthetic farnesoid X receptor (FXR) agonist GW4064 decreased mRNA and protein levels and also nuclear binding activity of HNF-4 alpha.	GW 4064	86-92	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	61-71
15692145-8	2005	Treatment of Huh7 cells with CDCA or the synthetic farnesoid X receptor (FXR) agonist GW4064 decreased mRNA and protein levels and also nuclear binding activity of HNF-4 alpha.	GW 4064	86-92	nuclear receptor subfamily 1 group H member 4	Homo sapiens	73-76
15692145-8	2005	Treatment of Huh7 cells with CDCA or the synthetic farnesoid X receptor (FXR) agonist GW4064 decreased mRNA and protein levels and also nuclear binding activity of HNF-4 alpha.	GW 4064	86-92	hepatocyte nuclear factor 4 alpha	Homo sapiens	164-175
15882126-2	2005	The nuclear farnesoid X receptor (FXR) is the receptor for bile acids, and GW4064 is a synthetic agonist at the FXR.	GW 4064	75-81	nuclear receptor subfamily 1, group H, member 4	Mus musculus	34-37
15882126-2	2005	The nuclear farnesoid X receptor (FXR) is the receptor for bile acids, and GW4064 is a synthetic agonist at the FXR.	GW 4064	75-81	nuclear receptor subfamily 1, group H, member 4	Mus musculus	112-115
15882126-8	2005	As FXR agonism with GW4064 has been shown to be useful in a mouse model of cholesterol gallstone disease, it should undergo further development for the treatment of this condition.	GW 4064	20-26	nuclear receptor subfamily 1, group H, member 4	Mus musculus	3-6
15644430-8	2005	These changes were reproduced by GW4064, a synthetic FXR ligand.	GW 4064	33-39	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	53-56
15810635-6	2005	When the same experiment was performed in the presence of a synthetic FXR ligand (GW4064), cPLA2 expression and activity were reduced, although COX-2 expression was unchanged.	GW 4064	82-88	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	91-96
15810635-6	2005	When the same experiment was performed in the presence of a synthetic FXR ligand (GW4064), cPLA2 expression and activity were reduced, although COX-2 expression was unchanged.	GW 4064	82-88	prostaglandin-endoperoxide synthase 2	Mus musculus	144-149
15810635-9	2005	A synthetic FXR ligand (GW4064) inhibited the induction of COX-2 activity (detected as PG production) by GCDC, suggesting its anticarcinogenic potential.	GW 4064	24-30	nuclear receptor subfamily 1, group H, member 4	Mus musculus	12-15
15810635-9	2005	A synthetic FXR ligand (GW4064) inhibited the induction of COX-2 activity (detected as PG production) by GCDC, suggesting its anticarcinogenic potential.	GW 4064	24-30	prostaglandin-endoperoxide synthase 2	Mus musculus	59-64
15309887-6	2004	Intestinal bile acid binding protein was activated by chenodeoxycholic acid and the synthetic FXR agonist GW4064 in Caco-2 and HT-29 but not in SW cells unless FXR was transfected.	GW 4064	106-112	nuclear receptor subfamily 1 group H member 4	Homo sapiens	94-97
15564327-7	2005	Consistent with these observations, treatment of C57BL6 mice with GW4064 significantly increased hepatic PEPCK expression.	GW 4064	66-72	phosphoenolpyruvate carboxykinase 1, cytosolic	Mus musculus	105-110
15342685-5	2004	The nonsteroidal synthetic FXR agonist GW4064 also decreases HL mRNA levels in HepG2 cells and in primary human hepatocytes.	GW 4064	39-45	nuclear receptor subfamily 1 group H member 4	Homo sapiens	27-30
15342685-7	2004	In addition, FXR-specific gene silencing using small interfering RNAs demonstrated that CDCA- and GW4064-mediated downregulation of HL transcript levels occurs via an FXR-dependent mechanism.	GW 4064	98-104	nuclear receptor subfamily 1 group H member 4	Homo sapiens	13-16
15342685-7	2004	In addition, FXR-specific gene silencing using small interfering RNAs demonstrated that CDCA- and GW4064-mediated downregulation of HL transcript levels occurs via an FXR-dependent mechanism.	GW 4064	98-104	nuclear receptor subfamily 1 group H member 4	Homo sapiens	167-170
14684751-6	2004	Similar results were also obtained from a glutathione S-transferase pull-down assay in which only CDCA and the synthetic FXR agonist GW4064 significantly increased the interaction of SRC-1 with FXR.	GW 4064	133-139	nuclear receptor subfamily 1 group H member 4	Homo sapiens	121-124
14684751-6	2004	Similar results were also obtained from a glutathione S-transferase pull-down assay in which only CDCA and the synthetic FXR agonist GW4064 significantly increased the interaction of SRC-1 with FXR.	GW 4064	133-139	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	183-188
14684751-6	2004	Similar results were also obtained from a glutathione S-transferase pull-down assay in which only CDCA and the synthetic FXR agonist GW4064 significantly increased the interaction of SRC-1 with FXR.	GW 4064	133-139	nuclear receptor subfamily 1 group H member 4	Homo sapiens	194-197
12754200-8	2003	Finally, Fisher rats treated with the synthetic FXR ligand GW4064 clearly show increased transcript levels of both the BACS and BAT mRNA.	GW 4064	59-65	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	48-51
14527955-5	2003	In FXR trans-activation assays, both the endogenous FXR agonist chenodeoxycholate and the synthetic agonist GW4064 activated the MDR3 promoter.	GW 4064	108-114	nuclear receptor subfamily 1 group H member 4	Homo sapiens	3-6
14527955-5	2003	In FXR trans-activation assays, both the endogenous FXR agonist chenodeoxycholate and the synthetic agonist GW4064 activated the MDR3 promoter.	GW 4064	108-114	ATP binding cassette subfamily B member 4	Homo sapiens	129-133
14527955-7	2003	Consistent with these data, MDR3 mRNA was significantly induced by both chenodeoxycholate and GW4064 in primary human hepatocytes in time- and dose-dependent fashions.	GW 4064	94-100	ATP binding cassette subfamily B member 4	Homo sapiens	28-32
12761213-5	2003	In primary human hepatocytes, both the endogenous FXR agonist chenodeoxycholate and synthetic FXR agonist GW4064 increased kininogen mRNA with a maximum induction of 8-10-fold.	GW 4064	106-112	nuclear receptor subfamily 1 group H member 4	Homo sapiens	94-97
14623915-4	2003	We investigated whether the synthetic FXR agonist GW4064 could protect against cholestatic liver damage in rat models of extrahepatic and intrahepatic cholestasis.	GW 4064	50-56	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	38-41
14623915-5	2003	In the bile duct-ligation and alpha-naphthylisothiocyanate models of cholestasis, GW4064 treatment resulted in significant reductions in serum alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase, as well as other markers of liver damage.	GW 4064	82-88	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	169-195
14623915-7	2003	Analysis of gene expression in livers from GW4064-treated cholestatic rats revealed decreased expression of bile acid biosynthetic genes and increased expression of genes involved in bile acid transport, including the phospholipid flippase MDR2.	GW 4064	43-49	ATP binding cassette subfamily B member 4	Rattus norvegicus	240-244
12891557-7	2003	Incubation of human primary hepatocytes and HepG2 cells with bile acids or the nonsteroidal synthetic FXR agonist GW4064 resulted in a dose-dependent down-regulation of Apo CIII gene expression.	GW 4064	114-120	nuclear receptor subfamily 1 group H member 4	Homo sapiens	102-105
12891557-7	2003	Incubation of human primary hepatocytes and HepG2 cells with bile acids or the nonsteroidal synthetic FXR agonist GW4064 resulted in a dose-dependent down-regulation of Apo CIII gene expression.	GW 4064	114-120	apolipoprotein C3	Homo sapiens	169-177
12754200-8	2003	Finally, Fisher rats treated with the synthetic FXR ligand GW4064 clearly show increased transcript levels of both the BACS and BAT mRNA.	GW 4064	59-65	solute carrier family 27 member 5	Rattus norvegicus	119-123
12754200-8	2003	Finally, Fisher rats treated with the synthetic FXR ligand GW4064 clearly show increased transcript levels of both the BACS and BAT mRNA.	GW 4064	59-65	bile acid CoA:amino acid N-acyltransferase	Rattus norvegicus	128-131
12525500-5	2003	In HepG2 cells, in the presence of an FXR agonist such as chenodeoxycholate or GW4064, GS enhanced endogenous BSEP expression with a maximum induction of 400-500% that induced by an FXR agonist alone.	GW 4064	79-85	nuclear receptor subfamily 1 group H member 4	Homo sapiens	38-41
12660231-2	2003	Treatment of human hepatocytes with either naturally occurring (chenodeoxycholic acid) or synthetic (GW4064) FXR ligands resulted in both induction of SDC1 mRNA and enhanced binding, internalization, and degradation of low density lipoprotein.	GW 4064	101-107	nuclear receptor subfamily 1 group H member 4	Homo sapiens	109-112
12660231-2	2003	Treatment of human hepatocytes with either naturally occurring (chenodeoxycholic acid) or synthetic (GW4064) FXR ligands resulted in both induction of SDC1 mRNA and enhanced binding, internalization, and degradation of low density lipoprotein.	GW 4064	101-107	syndecan 1	Homo sapiens	151-155
12519787-4	2003	Using real-time quantitative PCR and cotransfection reporter assays, we demonstrate that the RXR agonist LG100268 antagonizes induction of BSEP expression mediated by endogenous and synthetic FXR ligands, CDCA and GW4064, respectively.	GW 4064	214-220	retinoid X receptor alpha	Homo sapiens	93-96
12519787-4	2003	Using real-time quantitative PCR and cotransfection reporter assays, we demonstrate that the RXR agonist LG100268 antagonizes induction of BSEP expression mediated by endogenous and synthetic FXR ligands, CDCA and GW4064, respectively.	GW 4064	214-220	ATP binding cassette subfamily B member 11	Homo sapiens	139-143
12525500-5	2003	In HepG2 cells, in the presence of an FXR agonist such as chenodeoxycholate or GW4064, GS enhanced endogenous BSEP expression with a maximum induction of 400-500% that induced by an FXR agonist alone.	GW 4064	79-85	ATP binding cassette subfamily B member 11	Homo sapiens	110-114
12525500-5	2003	In HepG2 cells, in the presence of an FXR agonist such as chenodeoxycholate or GW4064, GS enhanced endogenous BSEP expression with a maximum induction of 400-500% that induced by an FXR agonist alone.	GW 4064	79-85	nuclear receptor subfamily 1 group H member 4	Homo sapiens	182-185
12554753-6	2003	Incubation of human hepatoma HepG2 cells with the natural FXR ligand chenodeoxycholic acid (CDCA) as well as with the nonsteroidal FXR agonist GW4064 resulted in a significant induction of PPARalpha mRNA levels.	GW 4064	143-149	nuclear receptor subfamily 1 group H member 4	Homo sapiens	131-134
12554753-6	2003	Incubation of human hepatoma HepG2 cells with the natural FXR ligand chenodeoxycholic acid (CDCA) as well as with the nonsteroidal FXR agonist GW4064 resulted in a significant induction of PPARalpha mRNA levels.	GW 4064	143-149	peroxisome proliferator activated receptor alpha	Homo sapiens	189-198
12052824-6	2002	Both the endogenous FXR agonist chenodeoxycholate (CDCA) and synthetic FXR ligand GW4064 effectively increased BSEP mRNA in both cell types.	GW 4064	82-88	nuclear receptor subfamily 1 group H member 4	Homo sapiens	71-74
12052824-6	2002	Both the endogenous FXR agonist chenodeoxycholate (CDCA) and synthetic FXR ligand GW4064 effectively increased BSEP mRNA in both cell types.	GW 4064	82-88	ATP binding cassette subfamily B member 11	Homo sapiens	111-115
34870866-15	2021	The FXR agonist GW4064 almost completely restored the dysregulated bile acid signaling and metabolic syndrome in iron-fed mice.	GW 4064	16-22	nuclear receptor subfamily 1, group H, member 4	Mus musculus	4-7
11706036-3	2002	MRP2 mRNA levels were induced following treatment of human or rat hepatocytes with either naturally occurring (chenodeoxycholic acid) or synthetic (GW4064) FXR ligands.	GW 4064	148-154	ATP binding cassette subfamily C member 2	Homo sapiens	0-4
11706036-3	2002	MRP2 mRNA levels were induced following treatment of human or rat hepatocytes with either naturally occurring (chenodeoxycholic acid) or synthetic (GW4064) FXR ligands.	GW 4064	148-154	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	156-159
34387888-6	2022	RESULTS: GW4064 (30mg/kg/day) added to PN on days 4-14 prevented hepatic injury and cholestasis, reversed the suppressed mRNA expression of Nr1h4/FXR, Abcb11/BSEP, Abcc2, Abcb4, and Abcg5/8, and normalized serum bile acids.	GW 4064	9-15	nuclear receptor subfamily 1, group H, member 4	Mus musculus	140-145
34387888-6	2022	RESULTS: GW4064 (30mg/kg/day) added to PN on days 4-14 prevented hepatic injury and cholestasis, reversed the suppressed mRNA expression of Nr1h4/FXR, Abcb11/BSEP, Abcc2, Abcb4, and Abcg5/8, and normalized serum bile acids.	GW 4064	9-15	nuclear receptor subfamily 1, group H, member 4	Mus musculus	146-149
34387888-6	2022	RESULTS: GW4064 (30mg/kg/day) added to PN on days 4-14 prevented hepatic injury and cholestasis, reversed the suppressed mRNA expression of Nr1h4/FXR, Abcb11/BSEP, Abcc2, Abcb4, and Abcg5/8, and normalized serum bile acids.	GW 4064	9-15	ATP-binding cassette, sub-family B (MDR/TAP), member 11	Mus musculus	151-157
34387888-6	2022	RESULTS: GW4064 (30mg/kg/day) added to PN on days 4-14 prevented hepatic injury and cholestasis, reversed the suppressed mRNA expression of Nr1h4/FXR, Abcb11/BSEP, Abcc2, Abcb4, and Abcg5/8, and normalized serum bile acids.	GW 4064	9-15	ATP-binding cassette, sub-family B (MDR/TAP), member 11	Mus musculus	158-162
34387888-6	2022	RESULTS: GW4064 (30mg/kg/day) added to PN on days 4-14 prevented hepatic injury and cholestasis, reversed the suppressed mRNA expression of Nr1h4/FXR, Abcb11/BSEP, Abcc2, Abcb4, and Abcg5/8, and normalized serum bile acids.	GW 4064	9-15	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	164-169
34387888-6	2022	RESULTS: GW4064 (30mg/kg/day) added to PN on days 4-14 prevented hepatic injury and cholestasis, reversed the suppressed mRNA expression of Nr1h4/FXR, Abcb11/BSEP, Abcc2, Abcb4, and Abcg5/8, and normalized serum bile acids.	GW 4064	9-15	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	171-176
34387888-6	2022	RESULTS: GW4064 (30mg/kg/day) added to PN on days 4-14 prevented hepatic injury and cholestasis, reversed the suppressed mRNA expression of Nr1h4/FXR, Abcb11/BSEP, Abcc2, Abcb4, and Abcg5/8, and normalized serum bile acids.	GW 4064	9-15	ATP binding cassette subfamily G member 5	Mus musculus	182-189
34387888-7	2022	Chromatin-immunoprecipitation of liver showed that GW4064 increased FXR binding to the Abcb11 promoter.	GW 4064	51-57	nuclear receptor subfamily 1, group H, member 4	Mus musculus	68-71
34387888-7	2022	Chromatin-immunoprecipitation of liver showed that GW4064 increased FXR binding to the Abcb11 promoter.	GW 4064	51-57	ATP-binding cassette, sub-family B (MDR/TAP), member 11	Mus musculus	87-93
34387888-8	2022	Furthermore, GW4064 prevented DSS-PN-induced hepatic macrophage accumulation, hepatic expression of genes associated with macrophage recruitment and activation (ll1b, Ccr2, Itgam, Ly6C), and hepatic macrophage cytokine transcription in response to LPS in vitro.	GW 4064	13-19	chemokine (C-C motif) receptor 2	Mus musculus	167-171
34387888-8	2022	Furthermore, GW4064 prevented DSS-PN-induced hepatic macrophage accumulation, hepatic expression of genes associated with macrophage recruitment and activation (ll1b, Ccr2, Itgam, Ly6C), and hepatic macrophage cytokine transcription in response to LPS in vitro.	GW 4064	13-19	integrin alpha M	Mus musculus	173-178
34387888-8	2022	Furthermore, GW4064 prevented DSS-PN-induced hepatic macrophage accumulation, hepatic expression of genes associated with macrophage recruitment and activation (ll1b, Ccr2, Itgam, Ly6C), and hepatic macrophage cytokine transcription in response to LPS in vitro.	GW 4064	13-19	lymphocyte antigen 6 complex, locus C1	Mus musculus	180-184
34387888-9	2022	In primary mouse hepatocytes, GW4064 activated transcription of FXR canonical targets, irrespective of IL-1beta exposure.	GW 4064	30-36	nuclear receptor subfamily 1, group H, member 4	Mus musculus	64-67
34387888-10	2022	Intestinal inflammation and ileal mRNAs (Nr1h4, Fgf15 and Ostalpha) were not different among groups, supporting a liver specific effect of GW4064 in this model CONCLUSION: GW4064 prevents PNAC in mice through restoration of hepatic FXR signaling resulting in increased expression of canalicular bile, sterol and phospholipid transporters, and suppression of macrophage recruitment and activation.	GW 4064	172-178	nuclear receptor subfamily 1, group H, member 4	Mus musculus	41-46
34387888-10	2022	Intestinal inflammation and ileal mRNAs (Nr1h4, Fgf15 and Ostalpha) were not different among groups, supporting a liver specific effect of GW4064 in this model CONCLUSION: GW4064 prevents PNAC in mice through restoration of hepatic FXR signaling resulting in increased expression of canalicular bile, sterol and phospholipid transporters, and suppression of macrophage recruitment and activation.	GW 4064	172-178	fibroblast growth factor 15	Mus musculus	48-53
34387888-10	2022	Intestinal inflammation and ileal mRNAs (Nr1h4, Fgf15 and Ostalpha) were not different among groups, supporting a liver specific effect of GW4064 in this model CONCLUSION: GW4064 prevents PNAC in mice through restoration of hepatic FXR signaling resulting in increased expression of canalicular bile, sterol and phospholipid transporters, and suppression of macrophage recruitment and activation.	GW 4064	172-178	solute carrier family 51, alpha subunit	Mus musculus	58-66
34387888-10	2022	Intestinal inflammation and ileal mRNAs (Nr1h4, Fgf15 and Ostalpha) were not different among groups, supporting a liver specific effect of GW4064 in this model CONCLUSION: GW4064 prevents PNAC in mice through restoration of hepatic FXR signaling resulting in increased expression of canalicular bile, sterol and phospholipid transporters, and suppression of macrophage recruitment and activation.	GW 4064	172-178	nuclear receptor subfamily 1, group H, member 4	Mus musculus	232-235
34881818-7	2022	Application of GW4064, an activator of FXR, to microbiota eliminated mice markedly mitigated IR-induced intestinal damage, reduced intestinal epithelial cell death and promoted the survival of IR mice.	GW 4064	15-21	nuclear receptor subfamily 1, group H, member 4	Mus musculus	39-42
12052824-11	2002	In an in vitro co-activator association assay, LCA decreased CDCA- and GW4064-induced FXR activation with an IC(50) of 1 microm.	GW 4064	71-77	nuclear receptor subfamily 1 group H member 4	Homo sapiens	86-89
12052824-12	2002	In HepG2 cells, LCA also effectively antagonized GW4064-enhanced FXR transactivation.	GW 4064	49-55	nuclear receptor subfamily 1 group H member 4	Homo sapiens	65-68
11927623-9	2002	The nonsteroidal synthetic FXR agonist GW4064 likewise decreased apoA-I mRNA levels and promoter activity in HepG2 cells.	GW 4064	39-45	nuclear receptor subfamily 1 group H member 4	Homo sapiens	27-30
11927623-9	2002	The nonsteroidal synthetic FXR agonist GW4064 likewise decreased apoA-I mRNA levels and promoter activity in HepG2 cells.	GW 4064	39-45	apolipoprotein A1	Homo sapiens	65-71
11607932-3	2001	GW4064 is a potent and selective nonsteroidal ligand for the nuclear bile acid receptor FXR (NR1H4).	GW 4064	0-6	nuclear receptor subfamily 1 group H member 4	Homo sapiens	88-91
11607932-3	2001	GW4064 is a potent and selective nonsteroidal ligand for the nuclear bile acid receptor FXR (NR1H4).	GW 4064	0-6	nuclear receptor subfamily 1 group H member 4	Homo sapiens	93-98
11607932-4	2001	Using GW4064 as a chemical tool, we have identified genes regulated by FXR in the liver, including those involved in bile acid synthesis and transport.	GW 4064	6-12	nuclear receptor subfamily 1 group H member 4	Homo sapiens	71-74
25599407-7	2015	Interestingly, in contrast to its effect on islets from lean mice, the FXR agonist GW4064 was ineffective in stimulating insulin secretion of islets from wild type mice fed a HFD or isolated islets kept in a glucolipotoxic medium.	GW 4064	83-89	nuclear receptor subfamily 1, group H, member 4	Mus musculus	71-74
34387888-4	2022	METHODS: To induce PNAC, male C57BL/6 mice were subjected to intestinal injury (2% dextran sodium sulfate for 4 days) followed by central venous catheterization and 14 day-infusion of PN with or without the FXR agonist GW4064.	GW 4064	219-225	nuclear receptor subfamily 1, group H, member 4	Mus musculus	207-210
34870866-8	2021	Mice fed an iron-rich diet were co-administered the FXR agonist GW4064.	GW 4064	64-70	nuclear receptor subfamily 1, group H, member 4	Mus musculus	52-55
34256254-5	2021	Thus, we decided to develop non-steroidal FXR agonists and discovered a series of novel FXR agonists which were synthesized from GW4064 by replacing the stilbene group with ketoxime ether.	GW 4064	129-135	nuclear receptor subfamily 1 group H member 4	Homo sapiens	42-45
34888230-6	2021	Importantly, FXR agonist (GW4064) can synergize with anti-PD-1 antibody (Ab) to inhibit HCC growth in tumor-bearing models.	GW 4064	26-32	nuclear receptor subfamily 1 group H member 4	Homo sapiens	13-16
34145381-4	2021	HepG2 cells and primary hepatocytes were incubated with chenodeoxycholic acid (CDCA), glycochenodeoxycholic acid (GCDCA), ursodeoxycholic acid (UCDA), or the synthetic FXR agonist GW4064 for 24 h. MTT tests demonstrated cell viability throughout experiments.	GW 4064	180-186	nuclear receptor subfamily 1 group H member 4	Homo sapiens	168-171
34145381-6	2021	Increased TF activity alongside enhanced thrombin generation was observed with CDCA and GW4064 but not with GCDCA and UDCA.	GW 4064	88-94	coagulation factor II, thrombin	Homo sapiens	41-49
34145381-8	2021	Quantitative polymerase chain reaction revealed upregulation of FXR target genes only by CDCA and GW4064.	GW 4064	98-104	nuclear receptor subfamily 1 group H member 4	Homo sapiens	64-67
34406989-7	2021	Functional studies in vitro showed that activation of the FXR in primary cultured astrocytes by chenodeoxycholic acid or GW4064 induced a marked increase in expression levels of small heterodimer partner mRNA and protein.	GW 4064	121-127	nuclear receptor subfamily 1, group H, member 4	Mus musculus	58-61
34256254-5	2021	Thus, we decided to develop non-steroidal FXR agonists and discovered a series of novel FXR agonists which were synthesized from GW4064 by replacing the stilbene group with ketoxime ether.	GW 4064	129-135	nuclear receptor subfamily 1 group H member 4	Homo sapiens	88-91
35614513-13	2022	Moreover, the FXR agonist GW4064 decreased the proliferation of CC cells by repressing the expression of beta-catenin.	GW 4064	26-32	nuclear receptor subfamily 1, group H, member 4	Mus musculus	14-17
35451003-6	2022	Agonistic activation of Fxr (GW4064) in the LShpKO did not alter the elevated basal expression of Cyp8b1 but lowered Cyp7a1 expression.	GW 4064	29-35	nuclear receptor subfamily 1, group H, member 4	Mus musculus	24-27
35451003-6	2022	Agonistic activation of Fxr (GW4064) in the LShpKO did not alter the elevated basal expression of Cyp8b1 but lowered Cyp7a1 expression.	GW 4064	29-35	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	117-123
34366680-5	2021	In vitro, FXR synthetic ligand GW4064 was used to detect the effects on ESCC cell proliferation, migration, apoptosis and cell cycles.	GW 4064	31-37	nuclear receptor subfamily 1, group H, member 4	Mus musculus	10-13
34366680-8	2021	Results: FXR synthetic ligand GW4064 impaired esophageal squamous cell carcinoma (ESCC) proliferation and migration, induced apoptosis and cell cycle arrest in vitro, accompanied by inhibition of some inflammatory genes and promotion of pro-apoptotic genes.	GW 4064	30-36	nuclear receptor subfamily 1, group H, member 4	Mus musculus	9-12
34366680-10	2021	Consistent with these results, GW4064 suppressed ESCC tumorigenesis in a xenograft model and suppressed the phosphorylation of ERK1/2 in tumors.	GW 4064	31-37	mitogen-activated protein kinase 3	Mus musculus	127-133
35614513-13	2022	Moreover, the FXR agonist GW4064 decreased the proliferation of CC cells by repressing the expression of beta-catenin.	GW 4064	26-32	catenin (cadherin associated protein), beta 1	Mus musculus	105-117
35216094-7	2022	FXR expressed in the intestinal epithelial cells is absolutely required for sustaining a basal expression of intestinal Trpm6 that can be robustly induced by the treatment of GW4064, a synthetic FXR agonist.	GW 4064	175-181	nuclear receptor subfamily 1, group H, member 4	Mus musculus	0-3
34998040-5	2022	Here we report the synthesis and characterization of compound HEC96719 a novel tricyclic FXR agonist based on a prior high-affinity nonsteroidal molecule GW4064.	GW 4064	154-160	nuclear receptor subfamily 1 group H member 4	Homo sapiens	89-92
34998040-6	2022	HEC96719 exhibits excellent potency superior to GW4064 and obeticholic acid in in vitro and in vivo assays of FXR activation.	GW 4064	48-54	nuclear receptor subfamily 1 group H member 4	Homo sapiens	110-113
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	GW 4064	298-304	solute carrier family 10 member 2	Homo sapiens	69-114
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	GW 4064	298-304	solute carrier family 10 member 2	Homo sapiens	116-120
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	GW 4064	298-304	fatty acid binding protein 6	Homo sapiens	127-158
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	GW 4064	298-304	fatty acid binding protein 6	Homo sapiens	160-165
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	GW 4064	298-304	solute carrier family 51 subunit alpha	Homo sapiens	175-207
35224661-7	2022	Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes.	GW 4064	298-304	solute carrier family 51 subunit alpha	Homo sapiens	209-217
35224782-7	2022	We showed that GW4064 obviously ameliorated subchondral bone deterioration, associated with reduction in tartrate-resistant acid phosphatase (TRAP) positive multinuclear osteoclast number, as well as articular cartilage degradation, which were blocked by the treatment with FXR antagonist Guggulsterone.	GW 4064	15-21	acid phosphatase 5, tartrate resistant	Mus musculus	105-140
35224782-7	2022	We showed that GW4064 obviously ameliorated subchondral bone deterioration, associated with reduction in tartrate-resistant acid phosphatase (TRAP) positive multinuclear osteoclast number, as well as articular cartilage degradation, which were blocked by the treatment with FXR antagonist Guggulsterone.	GW 4064	15-21	acid phosphatase 5, tartrate resistant	Mus musculus	142-146
35224782-7	2022	We showed that GW4064 obviously ameliorated subchondral bone deterioration, associated with reduction in tartrate-resistant acid phosphatase (TRAP) positive multinuclear osteoclast number, as well as articular cartilage degradation, which were blocked by the treatment with FXR antagonist Guggulsterone.	GW 4064	15-21	nuclear receptor subfamily 1, group H, member 4	Mus musculus	274-277
35224782-8	2022	Mechanistically, GW4064 impeded osteoclastogenesis through inhibiting subchondral bone osteoclast fusion via suppressing c-Jun N-terminal kinase (JNK) 1/2/nuclear factor of activated T-cells 1 (NFATc1) pathway.	GW 4064	17-23	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	194-200
35216094-7	2022	FXR expressed in the intestinal epithelial cells is absolutely required for sustaining a basal expression of intestinal Trpm6 that can be robustly induced by the treatment of GW4064, a synthetic FXR agonist.	GW 4064	175-181	transient receptor potential cation channel, subfamily M, member 6	Mus musculus	120-125
35216094-7	2022	FXR expressed in the intestinal epithelial cells is absolutely required for sustaining a basal expression of intestinal Trpm6 that can be robustly induced by the treatment of GW4064, a synthetic FXR agonist.	GW 4064	175-181	nuclear receptor subfamily 1, group H, member 4	Mus musculus	195-198
35058750-5	2021	We studied the role of FXR in brain control of energy homeostasis by treating wild-type and FXR-deficient mice by intracerebroventricular (ICV) injection with the reference FXR agonist GW4064.	GW 4064	185-191	nuclear receptor subfamily 1, group H, member 4	Mus musculus	173-176
33399988-4	2021	METHODS: We treated db/db mice with the FXR agonist GW4064 for 3 months and evaluated insulin resistance, lipid metabolism, renal functional changes, and structural changes in organs including those of the kidney, liver, pancreas, adipose tissue, aorta, and heart.	GW 4064	52-58	nuclear receptor subfamily 1, group H, member 4	Mus musculus	40-43
33895309-7	2021	FRET-based real-time monitoring of FXR activity revealed that isoCDCA>CDCA stimulated FXR, and isoDCA and isoUDCA allowed fully activated FXR to be re-stimulated by a second dose of GW4064.	GW 4064	182-188	nuclear receptor subfamily 1, group H, member 4	Mus musculus	35-38
33895309-8	2021	In vivo co-administration of a single dose of isoBAs followed by GW4064 cooperatively activated FXR, as did feeding of UDCA in a background of endogenous FXR ligands.	GW 4064	65-71	nuclear receptor subfamily 1, group H, member 4	Mus musculus	96-99
33968024-5	2021	Since CDCA is a well-known natural high-affinity ligand for the bile acid receptor farnesoid-x-receptor (FXR) while GW4064 is the synthetic specific agonist of this receptor, we then revealed that GW4064 significantly decreased IL-6 expression in RAW 264.7 cells and bone marrow-derived macrophages but not in FXR-/- macrophages upon LPS stimulation.	GW 4064	197-203	nuclear receptor subfamily 1, group H, member 4	Mus musculus	83-103
33968024-5	2021	Since CDCA is a well-known natural high-affinity ligand for the bile acid receptor farnesoid-x-receptor (FXR) while GW4064 is the synthetic specific agonist of this receptor, we then revealed that GW4064 significantly decreased IL-6 expression in RAW 264.7 cells and bone marrow-derived macrophages but not in FXR-/- macrophages upon LPS stimulation.	GW 4064	197-203	nuclear receptor subfamily 1, group H, member 4	Mus musculus	105-108
33968024-5	2021	Since CDCA is a well-known natural high-affinity ligand for the bile acid receptor farnesoid-x-receptor (FXR) while GW4064 is the synthetic specific agonist of this receptor, we then revealed that GW4064 significantly decreased IL-6 expression in RAW 264.7 cells and bone marrow-derived macrophages but not in FXR-/- macrophages upon LPS stimulation.	GW 4064	197-203	interleukin 6	Mus musculus	228-232
33968024-5	2021	Since CDCA is a well-known natural high-affinity ligand for the bile acid receptor farnesoid-x-receptor (FXR) while GW4064 is the synthetic specific agonist of this receptor, we then revealed that GW4064 significantly decreased IL-6 expression in RAW 264.7 cells and bone marrow-derived macrophages but not in FXR-/- macrophages upon LPS stimulation.	GW 4064	197-203	nuclear receptor subfamily 1, group H, member 4	Mus musculus	310-313
34045606-7	2021	Finally, using the synthetic, non-bile acid, FXR-agonist GW4064, we show that some of these effects are mediated through direct or indirect activation of FXR.	GW 4064	57-63	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	45-48
34045606-7	2021	Finally, using the synthetic, non-bile acid, FXR-agonist GW4064, we show that some of these effects are mediated through direct or indirect activation of FXR.	GW 4064	57-63	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	154-157
32662640-4	2020	M4 also significantly increased the expression of farnesoid X receptor (FXR), suppressed the purinergic ligand-gated ion channel 7 receptor (P2X7r) signaling pathway, and works as an FXR agonist, GW4064.	GW 4064	196-202	nuclear receptor subfamily 1, group H, member 4	Mus musculus	183-186
32846898-5	2020	FXR agonists chenodeoxycholic acid (CDCA) and GW4064 stimulated OCT2-mediated 3H-MPP+ uptake in human renal proximal tubular cells (RPTEC/TERT1 cells) and OCT2-CHO-K1 cells.	GW 4064	46-52	nuclear receptor subfamily 1 group H member 4	Homo sapiens	0-3
32846898-5	2020	FXR agonists chenodeoxycholic acid (CDCA) and GW4064 stimulated OCT2-mediated 3H-MPP+ uptake in human renal proximal tubular cells (RPTEC/TERT1 cells) and OCT2-CHO-K1 cells.	GW 4064	46-52	POU class 2 homeobox 2	Homo sapiens	64-68
32846898-5	2020	FXR agonists chenodeoxycholic acid (CDCA) and GW4064 stimulated OCT2-mediated 3H-MPP+ uptake in human renal proximal tubular cells (RPTEC/TERT1 cells) and OCT2-CHO-K1 cells.	GW 4064	46-52	POU class 2 homeobox 2	Homo sapiens	155-159
33311703-7	2020	Importantly, molecular modeling-based screening confirmed the action of the miR-21-targeting drug ivermectin and led to the identification of a new effective derivative, GW4064, for inhibiting oncogenic DDX23-miR-21 signaling.	GW 4064	170-176	microRNA 21	Homo sapiens	76-82
33311703-7	2020	Importantly, molecular modeling-based screening confirmed the action of the miR-21-targeting drug ivermectin and led to the identification of a new effective derivative, GW4064, for inhibiting oncogenic DDX23-miR-21 signaling.	GW 4064	170-176	DEAD-box helicase 23	Homo sapiens	203-208
33311703-7	2020	Importantly, molecular modeling-based screening confirmed the action of the miR-21-targeting drug ivermectin and led to the identification of a new effective derivative, GW4064, for inhibiting oncogenic DDX23-miR-21 signaling.	GW 4064	170-176	microRNA 21	Homo sapiens	209-215
32341465-8	2020	Farnesoid X receptor (FXR) inhibitor glycine-beta-muricholic acid or FXR knockdown reversed the downregulation of PepT1 expression by CDCA and GW4064 (another FXR agonist).	GW 4064	143-149	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	0-20
32341465-8	2020	Farnesoid X receptor (FXR) inhibitor glycine-beta-muricholic acid or FXR knockdown reversed the downregulation of PepT1 expression by CDCA and GW4064 (another FXR agonist).	GW 4064	143-149	nuclear receptor subfamily 1 group H member 4	Homo sapiens	22-25
32341465-8	2020	Farnesoid X receptor (FXR) inhibitor glycine-beta-muricholic acid or FXR knockdown reversed the downregulation of PepT1 expression by CDCA and GW4064 (another FXR agonist).	GW 4064	143-149	nuclear receptor subfamily 1 group H member 4	Homo sapiens	69-72
32341465-8	2020	Farnesoid X receptor (FXR) inhibitor glycine-beta-muricholic acid or FXR knockdown reversed the downregulation of PepT1 expression by CDCA and GW4064 (another FXR agonist).	GW 4064	143-149	solute carrier family 15 member 1	Homo sapiens	114-119
32341465-8	2020	Farnesoid X receptor (FXR) inhibitor glycine-beta-muricholic acid or FXR knockdown reversed the downregulation of PepT1 expression by CDCA and GW4064 (another FXR agonist).	GW 4064	143-149	nuclear receptor subfamily 1 group H member 4	Homo sapiens	69-72
31744088-3	2019	In this study, we synthesized novel FXR agonists 1-4 possessing isoxazole and N-substituted benzimidazole moieties, and compared their effects on osteoblast differentiation with the known FXR agonists, chenodeoxycholic acid and a synthetic compound, GW4064.	GW 4064	250-256	nuclear receptor subfamily 1, group H, member 4	Mus musculus	36-39
32258949-4	2020	Pretreatment of mice with FXR agonist 3-(2,6-dichlorophenyl)-4-(3"-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole (GW4064) attenuated liver ischemia/reperfusion injuries (IRIs) in wild-type but not FXR knockout mice.	GW 4064	128-134	nuclear receptor subfamily 1, group H, member 4	Mus musculus	26-29
32258949-7	2020	Pretreatment of KCs but not BMMs with GW4064 resulted in lower tumor necrosis factor alpha but higher interleukin-10 expressions following toll-like receptor stimulation.	GW 4064	38-44	tumor necrosis factor	Mus musculus	63-90
32258949-7	2020	Pretreatment of KCs but not BMMs with GW4064 resulted in lower tumor necrosis factor alpha but higher interleukin-10 expressions following toll-like receptor stimulation.	GW 4064	38-44	interleukin 10	Mus musculus	102-116
32258949-8	2020	FXR-targeted gene small heterodimer partner (SHP) was critical for the regulation of KC response by GW4064.	GW 4064	100-106	nuclear receptor subfamily 1, group H, member 4	Mus musculus	0-3
32258949-8	2020	FXR-targeted gene small heterodimer partner (SHP) was critical for the regulation of KC response by GW4064.	GW 4064	100-106	nuclear receptor subfamily 0, group B, member 2	Mus musculus	45-48
31911244-6	2020	Mechanistically, GW4064, an FXR agonist, was carried out to verify the mechanisms of geniposide in human HepG2 and Caco2 cells.	GW 4064	17-23	nuclear receptor subfamily 1 group H member 4	Homo sapiens	28-31
31932631-4	2020	GLP-1 secretion in response to SCFAs was evaluated ex vivo in murine colonic biopsies and in colonoids of wild-type (WT) and FXR knock-out (KO) mice, in vitro in GLUTag and NCI-H716 L-cells activated with the synthetic FXR agonist GW4064 and in vivo in WT and FXR KO mice after prebiotic supplementation.	GW 4064	231-237	glucagon	Mus musculus	0-5
31932631-5	2020	SCFA-induced GLP-1 secretion was blunted in colonic biopsies from GW4064-treated mice and enhanced in FXR KO colonoids.	GW 4064	66-72	glucagon	Mus musculus	13-18
31779647-4	2019	Their correlations were analyzed by Pearson"s test and verified by the introduction of FXR agonist, GW4064.	GW 4064	100-106	nuclear receptor subfamily 1 group H member 4	Homo sapiens	87-90
31779647-10	2019	As CCNG1 is a target for miR-23b-3p, the treatment of GW4064 induced the downregulation of CCNG1 through upregulating miR-23b-3p.	GW 4064	54-60	cyclin G1	Homo sapiens	3-8
31779647-10	2019	As CCNG1 is a target for miR-23b-3p, the treatment of GW4064 induced the downregulation of CCNG1 through upregulating miR-23b-3p.	GW 4064	54-60	microRNA 23b	Homo sapiens	25-32
31779647-10	2019	As CCNG1 is a target for miR-23b-3p, the treatment of GW4064 induced the downregulation of CCNG1 through upregulating miR-23b-3p.	GW 4064	54-60	cyclin G1	Homo sapiens	91-96
31561852-3	2019	We evaluated pharmacological activation of FXR with the synthetic agonist GW4064 using comprehensive proteomic analysis in colorectal cancer cell lines (HCT116, SW480, and DLD1).	GW 4064	74-80	nuclear receptor subfamily 1 group H member 4	Homo sapiens	43-46
31561852-9	2019	Co-treatment of TRAIL with GW4064 synergistically inhibited colorectal cancer cell proliferation as compared with single treatments.	GW 4064	27-33	TNF superfamily member 10	Homo sapiens	16-21
31905247-7	2020	It was consistently indicated that digeranyl bisphosphonate, a specific inhibitor of GGPPS, and GW4064, an agonist of FXR, could also alleviate acute obstructive cholestatic liver injury in vivo.	GW 4064	96-102	nuclear receptor subfamily 1, group H, member 4	Mus musculus	118-121
32565960-5	2020	Gain- and loss-of-function studies were conducted by transfecting colon cancer cells with FXR siRNA and treating them with the FXR agonist GW4064.	GW 4064	139-145	nuclear receptor subfamily 1 group H member 4	Homo sapiens	127-130
32565960-9	2020	The FXR agonist GW4064 significantly inhibited the proliferation of cells but promoted the transcriptional activity of beta-catenin.	GW 4064	16-22	nuclear receptor subfamily 1 group H member 4	Homo sapiens	4-7
32565960-9	2020	The FXR agonist GW4064 significantly inhibited the proliferation of cells but promoted the transcriptional activity of beta-catenin.	GW 4064	16-22	catenin beta 1	Homo sapiens	119-131
32145254-4	2020	C57BL/6 mice or primary cultured mouse hepatocytes were treated with the synthetic FXR ligand GW4064 or natural ligand CDCA.	GW 4064	94-100	nuclear receptor subfamily 1, group H, member 4	Mus musculus	83-86
32145254-6	2020	Real-time PCR and Western blot were applied to determine the expression of MT1 and other FXR target genes in the livers of mice and primary hepatocytes treated with GW4064 and CDCA.	GW 4064	165-171	metallothionein 1	Mus musculus	75-78
32145254-6	2020	Real-time PCR and Western blot were applied to determine the expression of MT1 and other FXR target genes in the livers of mice and primary hepatocytes treated with GW4064 and CDCA.	GW 4064	165-171	nuclear receptor subfamily 1, group H, member 4	Mus musculus	89-92
32145254-7	2020	Cellular and subcellular locations of MT1 in the livers of mice treated with GW4064 were examined using immunohistochemistry assay.	GW 4064	77-83	metallothionein 1	Mus musculus	38-41
32145254-10	2020	RNA-seq analysis revealed that GW4064 treatment significantly induced MT1 expression in mouse liver.	GW 4064	31-37	metallothionein 1	Mus musculus	70-73
32145254-11	2020	Consistently, MT1 expression in the hepatocytes of mouse livers and cultured hepatocytes was upregulated by GW4064 as well as CDCA.	GW 4064	108-114	metallothionein 1	Mus musculus	14-17
31911428-12	2020	Extended stimulation of FXR by the synthetic agonist GW4064, which is suggested to induce translocation of FXR from the cytosol into the nucleus, increased the inhibitory effect of atorvastatin.	GW 4064	53-59	nuclear receptor subfamily 1, group H, member 4	Mus musculus	24-27
31911428-12	2020	Extended stimulation of FXR by the synthetic agonist GW4064, which is suggested to induce translocation of FXR from the cytosol into the nucleus, increased the inhibitory effect of atorvastatin.	GW 4064	53-59	nuclear receptor subfamily 1, group H, member 4	Mus musculus	107-110
31836014-12	2019	The FXR agonist GW4064 significantly decreased the fasting blood glucose in mice challenged with FK506 for 3 months (P < 0.05), inhibited gluconeogenesis (P < 0.05) and significantly promoted glucose uptake (P < 0.05).	GW 4064	16-22	nuclear receptor subfamily 1, group H, member 4	Mus musculus	4-7
31779647-10	2019	As CCNG1 is a target for miR-23b-3p, the treatment of GW4064 induced the downregulation of CCNG1 through upregulating miR-23b-3p.	GW 4064	54-60	microRNA 23b	Homo sapiens	118-125
31779647-11	2019	The inhibition of miR-23b-3p obviously promoted cell viability, proliferation, and cell cycle progression but reduced apoptosis rate of MG-63 cells; however, the treatment of GW4064 could partially reverse the effects of the inhibition of miR-23b-3p on OS cells.	GW 4064	175-181	microRNA 23b	Homo sapiens	18-25
31779647-11	2019	The inhibition of miR-23b-3p obviously promoted cell viability, proliferation, and cell cycle progression but reduced apoptosis rate of MG-63 cells; however, the treatment of GW4064 could partially reverse the effects of the inhibition of miR-23b-3p on OS cells.	GW 4064	175-181	microRNA 23b	Homo sapiens	239-246
31779647-12	2019	CONCLUSIONS: Upregulated FXR by GW4064 can obviously suppress OS cell development, and the suppressive effects may rely on miR-23b-3p/CCNG1 pathway.	GW 4064	32-38	nuclear receptor subfamily 1 group H member 4	Homo sapiens	25-28
31744088-5	2019	Computer-assisted modeling suggested that the binding of the FXR agonist 3 with ligand binding domain of FXR was similar to GW4064.	GW 4064	124-130	nuclear receptor subfamily 1, group H, member 4	Mus musculus	61-64
31744088-5	2019	Computer-assisted modeling suggested that the binding of the FXR agonist 3 with ligand binding domain of FXR was similar to GW4064.	GW 4064	124-130	nuclear receptor subfamily 1, group H, member 4	Mus musculus	105-108
31191298-4	2019	The BSEP upstream molecule farnesoid X receptor was down-regulated by small interfering RNA (siRNA) technology or guggulsterones and up-regulated by lentivirus or GW4064.	GW 4064	163-169	ATP binding cassette subfamily B member 11	Rattus norvegicus	4-8
31298930-4	2019	Here, we show that agonist GW4064-mediated FXR activation inhibits the activity of the nonreceptor tyrosine kinase Src (proto-oncogene tyrosine-protein kinase), which is critical for regulation of yes-associated protein (YAP) phosphorylation and nuclear localization in renal fibrosis.	GW 4064	27-33	nuclear receptor subfamily 1, group H, member 4	Mus musculus	43-46
31298930-4	2019	Here, we show that agonist GW4064-mediated FXR activation inhibits the activity of the nonreceptor tyrosine kinase Src (proto-oncogene tyrosine-protein kinase), which is critical for regulation of yes-associated protein (YAP) phosphorylation and nuclear localization in renal fibrosis.	GW 4064	27-33	Rous sarcoma oncogene	Mus musculus	115-118
31298930-4	2019	Here, we show that agonist GW4064-mediated FXR activation inhibits the activity of the nonreceptor tyrosine kinase Src (proto-oncogene tyrosine-protein kinase), which is critical for regulation of yes-associated protein (YAP) phosphorylation and nuclear localization in renal fibrosis.	GW 4064	27-33	yes-associated protein 1	Mus musculus	197-219
31298930-4	2019	Here, we show that agonist GW4064-mediated FXR activation inhibits the activity of the nonreceptor tyrosine kinase Src (proto-oncogene tyrosine-protein kinase), which is critical for regulation of yes-associated protein (YAP) phosphorylation and nuclear localization in renal fibrosis.	GW 4064	27-33	yes-associated protein 1	Mus musculus	221-224
31298930-6	2019	Moreover, GW4064 treatment in HK2 cells increased Ser127 phosphorylation, cytosolic accumulation of YAP, and interaction of the hippo core kinases (Ste20-like kinase 1, large tumor suppressor kinase 1, and salvador homolog 1).	GW 4064	10-16	yes-associated protein 1	Mus musculus	100-103
31298930-6	2019	Moreover, GW4064 treatment in HK2 cells increased Ser127 phosphorylation, cytosolic accumulation of YAP, and interaction of the hippo core kinases (Ste20-like kinase 1, large tumor suppressor kinase 1, and salvador homolog 1).	GW 4064	10-16	salvador family WW domain containing 1	Mus musculus	148-224
30920307-0	2019	FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.	GW 4064	12-18	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	0-3
30920307-6	2019	After intervention with the FXR agonist GW4064, both the liver histology and serum transaminase activity were improved, which demonstrated the attenuation of SBR-ALD.	GW 4064	40-46	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	28-31
30920307-11	2019	This study showed that the FXR agonist GW4064 could correct BA dysmetabolism to alleviate hepatotoxicity in SBR animals.	GW 4064	39-45	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	27-30
30920307-14	2019	Concomitantly, FXR activation in the presence of GW4064 decreased BA production by repressing the expression of key synthetases, including CYP7A1, CYP8B1, and CYP27A1.	GW 4064	49-55	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	15-18
30920307-14	2019	Concomitantly, FXR activation in the presence of GW4064 decreased BA production by repressing the expression of key synthetases, including CYP7A1, CYP8B1, and CYP27A1.	GW 4064	49-55	cytochrome P450 family 7 subfamily A member 1	Rattus norvegicus	139-145
30920307-14	2019	Concomitantly, FXR activation in the presence of GW4064 decreased BA production by repressing the expression of key synthetases, including CYP7A1, CYP8B1, and CYP27A1.	GW 4064	49-55	cytochrome P450 family 8 subfamily B member 1	Rattus norvegicus	147-153
30920307-14	2019	Concomitantly, FXR activation in the presence of GW4064 decreased BA production by repressing the expression of key synthetases, including CYP7A1, CYP8B1, and CYP27A1.	GW 4064	49-55	cytochrome P450, family 27, subfamily a, polypeptide 1	Rattus norvegicus	159-166
30920307-15	2019	These findings provide a clinical research direction for the prevention of liver disease in patients with SBS.NEW & NOTEWORTHY This study assessed the impact of treatment with GW4064, a farnesoid X receptor agonist, on the development of short bowel resection (SBR) associated with liver disease in a rat model of SBR.	GW 4064	180-186	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	200-210
30864232-8	2019	However, response to FXR synthetic ligands was maintained in DKO mice as treatment with GW4064 resulted in similar changes in gene expression in all strains of mice.	GW 4064	88-94	nuclear receptor subfamily 1, group H, member 4	Mus musculus	21-24
31095863-8	2019	Knockdown of CYP7A1 via small interfering RNA or activation of FXR by GW4064 blocks the effect of TMAO-induced lipogenesis in palmitic acid-treated HepG2 cells.	GW 4064	70-76	nuclear receptor subfamily 1 group H member 4	Homo sapiens	63-66
30428773-0	2019	Farnesoid X Receptor Agonist GW4064 Inhibits Aromatase and ERbeta Expression in Human Endometriotic Stromal Cells.	GW 4064	29-35	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	10-20
30428773-0	2019	Farnesoid X Receptor Agonist GW4064 Inhibits Aromatase and ERbeta Expression in Human Endometriotic Stromal Cells.	GW 4064	29-35	estrogen receptor 2	Homo sapiens	59-65
30428773-4	2019	Here, we aimed to investigate whether FXR activation by its synthetic agonist GW4064 has a therapeutic effect on endometriosis and the underlying molecular mechanisms.	GW 4064	78-84	nuclear receptor subfamily 1 group H member 4	Homo sapiens	38-41
30428773-6	2019	The GW4064 treatment led to a dose-dependent decrease in aromatase and estrogen receptor beta (ERbeta) expression and induced ERK1/2, p38, AMPK, and Stat3 activation in ESCs.	GW 4064	4-10	estrogen receptor 2	Homo sapiens	71-93
30428773-6	2019	The GW4064 treatment led to a dose-dependent decrease in aromatase and estrogen receptor beta (ERbeta) expression and induced ERK1/2, p38, AMPK, and Stat3 activation in ESCs.	GW 4064	4-10	estrogen receptor 2	Homo sapiens	95-101
30428773-6	2019	The GW4064 treatment led to a dose-dependent decrease in aromatase and estrogen receptor beta (ERbeta) expression and induced ERK1/2, p38, AMPK, and Stat3 activation in ESCs.	GW 4064	4-10	mitogen-activated protein kinase 3	Homo sapiens	126-132
30428773-6	2019	The GW4064 treatment led to a dose-dependent decrease in aromatase and estrogen receptor beta (ERbeta) expression and induced ERK1/2, p38, AMPK, and Stat3 activation in ESCs.	GW 4064	4-10	mitogen-activated protein kinase 1	Homo sapiens	134-137
30428773-6	2019	The GW4064 treatment led to a dose-dependent decrease in aromatase and estrogen receptor beta (ERbeta) expression and induced ERK1/2, p38, AMPK, and Stat3 activation in ESCs.	GW 4064	4-10	signal transducer and activator of transcription 3	Homo sapiens	149-154
30428773-7	2019	In contrast, ERK1/2 inhibitor reversed the GW4064-induced reduction in aromatase expression.	GW 4064	43-49	mitogen-activated protein kinase 3	Homo sapiens	13-19
30428773-8	2019	In addition, treatment with p38, AMPK, and Stat3 inhibitors or small interfering RNAs could also reverse the GW4064-induced reduction of ERbeta expression in ESCs.	GW 4064	109-115	mitogen-activated protein kinase 1	Homo sapiens	28-31
30428773-8	2019	In addition, treatment with p38, AMPK, and Stat3 inhibitors or small interfering RNAs could also reverse the GW4064-induced reduction of ERbeta expression in ESCs.	GW 4064	109-115	signal transducer and activator of transcription 3	Homo sapiens	43-48
30428773-8	2019	In addition, treatment with p38, AMPK, and Stat3 inhibitors or small interfering RNAs could also reverse the GW4064-induced reduction of ERbeta expression in ESCs.	GW 4064	109-115	estrogen receptor 2	Homo sapiens	137-143
30428773-9	2019	The GW4064 treatment markedly increased Stat3 phosphorylation, enhancing the binding of Stat3 to the ESR2 promoter, which resulted in the downregulation of ERbeta.	GW 4064	4-10	signal transducer and activator of transcription 3	Homo sapiens	40-45
30428773-9	2019	The GW4064 treatment markedly increased Stat3 phosphorylation, enhancing the binding of Stat3 to the ESR2 promoter, which resulted in the downregulation of ERbeta.	GW 4064	4-10	signal transducer and activator of transcription 3	Homo sapiens	88-93
30428773-9	2019	The GW4064 treatment markedly increased Stat3 phosphorylation, enhancing the binding of Stat3 to the ESR2 promoter, which resulted in the downregulation of ERbeta.	GW 4064	4-10	estrogen receptor 2	Homo sapiens	101-105
30428773-9	2019	The GW4064 treatment markedly increased Stat3 phosphorylation, enhancing the binding of Stat3 to the ESR2 promoter, which resulted in the downregulation of ERbeta.	GW 4064	4-10	estrogen receptor 2	Homo sapiens	156-162
30428773-10	2019	Coimmunoprecipitation assay and chromatin immunoprecipitation analysis revealed that FXR was able to compete with cyclic AMP response element-binding (CREB) protein for binding to a common sequence on the aromatase promoter region after GW4064 treatment in ESCs.	GW 4064	237-243	nuclear receptor subfamily 1 group H member 4	Homo sapiens	85-88
30428773-10	2019	Coimmunoprecipitation assay and chromatin immunoprecipitation analysis revealed that FXR was able to compete with cyclic AMP response element-binding (CREB) protein for binding to a common sequence on the aromatase promoter region after GW4064 treatment in ESCs.	GW 4064	237-243	cAMP responsive element binding protein 1	Homo sapiens	151-155
30428773-11	2019	Moreover, treatment of endometriosis xenografts with GW4064 suppressed aromatase and ERbeta expression in nude mice.	GW 4064	53-59	estrogen receptor 2 (beta)	Mus musculus	85-91
30902657-0	2019	Farnesoid X receptor agonist GW4064 indirectly inhibits HCV entry into cells via down-regulating scavenger receptor class B type I. Farnesoid X receptor (FXR) agonists play important regulatory roles in bile acid, lipid and glucose metabolism in vitro and in vivo.	GW 4064	29-35	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	10-20
30902657-0	2019	Farnesoid X receptor agonist GW4064 indirectly inhibits HCV entry into cells via down-regulating scavenger receptor class B type I. Farnesoid X receptor (FXR) agonists play important regulatory roles in bile acid, lipid and glucose metabolism in vitro and in vivo.	GW 4064	29-35	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	142-152
30902657-0	2019	Farnesoid X receptor agonist GW4064 indirectly inhibits HCV entry into cells via down-regulating scavenger receptor class B type I. Farnesoid X receptor (FXR) agonists play important regulatory roles in bile acid, lipid and glucose metabolism in vitro and in vivo.	GW 4064	29-35	nuclear receptor subfamily 1 group H member 4	Homo sapiens	154-157
30902657-2	2019	This study investigated the effect and mechanism of FXR agonist GW4064 against HCV in vitro to explore the potential application of FXR agonists.	GW 4064	64-70	nuclear receptor subfamily 1 group H member 4	Homo sapiens	52-55
30902657-4	2019	GW4064 down-regulated the expression of scavenger receptor class B type I protein via FXR and thereby indirectly inhibited HCV entry into cells, leading to interruption of HCV life cycle.	GW 4064	0-6	nuclear receptor subfamily 1 group H member 4	Homo sapiens	86-89
31191305-3	2019	FNDC5 expression was highly induced by CDCA and GW4064 in hepatocytes, HepG2 cells, and the circulating level of Irisin increased in Rhesus macaques.	GW 4064	48-54	fibronectin type III domain containing 5	Homo sapiens	0-5
30768114-6	2019	This regulation was associated with the alterations in the expression of target genes in the enterohepatic farnesoid X receptor-fibroblast growth factor (FXR-FGF15) axis and could be reversed using an FXR agonist, GW4064.	GW 4064	214-220	nuclear receptor subfamily 1, group H, member 4	Mus musculus	154-157
30229432-4	2019	Furthermore, the reported agonists for the expression of DGKtheta, cAMP and GW4064, the known inhibitor for DGKtheta enzyme activity, R59949, and a potential regulator for DGKtheta enzyme expression, EGCG (the major catechin in green tea), were applied to the reporter cell line.	GW 4064	76-82	diacylglycerol kinase theta	Homo sapiens	108-116
30229432-4	2019	Furthermore, the reported agonists for the expression of DGKtheta, cAMP and GW4064, the known inhibitor for DGKtheta enzyme activity, R59949, and a potential regulator for DGKtheta enzyme expression, EGCG (the major catechin in green tea), were applied to the reporter cell line.	GW 4064	76-82	diacylglycerol kinase theta	Homo sapiens	108-116
30768114-6	2019	This regulation was associated with the alterations in the expression of target genes in the enterohepatic farnesoid X receptor-fibroblast growth factor (FXR-FGF15) axis and could be reversed using an FXR agonist, GW4064.	GW 4064	214-220	fibroblast growth factor 15	Mus musculus	158-163
30768114-6	2019	This regulation was associated with the alterations in the expression of target genes in the enterohepatic farnesoid X receptor-fibroblast growth factor (FXR-FGF15) axis and could be reversed using an FXR agonist, GW4064.	GW 4064	214-220	nuclear receptor subfamily 1, group H, member 4	Mus musculus	201-204
30176263-3	2018	We showed that FXR is expressed in human CAFs isolated from four patients and treatment with the selective FXR agonist GW4064 decreased CAF migration, stress-fiber formation and contractility.	GW 4064	119-125	nuclear receptor subfamily 1 group H member 4	Homo sapiens	15-18
30747230-5	2019	Conversely, the FXR agonist GW4064 synergistically enhanced bile acid-induced CDX2 promoter activity.	GW 4064	28-34	nuclear receptor subfamily 1 group H member 4	Homo sapiens	16-19
30747230-5	2019	Conversely, the FXR agonist GW4064 synergistically enhanced bile acid-induced CDX2 promoter activity.	GW 4064	28-34	caudal type homeobox 2	Homo sapiens	78-82
30747230-9	2019	Treatment with GW4064 or Z-guggulsterone enhanced and attenuated the binding activity of p50 to the CDX2 promoter, respectively.	GW 4064	15-21	nuclear factor kappa B subunit 1	Homo sapiens	89-92
30747230-9	2019	Treatment with GW4064 or Z-guggulsterone enhanced and attenuated the binding activity of p50 to the CDX2 promoter, respectively.	GW 4064	15-21	caudal type homeobox 2	Homo sapiens	100-104
30996771-3	2019	In this Letter, we have elaborated on the structure of GW4064, the first nonsteroidal agonist for FXR, to identify novel isoxazoles endowed with FXR agonistic activity and improved ADME properties.	GW 4064	55-61	nuclear receptor subfamily 1, group H, member 4	Mus musculus	98-101
30996771-3	2019	In this Letter, we have elaborated on the structure of GW4064, the first nonsteroidal agonist for FXR, to identify novel isoxazoles endowed with FXR agonistic activity and improved ADME properties.	GW 4064	55-61	nuclear receptor subfamily 1, group H, member 4	Mus musculus	145-148
30307769-4	2019	Treatment with the FXRalpha agonist GW4064 inhibited FXRalpha proviral effect on cccDNA similarly for wild-type and hepatitis B viral X protein (HBx)-deficient virus, whereas agonist-induced inhibition of pregenomic and precore RNA transcription and viral DNA secretion was HBx dependent.	GW 4064	36-42	X protein	Hepatitis B virus	145-148
30307769-4	2019	Treatment with the FXRalpha agonist GW4064 inhibited FXRalpha proviral effect on cccDNA similarly for wild-type and hepatitis B viral X protein (HBx)-deficient virus, whereas agonist-induced inhibition of pregenomic and precore RNA transcription and viral DNA secretion was HBx dependent.	GW 4064	36-42	X protein	Hepatitis B virus	274-277
30176263-3	2018	We showed that FXR is expressed in human CAFs isolated from four patients and treatment with the selective FXR agonist GW4064 decreased CAF migration, stress-fiber formation and contractility.	GW 4064	119-125	nuclear receptor subfamily 1 group H member 4	Homo sapiens	107-110
30106441-13	2018	In the present study, activation of FXR by GW4064 increased CCNG2 expression via suppression of miR-135A1 expression, and the FXR/miR-135A1/CCNG2 axis was demonstrated to be involved in mediating cell proliferation.	GW 4064	43-49	nuclear receptor subfamily 1 group H member 4	Homo sapiens	36-39
30106441-13	2018	In the present study, activation of FXR by GW4064 increased CCNG2 expression via suppression of miR-135A1 expression, and the FXR/miR-135A1/CCNG2 axis was demonstrated to be involved in mediating cell proliferation.	GW 4064	43-49	cyclin G2	Homo sapiens	60-65
30106441-13	2018	In the present study, activation of FXR by GW4064 increased CCNG2 expression via suppression of miR-135A1 expression, and the FXR/miR-135A1/CCNG2 axis was demonstrated to be involved in mediating cell proliferation.	GW 4064	43-49	microRNA 135a-1	Homo sapiens	96-105
30106441-13	2018	In the present study, activation of FXR by GW4064 increased CCNG2 expression via suppression of miR-135A1 expression, and the FXR/miR-135A1/CCNG2 axis was demonstrated to be involved in mediating cell proliferation.	GW 4064	43-49	cyclin G2	Homo sapiens	140-145
30106441-14	2018	In conclusion, activation of FXR by GW4064 suppresses cell proliferation and causes cell cycle arrest in CRC, and the miR-135A1/CCNG2 pathway was suggested to be involved in this step.	GW 4064	36-42	nuclear receptor subfamily 1 group H member 4	Homo sapiens	29-32
30139242-6	2018	We found that the FXRagonists GW4064 and INT-747 increased the protein abundance of AT2R and B2R in rat aortic VSMCs.AT2R blockade with PD123319 reversed the effects of FXR agonists on kallikrein activity, B2R, andbradykinin levels.	GW 4064	30-36	angiotensin II receptor, type 2	Rattus norvegicus	84-88
30139242-6	2018	We found that the FXRagonists GW4064 and INT-747 increased the protein abundance of AT2R and B2R in rat aortic VSMCs.AT2R blockade with PD123319 reversed the effects of FXR agonists on kallikrein activity, B2R, andbradykinin levels.	GW 4064	30-36	bradykinin receptor B2	Rattus norvegicus	93-96
30139242-6	2018	We found that the FXRagonists GW4064 and INT-747 increased the protein abundance of AT2R and B2R in rat aortic VSMCs.AT2R blockade with PD123319 reversed the effects of FXR agonists on kallikrein activity, B2R, andbradykinin levels.	GW 4064	30-36	angiotensin II receptor, type 2	Rattus norvegicus	117-121
30139242-6	2018	We found that the FXRagonists GW4064 and INT-747 increased the protein abundance of AT2R and B2R in rat aortic VSMCs.AT2R blockade with PD123319 reversed the effects of FXR agonists on kallikrein activity, B2R, andbradykinin levels.	GW 4064	30-36	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	18-21
30139242-6	2018	We found that the FXRagonists GW4064 and INT-747 increased the protein abundance of AT2R and B2R in rat aortic VSMCs.AT2R blockade with PD123319 reversed the effects of FXR agonists on kallikrein activity, B2R, andbradykinin levels.	GW 4064	30-36	bradykinin receptor B2	Rattus norvegicus	206-209
29668847-10	2018	Among the four down-stream soluble molecules of FXR, plasma adiponectin was most significantly increased by GW4064.	GW 4064	108-114	nuclear receptor subfamily 1, group H, member 4	Mus musculus	48-51
30139242-7	2018	Moreover, we found that GW4064 and INT-747 decreased intracellular [Ca2+], increasedSERCA activity, downregulated IP3R1 expression, and attenuated IP3-induced Ca2+ release.	GW 4064	24-30	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	114-119
29668847-5	2018	At 1 week after MI, both sham and MI mice were gavaged with 25 mg/kg/d of a synthetic FXR agonist (GW4064) or a vehicle control for 7 weeks, and cardiac performance was assessed by consecutive echocardiography studies.	GW 4064	99-105	nuclear receptor subfamily 1, group H, member 4	Mus musculus	86-89
29668847-10	2018	Among the four down-stream soluble molecules of FXR, plasma adiponectin was most significantly increased by GW4064.	GW 4064	108-114	adiponectin, C1Q and collagen domain containing	Mus musculus	60-71
29668847-7	2018	Moreover, GW4064 treatment increased angiogenesis and mitochondrial biogenesis, reduced cardiomyocyte loss and inflammation, and ameliorated cardiac remodelling as evidenced by heart weight, lung weight, atrial natriuretic peptide/brain natriuretic peptide levels, and myocardial fibrosis at 8 weeks post-MI.	GW 4064	10-16	natriuretic peptide type B	Mus musculus	231-256
29668847-8	2018	At the molecular level, GW4064 significantly increased FXR mRNA expression and transcriptional activity in heart tissue.	GW 4064	24-30	nuclear receptor subfamily 1, group H, member 4	Mus musculus	55-58
29668847-11	2018	In cultured adipocytes, GW4064 increased mRNA levels and protein expression of adiponectin.	GW 4064	24-30	adiponectin, C1Q and collagen domain containing	Mus musculus	79-90
29668847-12	2018	Conditioned medium of GW4064-treated adipocytes activated AMPK-PGC-1alpha signalling and reduced hypoxia-induced cardiomyocyte apoptosis, all of which were attenuated by an adiponectin neutralizing anti-body.	GW 4064	22-28	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	63-73
29668847-12	2018	Conditioned medium of GW4064-treated adipocytes activated AMPK-PGC-1alpha signalling and reduced hypoxia-induced cardiomyocyte apoptosis, all of which were attenuated by an adiponectin neutralizing anti-body.	GW 4064	22-28	adiponectin, C1Q and collagen domain containing	Mus musculus	173-184
29668847-13	2018	More importantly, when knocking-out adiponectin in mice, the cardioprotective effects of GW4064 were attenuated.	GW 4064	89-95	adiponectin, C1Q and collagen domain containing	Mus musculus	36-47
29849798-3	2018	Human gastric cell lines were treated with chenodeoxycholic acid (CDCA) or FXR agonist GW4064.	GW 4064	87-93	nuclear receptor subfamily 1 group H member 4	Homo sapiens	75-78
29377207-13	2018	Mice treated with GW4064 had increased, and FXR and SHP null mice had decreased, basal Xbp1s gene expression.	GW 4064	18-24	X-box binding protein 1	Mus musculus	87-91
29377207-7	2018	XBP1 pathway activation increased in Huh7-Ntcp and HepG2 cells treated with bile acids, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) or GW4064.	GW 4064	136-142	X-box binding protein 1	Homo sapiens	0-4
29377207-7	2018	XBP1 pathway activation increased in Huh7-Ntcp and HepG2 cells treated with bile acids, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) or GW4064.	GW 4064	136-142	MIR7-3 host gene	Homo sapiens	37-41
29377207-7	2018	XBP1 pathway activation increased in Huh7-Ntcp and HepG2 cells treated with bile acids, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) or GW4064.	GW 4064	136-142	solute carrier family 10 member 1	Homo sapiens	42-46
29958417-4	2018	FXR agonists (chenodeoxycholic acid, GW4064, and obeticholic acid):but not an antagonist (guggulsterone)—induced actin polymerization and expression of N-cadherin and phosphorylated focal adhesion kinase, although they were less effective than transforming growth factor beta (TGF-beta).	GW 4064	37-43	nuclear receptor subfamily 1 group H member 4	Homo sapiens	0-3
29958417-4	2018	FXR agonists (chenodeoxycholic acid, GW4064, and obeticholic acid):but not an antagonist (guggulsterone)—induced actin polymerization and expression of N-cadherin and phosphorylated focal adhesion kinase, although they were less effective than transforming growth factor beta (TGF-beta).	GW 4064	37-43	cadherin 2	Homo sapiens	162-172
29328388-8	2018	These results indicated that in WT mice, administration of GW4064 ameliorated LPS-mediated liver injury by upregulation of FXR expression, which was in part mediated by the TLR4/p38 MAPK pathway.	GW 4064	59-65	nuclear receptor subfamily 1, group H, member 4	Mus musculus	123-126
29351391-8	2018	DCA also induced nuclear accumulation of the farnesoid X receptor (FXR), whereas an FXR agonist, GW4064 (10 microM), inhibited wound closure.	GW 4064	97-103	nuclear receptor subfamily 1 group H member 4	Homo sapiens	84-87
29351391-9	2018	Both DCA and GW4064 attenuated the expression of CFTR Cl- channels, whereas inhibition of CFTR activity with either CFTR-inh-172 (10 microM) or GlyH-101 (25 microM) also prevented wound healing.	GW 4064	13-19	CF transmembrane conductance regulator	Homo sapiens	49-53
29328388-0	2018	GW4064 attenuates lipopolysaccharide-induced hepatic inflammation and apoptosis through inhibition of the Toll-like receptor 4-mediated p38 mitogen-activated protein kinase signaling pathway in mice.	GW 4064	0-6	toll-like receptor 4	Mus musculus	106-126
29328388-0	2018	GW4064 attenuates lipopolysaccharide-induced hepatic inflammation and apoptosis through inhibition of the Toll-like receptor 4-mediated p38 mitogen-activated protein kinase signaling pathway in mice.	GW 4064	0-6	mitogen-activated protein kinase 14	Mus musculus	136-139
29328388-3	2018	The present study investigated the capacity of the FXR agonist GW4064 to protect the livers of mice from lipopolysaccharide (LPS)-induced inflammation and apoptosis.	GW 4064	63-69	nuclear receptor subfamily 1, group H, member 4	Mus musculus	51-54
29328388-6	2018	Activation of FXR by GW4064 alleviated hepatic inflammation in the LPS-induced murine liver injury model as reflected by reduced serum levels of aspartate aminotransferase and pro-inflammatory cytokine mRNA expression, including tumor necrosis factor-alpha, as well as interleukin-6 and -1beta in WT mice.	GW 4064	21-27	nuclear receptor subfamily 1, group H, member 4	Mus musculus	14-17
29328388-6	2018	Activation of FXR by GW4064 alleviated hepatic inflammation in the LPS-induced murine liver injury model as reflected by reduced serum levels of aspartate aminotransferase and pro-inflammatory cytokine mRNA expression, including tumor necrosis factor-alpha, as well as interleukin-6 and -1beta in WT mice.	GW 4064	21-27	tumor necrosis factor	Mus musculus	229-256
29235094-3	2018	In the cellular experiments, FXR expression was up-regulated by either lentiviral transduction or GW4064 treatment and down-regulated by either siRNA technology or treatment with guggulsterones.	GW 4064	98-104	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	29-32
29328388-8	2018	These results indicated that in WT mice, administration of GW4064 ameliorated LPS-mediated liver injury by upregulation of FXR expression, which was in part mediated by the TLR4/p38 MAPK pathway.	GW 4064	59-65	toll-like receptor 4	Mus musculus	173-177
29328388-8	2018	These results indicated that in WT mice, administration of GW4064 ameliorated LPS-mediated liver injury by upregulation of FXR expression, which was in part mediated by the TLR4/p38 MAPK pathway.	GW 4064	59-65	mitogen-activated protein kinase 14	Mus musculus	178-181
28912067-3	2017	Treatment with specific FXR agonists (i.e., GW4064 and CDCA) significantly decreased both mRNA and protein levels of SULT1E1 in HepG2 cells.	GW 4064	44-50	nuclear receptor subfamily 1, group H, member 4	Mus musculus	24-27
29328388-6	2018	Activation of FXR by GW4064 alleviated hepatic inflammation in the LPS-induced murine liver injury model as reflected by reduced serum levels of aspartate aminotransferase and pro-inflammatory cytokine mRNA expression, including tumor necrosis factor-alpha, as well as interleukin-6 and -1beta in WT mice.	GW 4064	21-27	interleukin 6	Mus musculus	269-293
28912067-3	2017	Treatment with specific FXR agonists (i.e., GW4064 and CDCA) significantly decreased both mRNA and protein levels of SULT1E1 in HepG2 cells.	GW 4064	44-50	sulfotransferase family 1E, member 1	Mus musculus	117-124
28267333-3	2017	GW4064 and chenodeoxycholic acid (two specific FXR agonists) treatment of HepG2 cells led to a significant increase in the mRNA level of UGT2B10.	GW 4064	0-6	nuclear receptor subfamily 1 group H member 4	Homo sapiens	47-50
26646674-4	2017	METHODS: This study investigated the effect of LQ, metformin [an activator of activated AMP-activated protein kinase (AMPK)] and GW4064 [a ligand of farnesoid X receptor (FXR)] on mitochondrial dysfunction and oxidative stress induced by serum deprivation as well as its molecular mechanism, as assessed by immunoblot and flow cytometer assays.	GW 4064	129-135	nuclear receptor subfamily 1 group H member 4	Homo sapiens	149-169
28787755-0	2017	A rapid administration of GW4064 inhibits the NLRP3 inflammasome activation independent of farnesoid X receptor agonism.	GW 4064	26-32	NLR family pyrin domain containing 3	Homo sapiens	46-51
28787755-1	2017	GW4064 is a small molecule known to be an agonist of the nuclear farnesoid X receptor (FXR).	GW 4064	0-6	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	75-85
28787755-1	2017	GW4064 is a small molecule known to be an agonist of the nuclear farnesoid X receptor (FXR).	GW 4064	0-6	nuclear receptor subfamily 1 group H member 4	Homo sapiens	87-90
28787755-2	2017	We found that GW4064 inhibits the NLR family CARD domain containing 3 (NLRP3) inflammasome activation in an FXR-independent manner as evidenced by its similar inhibitory effect on NLRP3 inflammasome activation in FXR-deficient macrophages.	GW 4064	14-20	NLR family pyrin domain containing 3	Homo sapiens	71-76
28787755-2	2017	We found that GW4064 inhibits the NLR family CARD domain containing 3 (NLRP3) inflammasome activation in an FXR-independent manner as evidenced by its similar inhibitory effect on NLRP3 inflammasome activation in FXR-deficient macrophages.	GW 4064	14-20	nuclear receptor subfamily 1 group H member 4	Homo sapiens	108-111
28787755-2	2017	We found that GW4064 inhibits the NLR family CARD domain containing 3 (NLRP3) inflammasome activation in an FXR-independent manner as evidenced by its similar inhibitory effect on NLRP3 inflammasome activation in FXR-deficient macrophages.	GW 4064	14-20	NLR family pyrin domain containing 3	Homo sapiens	180-185
28787755-2	2017	We found that GW4064 inhibits the NLR family CARD domain containing 3 (NLRP3) inflammasome activation in an FXR-independent manner as evidenced by its similar inhibitory effect on NLRP3 inflammasome activation in FXR-deficient macrophages.	GW 4064	14-20	nuclear receptor subfamily 1 group H member 4	Homo sapiens	213-216
28787755-3	2017	Interestingly, GW4064 decreases the nigericin-induced oligomerization and ubiquitination of ASC which is critical for the NLRP3 inflammasome activation.	GW 4064	15-21	PYD and CARD domain containing	Homo sapiens	92-95
28787755-3	2017	Interestingly, GW4064 decreases the nigericin-induced oligomerization and ubiquitination of ASC which is critical for the NLRP3 inflammasome activation.	GW 4064	15-21	NLR family pyrin domain containing 3	Homo sapiens	122-127
28787755-4	2017	In vivo results indicate that GW4064 could partially rescue the symptoms of NLRP3-dependent inflammatory disease models.	GW 4064	30-36	NLR family pyrin domain containing 3	Homo sapiens	76-81
28787755-5	2017	These results not only necessitate cautious interpretation of the biological function of GW4064 as an FXR agonist, but also provide a potential therapeutic approach using GW4064 in the treatment of NLRP3-related diseases.	GW 4064	89-95	nuclear receptor subfamily 1 group H member 4	Homo sapiens	102-105
28787755-5	2017	These results not only necessitate cautious interpretation of the biological function of GW4064 as an FXR agonist, but also provide a potential therapeutic approach using GW4064 in the treatment of NLRP3-related diseases.	GW 4064	171-177	NLR family pyrin domain containing 3	Homo sapiens	198-203
28351411-16	2017	CONCLUSIONS: Our data suggest that FXR is dispensable for oligodendroglial differentiation and that FXR agonists, such as GW4064, represent a potential therapeutic approach for MS which specifically targets peripheral immune cells including macrophages but not brain-resident cells, such as oligodendrocytes, astrocytes or microglia.	GW 4064	122-128	nuclear receptor subfamily 1, group H, member 4	Mus musculus	100-103
28267333-3	2017	GW4064 and chenodeoxycholic acid (two specific FXR agonists) treatment of HepG2 cells led to a significant increase in the mRNA level of UGT2B10.	GW 4064	0-6	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	137-144
28647362-0	2017	Farnesoid X receptor agonist GW4064 ameliorates lipopolysaccharide-induced ileocolitis through TLR4/MyD88 pathway related mitochondrial dysfunction in mice.	GW 4064	29-35	toll-like receptor 4	Mus musculus	95-99
28647362-0	2017	Farnesoid X receptor agonist GW4064 ameliorates lipopolysaccharide-induced ileocolitis through TLR4/MyD88 pathway related mitochondrial dysfunction in mice.	GW 4064	29-35	myeloid differentiation primary response gene 88	Mus musculus	100-105
28647362-3	2017	Here we show the mechanisms of FXR agonist, GW4064, inhibits mucosal injury in ileum caused by lipopolysaccharides (LPS).	GW 4064	44-50	nuclear receptor subfamily 1, group H, member 4	Mus musculus	31-34
28647362-6	2017	Interesting, GW4064 suppresses NACHT, LRR and PYD domains-containing protein 3 (NALP3) inflammasome mediates tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and IL-1beta, as well as mitochondrial respiratory complexes mRNA expression in WT and FXR KO mice treated with LPS.	GW 4064	13-19	NLR family, pyrin domain containing 3	Mus musculus	31-78
28647362-6	2017	Interesting, GW4064 suppresses NACHT, LRR and PYD domains-containing protein 3 (NALP3) inflammasome mediates tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and IL-1beta, as well as mitochondrial respiratory complexes mRNA expression in WT and FXR KO mice treated with LPS.	GW 4064	13-19	NLR family, pyrin domain containing 3	Mus musculus	80-85
28647362-6	2017	Interesting, GW4064 suppresses NACHT, LRR and PYD domains-containing protein 3 (NALP3) inflammasome mediates tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and IL-1beta, as well as mitochondrial respiratory complexes mRNA expression in WT and FXR KO mice treated with LPS.	GW 4064	13-19	tumor necrosis factor	Mus musculus	109-136
28647362-6	2017	Interesting, GW4064 suppresses NACHT, LRR and PYD domains-containing protein 3 (NALP3) inflammasome mediates tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and IL-1beta, as well as mitochondrial respiratory complexes mRNA expression in WT and FXR KO mice treated with LPS.	GW 4064	13-19	tumor necrosis factor	Mus musculus	138-147
28647362-6	2017	Interesting, GW4064 suppresses NACHT, LRR and PYD domains-containing protein 3 (NALP3) inflammasome mediates tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and IL-1beta, as well as mitochondrial respiratory complexes mRNA expression in WT and FXR KO mice treated with LPS.	GW 4064	13-19	interleukin 6	Mus musculus	150-168
28647362-6	2017	Interesting, GW4064 suppresses NACHT, LRR and PYD domains-containing protein 3 (NALP3) inflammasome mediates tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and IL-1beta, as well as mitochondrial respiratory complexes mRNA expression in WT and FXR KO mice treated with LPS.	GW 4064	13-19	interleukin 1 beta	Mus musculus	173-181
28647362-6	2017	Interesting, GW4064 suppresses NACHT, LRR and PYD domains-containing protein 3 (NALP3) inflammasome mediates tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and IL-1beta, as well as mitochondrial respiratory complexes mRNA expression in WT and FXR KO mice treated with LPS.	GW 4064	13-19	nuclear receptor subfamily 1, group H, member 4	Mus musculus	256-259
26646674-4	2017	METHODS: This study investigated the effect of LQ, metformin [an activator of activated AMP-activated protein kinase (AMPK)] and GW4064 [a ligand of farnesoid X receptor (FXR)] on mitochondrial dysfunction and oxidative stress induced by serum deprivation as well as its molecular mechanism, as assessed by immunoblot and flow cytometer assays.	GW 4064	129-135	nuclear receptor subfamily 1 group H member 4	Homo sapiens	171-174
26646674-9	2017	LQ also induced protein and mRNA expression of both FXR as well as small heterodimer partner, which is important since treatment with FXR ligand GW4064 protected hepatocytes against cell death and mitochondrial damage induced by serum deprivation.	GW 4064	145-151	nuclear receptor subfamily 1 group H member 4	Homo sapiens	52-55
26646674-9	2017	LQ also induced protein and mRNA expression of both FXR as well as small heterodimer partner, which is important since treatment with FXR ligand GW4064 protected hepatocytes against cell death and mitochondrial damage induced by serum deprivation.	GW 4064	145-151	nuclear receptor subfamily 1 group H member 4	Homo sapiens	134-137
28086800-10	2017	Expectedly, GW4064 induced phosphorylation of Akt, expression of the anti-apoptotic molecules (Bcl-xL and Bcl-2), and reduced harmful hepatic molecules (Fas ligand and Fas).	GW 4064	12-18	BCL2-like 1	Mus musculus	95-101
28086800-6	2017	RESULTS: An FXR-specific agonist, GW4064, induced expressions of the p62/SQSTM1 gene and protein in AML12 mouse liver cells.	GW 4064	34-40	nuclear receptor subfamily 1, group H, member 4	Mus musculus	12-15
28086800-10	2017	Expectedly, GW4064 induced phosphorylation of Akt, expression of the anti-apoptotic molecules (Bcl-xL and Bcl-2), and reduced harmful hepatic molecules (Fas ligand and Fas).	GW 4064	12-18	B cell leukemia/lymphoma 2	Mus musculus	106-111
28086800-6	2017	RESULTS: An FXR-specific agonist, GW4064, induced expressions of the p62/SQSTM1 gene and protein in AML12 mouse liver cells.	GW 4064	34-40	sequestosome 1	Mus musculus	69-72
28086800-11	2017	GW4064 promoted hepatocyte survival, which was cancelled by p62/SQSTM1 siRNA.	GW 4064	0-6	sequestosome 1	Mus musculus	60-63
28086800-6	2017	RESULTS: An FXR-specific agonist, GW4064, induced expressions of the p62/SQSTM1 gene and protein in AML12 mouse liver cells.	GW 4064	34-40	sequestosome 1	Mus musculus	73-79
28086800-7	2017	Because we previously reported p62/SQSTM1 as a key molecule for antioxidation and cell survival in hepatocytes, we next examined the activation of nuclear factor erythroid 2-related factor-2 (Nrf2) and induction of the antioxidant molecules by GW4064.	GW 4064	244-250	sequestosome 1	Mus musculus	31-34
28086800-11	2017	GW4064 promoted hepatocyte survival, which was cancelled by p62/SQSTM1 siRNA.	GW 4064	0-6	sequestosome 1	Mus musculus	64-70
28086800-8	2017	GW4064 activated Nrf2 and subsequently induced antioxidant molecules (Nrf2, catalase, HO-1, and thioredoxin).	GW 4064	0-6	nuclear factor, erythroid derived 2, like 2	Mus musculus	17-21
28086800-8	2017	GW4064 activated Nrf2 and subsequently induced antioxidant molecules (Nrf2, catalase, HO-1, and thioredoxin).	GW 4064	0-6	nuclear factor, erythroid derived 2, like 2	Mus musculus	70-74
28086800-13	2017	Furthermore, GW4064 induced the expression of small heterodimer partners (SHP) and suppressed liver X receptor (LXR)-induced steatosis in hepatocytes, expecting the in vivo protective effect of FXR on liver injury especially with steatosis.	GW 4064	13-19	nuclear receptor subfamily 0, group B, member 2	Mus musculus	74-77
28086800-8	2017	GW4064 activated Nrf2 and subsequently induced antioxidant molecules (Nrf2, catalase, HO-1, and thioredoxin).	GW 4064	0-6	catalase	Mus musculus	76-84
28086800-13	2017	Furthermore, GW4064 induced the expression of small heterodimer partners (SHP) and suppressed liver X receptor (LXR)-induced steatosis in hepatocytes, expecting the in vivo protective effect of FXR on liver injury especially with steatosis.	GW 4064	13-19	nuclear receptor subfamily 1, group H, member 3	Mus musculus	94-110
28086800-8	2017	GW4064 activated Nrf2 and subsequently induced antioxidant molecules (Nrf2, catalase, HO-1, and thioredoxin).	GW 4064	0-6	heme oxygenase 1	Mus musculus	86-90
28086800-13	2017	Furthermore, GW4064 induced the expression of small heterodimer partners (SHP) and suppressed liver X receptor (LXR)-induced steatosis in hepatocytes, expecting the in vivo protective effect of FXR on liver injury especially with steatosis.	GW 4064	13-19	nuclear receptor subfamily 1, group H, member 3	Mus musculus	112-115
28086800-8	2017	GW4064 activated Nrf2 and subsequently induced antioxidant molecules (Nrf2, catalase, HO-1, and thioredoxin).	GW 4064	0-6	thioredoxin 1	Mus musculus	96-107
28086800-10	2017	Expectedly, GW4064 induced phosphorylation of Akt, expression of the anti-apoptotic molecules (Bcl-xL and Bcl-2), and reduced harmful hepatic molecules (Fas ligand and Fas).	GW 4064	12-18	thymoma viral proto-oncogene 1	Mus musculus	46-49
28086800-13	2017	Furthermore, GW4064 induced the expression of small heterodimer partners (SHP) and suppressed liver X receptor (LXR)-induced steatosis in hepatocytes, expecting the in vivo protective effect of FXR on liver injury especially with steatosis.	GW 4064	13-19	nuclear receptor subfamily 1, group H, member 4	Mus musculus	194-197
28086800-14	2017	In the hepatectomy model of db/db mice with fatty liver, pre-treatment by GW4064 significantly reduced post-PH liver injury (serum levels of LDH, AST & ALT and histological study) and improved steatosis.	GW 4064	74-80	transmembrane protease, serine 11d	Mus musculus	146-149
28086800-14	2017	In the hepatectomy model of db/db mice with fatty liver, pre-treatment by GW4064 significantly reduced post-PH liver injury (serum levels of LDH, AST & ALT and histological study) and improved steatosis.	GW 4064	74-80	glutamic pyruvic transaminase, soluble	Mus musculus	156-159
28086800-15	2017	The key molecules, p62/SQSTM1, Nrf2 and SHP were upregulated in fatty liver tissue by GW4064 treatment.	GW 4064	86-92	sequestosome 1	Mus musculus	19-22
28086800-15	2017	The key molecules, p62/SQSTM1, Nrf2 and SHP were upregulated in fatty liver tissue by GW4064 treatment.	GW 4064	86-92	sequestosome 1	Mus musculus	23-29
28086800-15	2017	The key molecules, p62/SQSTM1, Nrf2 and SHP were upregulated in fatty liver tissue by GW4064 treatment.	GW 4064	86-92	nuclear factor, erythroid derived 2, like 2	Mus musculus	31-35
28086800-15	2017	The key molecules, p62/SQSTM1, Nrf2 and SHP were upregulated in fatty liver tissue by GW4064 treatment.	GW 4064	86-92	nuclear receptor subfamily 0, group B, member 2	Mus musculus	40-43
26450152-4	2016	In this study, we reported that FXR agonist GW4064 reduced high glucose induced human mesangial cells (HMCs) inflammation, fibrosis and proliferation by downregulating visfatin expression, which can be blunted by exogenous visfatin treatment.	GW 4064	44-50	nuclear receptor subfamily 1 group H member 4	Homo sapiens	32-35
27471003-4	2016	Activation of FXR by chenodeoxycholic acid (CDCA) or GW4064 significantly decreased PLA2G12B expression in HepG2 cells.	GW 4064	53-59	nuclear receptor subfamily 1 group H member 4	Homo sapiens	14-17
27471003-4	2016	Activation of FXR by chenodeoxycholic acid (CDCA) or GW4064 significantly decreased PLA2G12B expression in HepG2 cells.	GW 4064	53-59	phospholipase A2 group XIIB	Homo sapiens	84-92
27609522-0	2016	Restoration of enterohepatic bile acid pathways in pregnant mice following short term activation of Fxr by GW4064.	GW 4064	107-113	nuclear receptor subfamily 1, group H, member 4	Mus musculus	100-103
27609522-5	2016	The objective of this study was to determine whether short-term treatment of pregnant mice with GW4064 (a potent FXR agonist) restores Fxr signaling to the level observed in virgin mice.	GW 4064	96-102	nuclear receptor subfamily 1, group H, member 4	Mus musculus	113-116
27609522-5	2016	The objective of this study was to determine whether short-term treatment of pregnant mice with GW4064 (a potent FXR agonist) restores Fxr signaling to the level observed in virgin mice.	GW 4064	96-102	nuclear receptor subfamily 1, group H, member 4	Mus musculus	135-138
27609522-7	2016	Treatment of pregnant mice with GW4064 induced ileal Fgf15, Shp and Ostalpha/beta mRNAs, and restored hepatic Shp, Bal, Ntcp, and Bsep back to vehicle-treated virgin levels.	GW 4064	32-38	fibroblast growth factor 15	Mus musculus	53-58
27609522-7	2016	Treatment of pregnant mice with GW4064 induced ileal Fgf15, Shp and Ostalpha/beta mRNAs, and restored hepatic Shp, Bal, Ntcp, and Bsep back to vehicle-treated virgin levels.	GW 4064	32-38	nuclear receptor subfamily 0, group B, member 2	Mus musculus	60-63
27609522-7	2016	Treatment of pregnant mice with GW4064 induced ileal Fgf15, Shp and Ostalpha/beta mRNAs, and restored hepatic Shp, Bal, Ntcp, and Bsep back to vehicle-treated virgin levels.	GW 4064	32-38	nuclear receptor subfamily 0, group B, member 2	Mus musculus	110-113
27609522-7	2016	Treatment of pregnant mice with GW4064 induced ileal Fgf15, Shp and Ostalpha/beta mRNAs, and restored hepatic Shp, Bal, Ntcp, and Bsep back to vehicle-treated virgin levels.	GW 4064	32-38	poly (ADP-ribose) polymerase family, member 9	Mus musculus	115-118
27609522-7	2016	Treatment of pregnant mice with GW4064 induced ileal Fgf15, Shp and Ostalpha/beta mRNAs, and restored hepatic Shp, Bal, Ntcp, and Bsep back to vehicle-treated virgin levels.	GW 4064	32-38	solute carrier family 10 (sodium/bile acid cotransporter family), member 1	Mus musculus	120-124
27609522-7	2016	Treatment of pregnant mice with GW4064 induced ileal Fgf15, Shp and Ostalpha/beta mRNAs, and restored hepatic Shp, Bal, Ntcp, and Bsep back to vehicle-treated virgin levels.	GW 4064	32-38	ATP-binding cassette, sub-family B (MDR/TAP), member 11	Mus musculus	130-134
27609522-8	2016	Pregnant mice exhibited 2.5-fold increase in Cyp7a1 mRNA compared to virgin controls, which was reduced by GW4064.	GW 4064	107-113	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	45-51
27609522-9	2016	Similarly treatment of mouse primary hepatocytes with plasma isolated from pregnant mice induced Cyp7a1 mRNA by nearly 3-fold as compared to virgin plasma, which could be attenuated by co-treatment with either GW4064 or recombinant FGF19 protein.	GW 4064	210-216	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	97-103
26899873-4	2016	Herein, we demonstrated, for the first time, that the synthetic FXR agonist GW4064, inhibiting leptin signaling, affects the tumor-promoting activities of CAFs in breast malignancy.	GW 4064	76-82	nuclear receptor subfamily 1 group H member 4	Homo sapiens	64-67
26899873-8	2016	Interestingly, GW4064-treated tumors exhibited decreased levels of leptin-regulated proteins along with a strong staining intensity for SOCS3.	GW 4064	15-21	suppressor of cytokine signaling 3	Homo sapiens	136-141
26545738-4	2016	We show that activation of the nuclear receptor FXR, either by its endogenous ligand CDCA or the synthetic GW4064, leads to cell death in four breast cancer cell lines with distinct phenotypes: MCF-10A (normal), MCF-7 (receptor positive), MDA-MB-231 and MDA-MB-468 (triple negative).	GW 4064	107-113	nuclear receptor subfamily 1 group H member 4	Homo sapiens	48-51
29283075-4	2017	RESULTS: In human hepatocytes, treatment with the FXR agonists GW4064 (1.0 microM) and WAY362450 (0.1 microM) did not significantly induce the mRNA expression of BACS and BAT genes.	GW 4064	63-69	nuclear receptor subfamily 1 group H member 4	Homo sapiens	50-53
29283075-6	2017	Interestingly, a follow up study conducted in rat hepatocytes indicated that GW4064 induced the BACS gene while WAY362450 induced the BAT gene, confirming literature results that these genes can be induced in rat.	GW 4064	77-83	solute carrier family 27 member 5	Rattus norvegicus	96-100
27758768-3	2016	In this study, we show that FXR is present in human platelets and FXR ligands, GW4064 and 6alpha-ethyl-chenodeoxycholic acid, modulate platelet activation nongenomically.	GW 4064	79-85	nuclear receptor subfamily 1 group H member 4	Homo sapiens	28-31
27758768-3	2016	In this study, we show that FXR is present in human platelets and FXR ligands, GW4064 and 6alpha-ethyl-chenodeoxycholic acid, modulate platelet activation nongenomically.	GW 4064	79-85	nuclear receptor subfamily 1 group H member 4	Homo sapiens	66-69
27758768-9	2016	The atheroprotective effects of GW4064, with its novel antiplatelet effects, indicate FXR as a potential target for the prevention of atherothrombotic disease.	GW 4064	32-38	nuclear receptor subfamily 1 group H member 4	Homo sapiens	86-89
28066584-9	2016	FXR agonist GW4064 remarkably enhanced and FXR antagonist Z-Guggulsterone significantly inhibited EMT changes in TGF-beta1-treated HBE cells.	GW 4064	12-18	nuclear receptor subfamily 1 group H member 4	Homo sapiens	0-3
28066584-10	2016	Both chenodeoxycholic acid (CDCA) and GW4064 increased COX-2 expression in HBE cells, whereas Z-Guggulsterone dramatically restrained CDCA-induced COX-2 expression.	GW 4064	38-44	prostaglandin-endoperoxide synthase 2	Homo sapiens	55-60
27251172-4	2016	In HepaRG cells, FXR agonists (6-ethyl chenodeoxycholic acid and GW4064), but no antagonist, and an FXR-unrelated bile salt inhibited viral mRNA, DNA, and protein production (IC50, 0.1-0.5 muM) and reduced covalently closed circular DNA pool size.	GW 4064	65-71	nuclear receptor subfamily 1 group H member 4	Homo sapiens	17-20
27127878-3	2016	In the present study, we for the first time tested the effect of farnesoid X receptor (FXR) agonists GW4064 and CDCA (chenodeoxycholic acid) in combination with cisplatin (CDDP) on increasing the chemosensitivity in BTC.	GW 4064	101-107	nuclear receptor subfamily 1 group H member 4	Homo sapiens	87-90
27127878-6	2016	Moreover, the experiments on tumor-bearing mice showed that GW4064/CDDP co-treatment inhibited the tumor growth in vivo by up-regulating SHP expression and down-regulating STAT3 phosphorylation.	GW 4064	60-66	nuclear receptor subfamily 0, group B, member 2	Mus musculus	137-140
27127878-6	2016	Moreover, the experiments on tumor-bearing mice showed that GW4064/CDDP co-treatment inhibited the tumor growth in vivo by up-regulating SHP expression and down-regulating STAT3 phosphorylation.	GW 4064	60-66	signal transducer and activator of transcription 3	Mus musculus	172-177
26950211-12	2016	GCDCA-, CDCA- and GW4064- preconditioning enhanced ABCB11 mRNA levels, but in contrast to the bile acids, GW4064 did not significantly reduce GCDCA-induced caspase-3/7 activity.	GW 4064	18-24	ATP binding cassette subfamily B member 11	Homo sapiens	51-57
26710942-7	2016	It was found that the FXR agonists GW4064 and INT-747, in a dose-dependent manner, increased the protein abundance of AT2 R, B2 R and SHP-1 and decreased that of AT1 R.	GW 4064	35-41	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	22-25
26710942-7	2016	It was found that the FXR agonists GW4064 and INT-747, in a dose-dependent manner, increased the protein abundance of AT2 R, B2 R and SHP-1 and decreased that of AT1 R.	GW 4064	35-41	angiotensin II receptor, type 2	Rattus norvegicus	118-123
26710942-7	2016	It was found that the FXR agonists GW4064 and INT-747, in a dose-dependent manner, increased the protein abundance of AT2 R, B2 R and SHP-1 and decreased that of AT1 R.	GW 4064	35-41	bradykinin receptor B2	Rattus norvegicus	125-129
26710942-7	2016	It was found that the FXR agonists GW4064 and INT-747, in a dose-dependent manner, increased the protein abundance of AT2 R, B2 R and SHP-1 and decreased that of AT1 R.	GW 4064	35-41	angiotensin II receptor, type 1a	Rattus norvegicus	162-167
26450152-4	2016	In this study, we reported that FXR agonist GW4064 reduced high glucose induced human mesangial cells (HMCs) inflammation, fibrosis and proliferation by downregulating visfatin expression, which can be blunted by exogenous visfatin treatment.	GW 4064	44-50	nicotinamide phosphoribosyltransferase	Homo sapiens	168-176
26450152-4	2016	In this study, we reported that FXR agonist GW4064 reduced high glucose induced human mesangial cells (HMCs) inflammation, fibrosis and proliferation by downregulating visfatin expression, which can be blunted by exogenous visfatin treatment.	GW 4064	44-50	nicotinamide phosphoribosyltransferase	Homo sapiens	223-231
26450152-6	2016	In vivo study also showed that GW4064 ameliorated the progression of DN in db/db mice with a decreased visfatin expression.	GW 4064	31-37	nicotinamide phosphoribosyltransferase	Mus musculus	103-111
26324224-4	2015	The treatment of FXR agonist GW4064/antagonist guggulsterone (Gug.)	GW 4064	29-35	nuclear receptor subfamily 1 group H member 4	Homo sapiens	17-20
26505219-3	2016	Activation of FXR by a synthetic agonist, GW4064, in mice increased occupancy of FXR and its DNA-binding partner, retinoid X receptor-alpha, at FGF15-signaling component genes, particularly betaKL, and induced expression of these genes.	GW 4064	42-48	nuclear receptor subfamily 1, group H, member 4	Mus musculus	14-17
26505219-3	2016	Activation of FXR by a synthetic agonist, GW4064, in mice increased occupancy of FXR and its DNA-binding partner, retinoid X receptor-alpha, at FGF15-signaling component genes, particularly betaKL, and induced expression of these genes.	GW 4064	42-48	nuclear receptor subfamily 1, group H, member 4	Mus musculus	81-84
26505219-3	2016	Activation of FXR by a synthetic agonist, GW4064, in mice increased occupancy of FXR and its DNA-binding partner, retinoid X receptor-alpha, at FGF15-signaling component genes, particularly betaKL, and induced expression of these genes.	GW 4064	42-48	retinoid X receptor alpha	Mus musculus	114-139
26505219-3	2016	Activation of FXR by a synthetic agonist, GW4064, in mice increased occupancy of FXR and its DNA-binding partner, retinoid X receptor-alpha, at FGF15-signaling component genes, particularly betaKL, and induced expression of these genes.	GW 4064	42-48	fibroblast growth factor 15	Mus musculus	144-149
26505219-3	2016	Activation of FXR by a synthetic agonist, GW4064, in mice increased occupancy of FXR and its DNA-binding partner, retinoid X receptor-alpha, at FGF15-signaling component genes, particularly betaKL, and induced expression of these genes.	GW 4064	42-48	klotho beta	Mus musculus	190-196
26505219-7	2016	In mice, transient inductions of intestinal Fgf15 and hepatic betaKL were temporally correlated after GW4064 treatment, and pretreatment of hepatocytes with GW4064 before FGF19 treatment enhanced FGF19 signaling, which was abolished by transcriptional inhibition or betaKL down-regulation.	GW 4064	157-163	fibroblast growth factor 15	Mus musculus	44-49
26505219-7	2016	In mice, transient inductions of intestinal Fgf15 and hepatic betaKL were temporally correlated after GW4064 treatment, and pretreatment of hepatocytes with GW4064 before FGF19 treatment enhanced FGF19 signaling, which was abolished by transcriptional inhibition or betaKL down-regulation.	GW 4064	157-163	klotho beta	Mus musculus	62-68
26505219-7	2016	In mice, transient inductions of intestinal Fgf15 and hepatic betaKL were temporally correlated after GW4064 treatment, and pretreatment of hepatocytes with GW4064 before FGF19 treatment enhanced FGF19 signaling, which was abolished by transcriptional inhibition or betaKL down-regulation.	GW 4064	157-163	fibroblast growth factor 15	Mus musculus	196-201
26505219-7	2016	In mice, transient inductions of intestinal Fgf15 and hepatic betaKL were temporally correlated after GW4064 treatment, and pretreatment of hepatocytes with GW4064 before FGF19 treatment enhanced FGF19 signaling, which was abolished by transcriptional inhibition or betaKL down-regulation.	GW 4064	157-163	klotho beta	Mus musculus	266-272
26670557-4	2015	The high-affinity FXR agonist GW4064 blocks Gly-MCA action in the gut, and intestine-specific Fxr-null mice are unresponsive to the beneficial effects of Gly-MCA.	GW 4064	30-36	nuclear receptor subfamily 1, group H, member 4	Mus musculus	18-21
26583035-6	2015	Human kidney 2 (HK2) cells were exposed to high glucose with or without the FXR agonist GW4064 or when FXR mRNA was silenced.	GW 4064	88-94	nuclear receptor subfamily 1 group H member 4	Homo sapiens	76-79
26583035-8	2015	HK2 cells exposed to high glucose had reduced FXR expression and increased MCP-1, TGF-beta1, fibronectin and collagen IV expression, which was reversed in the presence of GW4064.	GW 4064	171-177	hexokinase 2	Homo sapiens	0-3
26583035-8	2015	HK2 cells exposed to high glucose had reduced FXR expression and increased MCP-1, TGF-beta1, fibronectin and collagen IV expression, which was reversed in the presence of GW4064.	GW 4064	171-177	nuclear receptor subfamily 1 group H member 4	Homo sapiens	46-49
26583035-8	2015	HK2 cells exposed to high glucose had reduced FXR expression and increased MCP-1, TGF-beta1, fibronectin and collagen IV expression, which was reversed in the presence of GW4064.	GW 4064	171-177	C-C motif chemokine ligand 2	Homo sapiens	75-80
26583035-8	2015	HK2 cells exposed to high glucose had reduced FXR expression and increased MCP-1, TGF-beta1, fibronectin and collagen IV expression, which was reversed in the presence of GW4064.	GW 4064	171-177	transforming growth factor beta 1	Homo sapiens	82-91
26583035-8	2015	HK2 cells exposed to high glucose had reduced FXR expression and increased MCP-1, TGF-beta1, fibronectin and collagen IV expression, which was reversed in the presence of GW4064.	GW 4064	171-177	fibronectin 1	Homo sapiens	93-104
25934227-0	2015	Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.	GW 4064	17-23	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	65-75
26416445-4	2015	In the present study, we found that activation of FXR by its specific agonist GW4064 in HCC cells inhibited cell growth, induced cell cycle arrest at G1 phase, elevated p21 expression and repressed STAT3 activity.	GW 4064	78-84	nuclear receptor subfamily 1, group H, member 4	Mus musculus	50-53
26416445-4	2015	In the present study, we found that activation of FXR by its specific agonist GW4064 in HCC cells inhibited cell growth, induced cell cycle arrest at G1 phase, elevated p21 expression and repressed STAT3 activity.	GW 4064	78-84	transcription elongation factor A (SII)-like 1	Mus musculus	169-172
26416445-4	2015	In the present study, we found that activation of FXR by its specific agonist GW4064 in HCC cells inhibited cell growth, induced cell cycle arrest at G1 phase, elevated p21 expression and repressed STAT3 activity.	GW 4064	78-84	signal transducer and activator of transcription 3	Mus musculus	198-203
26416445-8	2015	The in vivo study in nude mice showed that treatment with FXR ligand GW4064 could decelerate the growth of HCC xenografts, up-regulate SOCS3 and p21 expression and inhibit STAT3 phosphorylation in the xenografts.	GW 4064	69-75	nuclear receptor subfamily 1, group H, member 4	Mus musculus	58-61
26416445-8	2015	The in vivo study in nude mice showed that treatment with FXR ligand GW4064 could decelerate the growth of HCC xenografts, up-regulate SOCS3 and p21 expression and inhibit STAT3 phosphorylation in the xenografts.	GW 4064	69-75	suppressor of cytokine signaling 3	Mus musculus	135-140
26416445-8	2015	The in vivo study in nude mice showed that treatment with FXR ligand GW4064 could decelerate the growth of HCC xenografts, up-regulate SOCS3 and p21 expression and inhibit STAT3 phosphorylation in the xenografts.	GW 4064	69-75	transcription elongation factor A (SII)-like 1	Mus musculus	145-148
26321738-13	2015	Moreover, the livers of GW4064-treated mice showed increased expression of FXR and several related target genes involved in phase II and phase III xenobiotic metabolism.	GW 4064	24-30	nuclear receptor subfamily 1, group H, member 4	Mus musculus	75-78
26697325-1	2015	To assess the effect of farnesoid X receptor (FXR), a bile acid nuclear receptor, on renal proximal tubular cells, primary cultured mouse kidney proximal tubular cells were treated with GW4064 (a FXR agonist) or DMSO (as controls) overnight.	GW 4064	186-192	nuclear receptor subfamily 1, group H, member 4	Mus musculus	196-199
26416445-8	2015	The in vivo study in nude mice showed that treatment with FXR ligand GW4064 could decelerate the growth of HCC xenografts, up-regulate SOCS3 and p21 expression and inhibit STAT3 phosphorylation in the xenografts.	GW 4064	69-75	signal transducer and activator of transcription 3	Mus musculus	172-177
26321738-6	2015	In addition, the protective effect of the selective FXR agonist GW4064 on triptolide-induced hepatotoxicity was explored in BALB/c mice.	GW 4064	64-70	nuclear receptor subfamily 1, group H, member 4	Mus musculus	52-55
26321738-12	2015	In BALB/c mice, treatment with the FXR agonist GW4064 attenuated triptolide-induced liver dysfunction, structural damage, glutathione depletion and lipid peroxidation.	GW 4064	47-53	nuclear receptor subfamily 1, group H, member 4	Mus musculus	35-38
25934227-3	2015	Evaluation of the co-crystal structures of the widely used FXR agonist GW4064 and related compounds in complex with the FXR ligand binding domain indicated that their disubstituted isoxazole moiety is especially relevant for FXR activation.	GW 4064	71-77	nuclear receptor subfamily 1 group H member 4	Homo sapiens	59-62
25934227-3	2015	Evaluation of the co-crystal structures of the widely used FXR agonist GW4064 and related compounds in complex with the FXR ligand binding domain indicated that their disubstituted isoxazole moiety is especially relevant for FXR activation.	GW 4064	71-77	nuclear receptor subfamily 1 group H member 4	Homo sapiens	120-123
25934227-3	2015	Evaluation of the co-crystal structures of the widely used FXR agonist GW4064 and related compounds in complex with the FXR ligand binding domain indicated that their disubstituted isoxazole moiety is especially relevant for FXR activation.	GW 4064	71-77	nuclear receptor subfamily 1 group H member 4	Homo sapiens	120-123
25725071-7	2015	Interestingly, GW4064 did not repress expression of CYP2B6, another target gene of PXR and CAR; GW4064 enhanced CYP2B6 promoter activity.	GW 4064	96-102	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	112-118
25926433-6	2015	The objective of this study is to investigate whether an agonist of FXR, 3-(2,6-dichlorophenyl)-4-(3"-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole (GW4064), alters CYP2D6 expression and activity.	GW 4064	163-169	nuclear receptor subfamily 1, group H, member 4	Mus musculus	68-71
25926433-7	2015	In CYP2D6-humanized transgenic mice, GW4064 decreased hepatic CYP2D6 expression and activity (by 2-fold) while increasing SHP expression (by 2-fold) and SHP recruitment to the CYP2D6 promoter.	GW 4064	37-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	3-9
25926433-7	2015	In CYP2D6-humanized transgenic mice, GW4064 decreased hepatic CYP2D6 expression and activity (by 2-fold) while increasing SHP expression (by 2-fold) and SHP recruitment to the CYP2D6 promoter.	GW 4064	37-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	62-68
25926433-7	2015	In CYP2D6-humanized transgenic mice, GW4064 decreased hepatic CYP2D6 expression and activity (by 2-fold) while increasing SHP expression (by 2-fold) and SHP recruitment to the CYP2D6 promoter.	GW 4064	37-43	nuclear receptor subfamily 0, group B, member 2	Mus musculus	122-125
25926433-7	2015	In CYP2D6-humanized transgenic mice, GW4064 decreased hepatic CYP2D6 expression and activity (by 2-fold) while increasing SHP expression (by 2-fold) and SHP recruitment to the CYP2D6 promoter.	GW 4064	37-43	nuclear receptor subfamily 0, group B, member 2	Mus musculus	153-156
25926433-7	2015	In CYP2D6-humanized transgenic mice, GW4064 decreased hepatic CYP2D6 expression and activity (by 2-fold) while increasing SHP expression (by 2-fold) and SHP recruitment to the CYP2D6 promoter.	GW 4064	37-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	62-68
25926433-8	2015	CYP2D6 repression by GW4064 was abrogated in Shp(-/-);CYP2D6 mice, indicating a critical role of SHP in CYP2D6 regulation by GW4064.	GW 4064	21-27	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
25926433-8	2015	CYP2D6 repression by GW4064 was abrogated in Shp(-/-);CYP2D6 mice, indicating a critical role of SHP in CYP2D6 regulation by GW4064.	GW 4064	21-27	nuclear receptor subfamily 0, group B, member 2	Mus musculus	45-48
25926433-8	2015	CYP2D6 repression by GW4064 was abrogated in Shp(-/-);CYP2D6 mice, indicating a critical role of SHP in CYP2D6 regulation by GW4064.	GW 4064	21-27	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
25926433-8	2015	CYP2D6 repression by GW4064 was abrogated in Shp(-/-);CYP2D6 mice, indicating a critical role of SHP in CYP2D6 regulation by GW4064.	GW 4064	21-27	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
25926433-8	2015	CYP2D6 repression by GW4064 was abrogated in Shp(-/-);CYP2D6 mice, indicating a critical role of SHP in CYP2D6 regulation by GW4064.	GW 4064	125-131	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
25926433-8	2015	CYP2D6 repression by GW4064 was abrogated in Shp(-/-);CYP2D6 mice, indicating a critical role of SHP in CYP2D6 regulation by GW4064.	GW 4064	125-131	nuclear receptor subfamily 0, group B, member 2	Mus musculus	45-48
25926433-8	2015	CYP2D6 repression by GW4064 was abrogated in Shp(-/-);CYP2D6 mice, indicating a critical role of SHP in CYP2D6 regulation by GW4064.	GW 4064	125-131	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
25926433-8	2015	CYP2D6 repression by GW4064 was abrogated in Shp(-/-);CYP2D6 mice, indicating a critical role of SHP in CYP2D6 regulation by GW4064.	GW 4064	125-131	nuclear receptor subfamily 0, group B, member 2	Mus musculus	97-100
25926433-8	2015	CYP2D6 repression by GW4064 was abrogated in Shp(-/-);CYP2D6 mice, indicating a critical role of SHP in CYP2D6 regulation by GW4064.	GW 4064	125-131	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
25926433-9	2015	Also, GW4064 decreased CYP2D6 expression (by 2-fold) in primary human hepatocytes, suggesting that the results obtained in CYP2D6-humanized transgenic mice can be translated to humans.	GW 4064	6-12	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	23-29
25926433-9	2015	Also, GW4064 decreased CYP2D6 expression (by 2-fold) in primary human hepatocytes, suggesting that the results obtained in CYP2D6-humanized transgenic mice can be translated to humans.	GW 4064	6-12	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	123-129
25926433-10	2015	This proof of concept study provides evidence for CYP2D6 regulation by an inducer of SHP expression, namely, the FXR agonist GW4064.	GW 4064	125-131	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	50-56
25926433-10	2015	This proof of concept study provides evidence for CYP2D6 regulation by an inducer of SHP expression, namely, the FXR agonist GW4064.	GW 4064	125-131	nuclear receptor subfamily 0, group B, member 2	Mus musculus	85-88
25926433-10	2015	This proof of concept study provides evidence for CYP2D6 regulation by an inducer of SHP expression, namely, the FXR agonist GW4064.	GW 4064	125-131	nuclear receptor subfamily 1, group H, member 4	Mus musculus	113-116
26098428-5	2015	Distinctly from CDCA, MG132 prevented SHP and an exogenous FXR agonist, GW4064 from reducing HIF-1alpha protein.	GW 4064	72-78	nuclear receptor subfamily 1 group H member 4	Homo sapiens	59-62
26098428-5	2015	Distinctly from CDCA, MG132 prevented SHP and an exogenous FXR agonist, GW4064 from reducing HIF-1alpha protein.	GW 4064	72-78	hypoxia inducible factor 1 subunit alpha	Homo sapiens	93-103
25725071-0	2015	GW4064, an agonist of farnesoid X receptor, represses CYP3A4 expression in human hepatocytes by inducing small heterodimer partner expression.	GW 4064	0-6	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	32-42
25725071-0	2015	GW4064, an agonist of farnesoid X receptor, represses CYP3A4 expression in human hepatocytes by inducing small heterodimer partner expression.	GW 4064	0-6	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-60
25725071-5	2015	In human hepatocytes, treatment of GW4064 (1 muM) for 48 hours resulted in a 75% decrease in CYP3A4 mRNA expression and a 25% decrease in CYP3A4 activity, accompanied by ~3-fold increase in SHP mRNA expression.	GW 4064	35-41	latexin	Homo sapiens	45-48
25725071-5	2015	In human hepatocytes, treatment of GW4064 (1 muM) for 48 hours resulted in a 75% decrease in CYP3A4 mRNA expression and a 25% decrease in CYP3A4 activity, accompanied by ~3-fold increase in SHP mRNA expression.	GW 4064	35-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
25725071-5	2015	In human hepatocytes, treatment of GW4064 (1 muM) for 48 hours resulted in a 75% decrease in CYP3A4 mRNA expression and a 25% decrease in CYP3A4 activity, accompanied by ~3-fold increase in SHP mRNA expression.	GW 4064	35-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-144
25725071-5	2015	In human hepatocytes, treatment of GW4064 (1 muM) for 48 hours resulted in a 75% decrease in CYP3A4 mRNA expression and a 25% decrease in CYP3A4 activity, accompanied by ~3-fold increase in SHP mRNA expression.	GW 4064	35-41	nuclear receptor subfamily 0 group B member 2	Homo sapiens	190-193
25725071-8	2015	In conclusion, GW4064 represses CYP3A4 expression in human hepatocytes, potentially through upregulation of SHP expression and subsequent repression of CYP3A4 promoter activity.	GW 4064	15-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
25725071-8	2015	In conclusion, GW4064 represses CYP3A4 expression in human hepatocytes, potentially through upregulation of SHP expression and subsequent repression of CYP3A4 promoter activity.	GW 4064	15-21	nuclear receptor subfamily 0 group B member 2	Homo sapiens	108-111
25725071-8	2015	In conclusion, GW4064 represses CYP3A4 expression in human hepatocytes, potentially through upregulation of SHP expression and subsequent repression of CYP3A4 promoter activity.	GW 4064	15-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	152-158
25466848-6	2015	RESULTS: 13 nuclear hormone receptor ligands were assayed, being GW4064 (FXR ligand) the most potent activator.	GW 4064	65-71	nuclear receptor subfamily 1 group H member 4	Homo sapiens	73-76
25987835-4	2015	In addition, we investigated the effects of farnesoid X receptor agonist GW4064 on hepatic ApoM expression in vitro.	GW 4064	73-79	apolipoprotein M	Homo sapiens	91-95
25987835-5	2015	In HepG2 cell cultures, both mRNA and protein levels of ApoM and LRH-1 were decreased in a time-dependent manner in the presence of 1 muM GW4064, and the inhibition effect was gradually attenuated after 24 hours.	GW 4064	138-144	apolipoprotein M	Homo sapiens	56-60
25987835-5	2015	In HepG2 cell cultures, both mRNA and protein levels of ApoM and LRH-1 were decreased in a time-dependent manner in the presence of 1 muM GW4064, and the inhibition effect was gradually attenuated after 24 hours.	GW 4064	138-144	nuclear receptor subfamily 5 group A member 2	Homo sapiens	65-70
25499883-0	2015	Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists.	GW 4064	32-38	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	52-62
25499883-2	2015	Previous work has described GW4064 as an FXR agonist with an interesting activity profile.	GW 4064	28-34	nuclear receptor subfamily 1 group H member 4	Homo sapiens	41-44
25593129-3	2015	Consistent with this observation, treatment of mice with FXR-specific agonists (GSK2324 or GW4064) rapidly increased hepatic levels of Srebp-2 mRNA, precursor sterol response element binding protein 2 (pSREBP-2) protein, and miR-33.	GW 4064	91-97	nuclear receptor subfamily 1, group H, member 4	Mus musculus	57-60
25593129-3	2015	Consistent with this observation, treatment of mice with FXR-specific agonists (GSK2324 or GW4064) rapidly increased hepatic levels of Srebp-2 mRNA, precursor sterol response element binding protein 2 (pSREBP-2) protein, and miR-33.	GW 4064	91-97	sterol regulatory element binding factor 2	Mus musculus	135-142
25593129-3	2015	Consistent with this observation, treatment of mice with FXR-specific agonists (GSK2324 or GW4064) rapidly increased hepatic levels of Srebp-2 mRNA, precursor sterol response element binding protein 2 (pSREBP-2) protein, and miR-33.	GW 4064	91-97	microRNA 33	Mus musculus	225-231
25496033-8	2015	FXR knockdown abolished the inhibition of 3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]-Benzoic acid (GW4064) on JNK phosphorylation and ROS production induced by H2O2in HepG2 cells.	GW 4064	153-159	nuclear receptor subfamily 1 group H member 4	Homo sapiens	0-3
25496033-11	2015	SOD3 knockdown abolished the inhibition of GW4064 on JNK phosphorylation induced by H2O2in HepG2 cells.	GW 4064	43-49	superoxide dismutase 3	Homo sapiens	0-4
25496033-11	2015	SOD3 knockdown abolished the inhibition of GW4064 on JNK phosphorylation induced by H2O2in HepG2 cells.	GW 4064	43-49	mitogen-activated protein kinase 8	Homo sapiens	53-56
26574146-7	2015	GW4064, a farnesoid X receptor agonist, decreases hepatic CYP2D6 expression and activity while increasing small heterodimer partner expression and its recruitment to the CYP2D6 promoter.	GW 4064	0-6	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	58-64
26574146-7	2015	GW4064, a farnesoid X receptor agonist, decreases hepatic CYP2D6 expression and activity while increasing small heterodimer partner expression and its recruitment to the CYP2D6 promoter.	GW 4064	0-6	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	170-176
25400456-0	2014	GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells.	GW 4064	0-6	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	20-30
25419825-8	2014	Furthermore, we found that administration of TNF-alpha, the bile acid, chenodeoxycholic acid, and FXR nuclear receptor activation (GW4064) induced apoptosis and impaired SP-B and SP-C production in alveolar epithelial cells in vitro.	GW 4064	131-137	tumor necrosis factor	Homo sapiens	45-54
25419825-8	2014	Furthermore, we found that administration of TNF-alpha, the bile acid, chenodeoxycholic acid, and FXR nuclear receptor activation (GW4064) induced apoptosis and impaired SP-B and SP-C production in alveolar epithelial cells in vitro.	GW 4064	131-137	surfactant protein B	Homo sapiens	170-174
25419825-8	2014	Furthermore, we found that administration of TNF-alpha, the bile acid, chenodeoxycholic acid, and FXR nuclear receptor activation (GW4064) induced apoptosis and impaired SP-B and SP-C production in alveolar epithelial cells in vitro.	GW 4064	131-137	surfactant protein C	Homo sapiens	179-183
25400456-3	2014	Moreover, mRNA expression of AdipoR2 and OB-Rb was also examined using fluorescent real-time PCR at 0, 12, 24, and 48 h in HepG2 cells treated with GW4064.	GW 4064	148-154	adiponectin receptor 2	Homo sapiens	29-36
24597548-0	2014	Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors.	GW 4064	22-28	nuclear receptor subfamily 1 group H member 4	Homo sapiens	10-13
23916961-6	2014	Antidiarrhoeal efficacy of GW4064 was assessed using two in vivo mouse models: the ovalbumin-induced diarrhoea model and cholera toxin (CTX)-induced intestinal fluid accumulation.	GW 4064	27-33	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	83-92
23916961-7	2014	RESULTS: GW4064 (5 mumol/L; 24 h), a specific FXR agonist, induced nuclear translocation of the receptor in T84 cells and attenuated Cl(-) secretory responses to both Ca(2+) and cAMP-dependent agonists.	GW 4064	9-15	nuclear receptor subfamily 1 group H member 4	Homo sapiens	46-49
23916961-8	2014	GW4064 also prevented agonist-induced inhibition of NHE3 in Caco-2 cells.	GW 4064	0-6	solute carrier family 9 member A3	Homo sapiens	52-56
23916961-9	2014	In mice, intraperitoneal administration of GW4064 (50 mg/mL) also inhibited Ca(2+) and cAMP-dependent secretory responses across ex vivo colonic tissues and prevented ovalbumin-induced diarrhoea and CTX-induced intestinal fluid accumulation in vivo.	GW 4064	43-49	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	167-176
24597548-10	2014	Taken together, our results demonstrate identification of histamine receptors as alternate targets for GW4064, which not only necessitates cautious interpretation of the biological functions attributed to FXR using GW4064 as a pharmacological tool but also provides a basis for the rational designing of new pharmacophores for histamine receptor modulation.	GW 4064	103-109	nuclear receptor subfamily 1 group H member 4	Homo sapiens	205-208
25339829-0	2014	FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.	GW 4064	12-18	nuclear receptor subfamily 1, group H, member 4	Mus musculus	0-3
25339829-1	2014	AIM: To examine the effect of farnesoid X receptor (FXR) activation by GW4064 on endotoxin-induced hepatic inflammation in nonalcoholic fatty liver disease (NAFLD) and the underlying mechanism.	GW 4064	71-77	nuclear receptor subfamily 1, group H, member 4	Mus musculus	52-55
25339829-7	2014	Activation of FXR by GW4064 alleviated hepatic inflammation induced by endotoxin in a murine NAFLD model fed an HF diet as reflected by reduced serum levels of aspartate aminotransferase and alanine aminotransferase.	GW 4064	21-27	nuclear receptor subfamily 1, group H, member 4	Mus musculus	14-17
25010412-8	2014	In addition, cell-permeable bile acids reduced HDL endocytosis by farnesoid X receptor (FXR) activation: chenodeoxycholate and the non-steroidal FXR agonist GW4064 reduced HDL endocytosis, whereas selective CE uptake was unaltered.	GW 4064	157-163	nuclear receptor subfamily 1 group H member 4	Homo sapiens	88-91
25010412-8	2014	In addition, cell-permeable bile acids reduced HDL endocytosis by farnesoid X receptor (FXR) activation: chenodeoxycholate and the non-steroidal FXR agonist GW4064 reduced HDL endocytosis, whereas selective CE uptake was unaltered.	GW 4064	157-163	nuclear receptor subfamily 1 group H member 4	Homo sapiens	145-148
24597548-1	2014	The synthetic nuclear bile acid receptor (farnesoid X receptor [FXR]) agonist GW4064 is extensively used as a specific pharmacological tool to illustrate FXR functions.	GW 4064	78-84	nuclear receptor subfamily 1 group H member 4	Homo sapiens	64-67
24597548-1	2014	The synthetic nuclear bile acid receptor (farnesoid X receptor [FXR]) agonist GW4064 is extensively used as a specific pharmacological tool to illustrate FXR functions.	GW 4064	78-84	nuclear receptor subfamily 1 group H member 4	Homo sapiens	154-157
24597548-2	2014	We noticed that GW4064 activated empty luciferase reporters in FXR-deficient HEK-293T cells.	GW 4064	16-22	nuclear receptor subfamily 1 group H member 4	Homo sapiens	63-66
24597548-9	2014	We also found that MCF-7 breast cancer cells, reported to undergo GW4064-induced apoptosis in an FXR-dependent manner, did not express FXR, and the GW4064-mediated apoptosis, also apparent in HEK-293T cells, could be blocked by selective histamine receptor regulators.	GW 4064	66-72	nuclear receptor subfamily 1 group H member 4	Homo sapiens	97-100
24297698-5	2014	Here, we showed that, in hepatocarcinoma-derived Huh-7 cells, combined activation of FXRalpha by GW4064 and SIRT1 by activator 3 increased HBV core promoter-controlled luciferase expression by 25-fold, compared with a 10-fold increase with GW4064 alone.	GW 4064	240-246	sirtuin 1	Homo sapiens	108-113
24335393-6	2014	SULT1C2 protein content was strongly increased by 1,25(OH)2D3 treatment and moderately increased by GW3965, GW4064, and rifampicin.	GW 4064	108-114	sulfotransferase family 1C member 4	Homo sapiens	0-7
24335393-8	2014	Treatment with GW3965, GW4064, or 1,25(OH)2D3 increased reporter activity ~2-, 5-, and 5.5-fold, respectively, from a construct containing mostly intron 1 of the SULT1C2 gene.	GW 4064	23-29	sulfotransferase family 1C member 4	Homo sapiens	162-169
24115725-4	2014	Among the selected compounds, the stilbene carboxylic acid GW4064 was identified as an effective antagonist of EphA2, being able to block EphA2 activation in prostate carcinoma cells, in the micromolar range.	GW 4064	59-65	EPH receptor A2	Homo sapiens	111-116
24321096-4	2014	In reporter assays, active SREBP-2 overexpression suppressed GW4064/FXR-mediated increase in reporter activities in regions containing the IR-1 motif (+848 to +5200) in the FGF19 gene.	GW 4064	61-67	sterol regulatory element binding transcription factor 2	Homo sapiens	27-34
24321096-4	2014	In reporter assays, active SREBP-2 overexpression suppressed GW4064/FXR-mediated increase in reporter activities in regions containing the IR-1 motif (+848 to +5200) in the FGF19 gene.	GW 4064	61-67	nuclear receptor subfamily 1 group H member 4	Homo sapiens	68-71
24321096-4	2014	In reporter assays, active SREBP-2 overexpression suppressed GW4064/FXR-mediated increase in reporter activities in regions containing the IR-1 motif (+848 to +5200) in the FGF19 gene.	GW 4064	61-67	fibroblast growth factor 19	Homo sapiens	173-178
24115725-4	2014	Among the selected compounds, the stilbene carboxylic acid GW4064 was identified as an effective antagonist of EphA2, being able to block EphA2 activation in prostate carcinoma cells, in the micromolar range.	GW 4064	59-65	EPH receptor A2	Homo sapiens	138-143
24463129-4	2014	RESULTS: The mRNA expressions of FXR, PPARgamma2, adiponectin, and AdipoR2 in 3T3-L1 preadipocytes and AdipoR2 in HepG2 cells treated with GW4064 was significantly increased compared with the control group (all P<0.05).	GW 4064	139-145	adiponectin, C1Q and collagen domain containing	Homo sapiens	50-61
25388536-3	2014	The quest for synthetic non-steroidal FXR agonists with general drug likeliness and improved pharmacokinetic and - dynamic properties has started more than a decade ago: The first non-steroidal and selective FXR agonist with decent submicromolar potency, GW4064, was patented in 1998 and published in 2000.	GW 4064	255-261	nuclear receptor subfamily 1 group H member 4	Homo sapiens	38-41
25388536-3	2014	The quest for synthetic non-steroidal FXR agonists with general drug likeliness and improved pharmacokinetic and - dynamic properties has started more than a decade ago: The first non-steroidal and selective FXR agonist with decent submicromolar potency, GW4064, was patented in 1998 and published in 2000.	GW 4064	255-261	nuclear receptor subfamily 1 group H member 4	Homo sapiens	208-211
25388536-4	2014	Since then, many pharmaceutical companies have taken GW4064 as a structural template for their efforts in identifying novel patentable FXR agonists with the GW-derived trisubstituted isoxazole general structure.	GW 4064	53-59	nuclear receptor subfamily 1 group H member 4	Homo sapiens	135-138
24463129-1	2014	OBJECTIVE: To investigate the effects of GW4064, a farnesoid X receptor (FXR) agonist, on adiponectin and its receptors during the differentiation of 3T3-L1 preadipocytes and on adiponectin receptors in HepG2 cells.	GW 4064	41-47	adiponectin, C1Q and collagen domain containing	Homo sapiens	90-101
24463129-4	2014	RESULTS: The mRNA expressions of FXR, PPARgamma2, adiponectin, and AdipoR2 in 3T3-L1 preadipocytes and AdipoR2 in HepG2 cells treated with GW4064 was significantly increased compared with the control group (all P<0.05).	GW 4064	139-145	adiponectin receptor 2	Homo sapiens	67-74
24463129-4	2014	RESULTS: The mRNA expressions of FXR, PPARgamma2, adiponectin, and AdipoR2 in 3T3-L1 preadipocytes and AdipoR2 in HepG2 cells treated with GW4064 was significantly increased compared with the control group (all P<0.05).	GW 4064	139-145	adiponectin receptor 2	Homo sapiens	103-110
24463129-5	2014	The protein level of adiponectin was also significantly increased after GW4064 treatment.	GW 4064	72-78	adiponectin, C1Q and collagen domain containing	Homo sapiens	21-32
24463129-7	2014	CONCLUSION: GW4064 can up-regulate the expressions of FXR, PPARgamma2, adiponectin, AdipoR2 in 3T3-L1 preadipocytes and AdipoR2 in HepG2 cells.	GW 4064	12-18	nuclear receptor subfamily 1 group H member 4	Homo sapiens	54-57
24463129-7	2014	CONCLUSION: GW4064 can up-regulate the expressions of FXR, PPARgamma2, adiponectin, AdipoR2 in 3T3-L1 preadipocytes and AdipoR2 in HepG2 cells.	GW 4064	12-18	adiponectin, C1Q and collagen domain containing	Homo sapiens	71-82
24463129-7	2014	CONCLUSION: GW4064 can up-regulate the expressions of FXR, PPARgamma2, adiponectin, AdipoR2 in 3T3-L1 preadipocytes and AdipoR2 in HepG2 cells.	GW 4064	12-18	adiponectin receptor 2	Homo sapiens	84-91
24463129-7	2014	CONCLUSION: GW4064 can up-regulate the expressions of FXR, PPARgamma2, adiponectin, AdipoR2 in 3T3-L1 preadipocytes and AdipoR2 in HepG2 cells.	GW 4064	12-18	adiponectin receptor 2	Homo sapiens	120-127
24211198-6	2013	The FXR agonist Chenodeoxycholic acid (CDCA) and GW4064 both can activate the expression of apoF in liver cell lines and in C57/BL6 mouse liver.	GW 4064	49-55	apolipoprotein F	Mus musculus	92-96
23680185-6	2013	In human hepatocytes, the activation of FXR with the agonist GW4064 resulted in a significant protection against cisplatin-induced toxicity.	GW 4064	61-67	nuclear receptor subfamily 1 group H member 4	Homo sapiens	40-43
23928191-6	2013	When FXR was expressed in liver and intestinal cells the magnitude of the response to GW4064 and bile acids differs among FXR isoforms.	GW 4064	86-92	nuclear receptor subfamily 1 group H member 4	Homo sapiens	5-8
23928191-6	2013	When FXR was expressed in liver and intestinal cells the magnitude of the response to GW4064 and bile acids differs among FXR isoforms.	GW 4064	86-92	nuclear receptor subfamily 1 group H member 4	Homo sapiens	122-125
23680185-7	2013	In human hepatoma Alexander cells, with negligible endogenous expression of FXR, GW4064 also protected against cisplatin-induced toxicity, but only if they were previously transfected with FXR/RXR.	GW 4064	81-87	nuclear receptor subfamily 1 group H member 4	Homo sapiens	189-192
23680185-7	2013	In human hepatoma Alexander cells, with negligible endogenous expression of FXR, GW4064 also protected against cisplatin-induced toxicity, but only if they were previously transfected with FXR/RXR.	GW 4064	81-87	retinoid X receptor alpha	Homo sapiens	193-196
23680185-9	2013	In both models, cisplatin, even in the absence of FXR agonists, such as bile acids and GW4064, was able to up-regulate FXR targets genes, which was due to FXR-mediated trans-activation of response elements in the promoter region.	GW 4064	87-93	nuclear receptor subfamily 1 group H member 4	Homo sapiens	119-122
23680185-9	2013	In both models, cisplatin, even in the absence of FXR agonists, such as bile acids and GW4064, was able to up-regulate FXR targets genes, which was due to FXR-mediated trans-activation of response elements in the promoter region.	GW 4064	87-93	nuclear receptor subfamily 1 group H member 4	Homo sapiens	119-122
23609136-10	2013	In vitro, activation of FXR by bile acids (chenodeoxycholic acid [CDCA] or 6-ECDCA) or FXR agonists (GW4064 or Fexaramine) significantly enhanced osteoblastic differentiation through the upregulation of Runx2 and enhanced extracellular signal-regulated kinase (ERK) and beta-catenin signaling.	GW 4064	101-107	nuclear receptor subfamily 1, group H, member 4	Mus musculus	24-27
23609136-10	2013	In vitro, activation of FXR by bile acids (chenodeoxycholic acid [CDCA] or 6-ECDCA) or FXR agonists (GW4064 or Fexaramine) significantly enhanced osteoblastic differentiation through the upregulation of Runx2 and enhanced extracellular signal-regulated kinase (ERK) and beta-catenin signaling.	GW 4064	101-107	nuclear receptor subfamily 1, group H, member 4	Mus musculus	87-90
23609136-10	2013	In vitro, activation of FXR by bile acids (chenodeoxycholic acid [CDCA] or 6-ECDCA) or FXR agonists (GW4064 or Fexaramine) significantly enhanced osteoblastic differentiation through the upregulation of Runx2 and enhanced extracellular signal-regulated kinase (ERK) and beta-catenin signaling.	GW 4064	101-107	runt related transcription factor 2	Mus musculus	203-208
23609136-10	2013	In vitro, activation of FXR by bile acids (chenodeoxycholic acid [CDCA] or 6-ECDCA) or FXR agonists (GW4064 or Fexaramine) significantly enhanced osteoblastic differentiation through the upregulation of Runx2 and enhanced extracellular signal-regulated kinase (ERK) and beta-catenin signaling.	GW 4064	101-107	mitogen-activated protein kinase 1	Mus musculus	222-259
23609136-10	2013	In vitro, activation of FXR by bile acids (chenodeoxycholic acid [CDCA] or 6-ECDCA) or FXR agonists (GW4064 or Fexaramine) significantly enhanced osteoblastic differentiation through the upregulation of Runx2 and enhanced extracellular signal-regulated kinase (ERK) and beta-catenin signaling.	GW 4064	101-107	mitogen-activated protein kinase 1	Mus musculus	261-264
23609136-10	2013	In vitro, activation of FXR by bile acids (chenodeoxycholic acid [CDCA] or 6-ECDCA) or FXR agonists (GW4064 or Fexaramine) significantly enhanced osteoblastic differentiation through the upregulation of Runx2 and enhanced extracellular signal-regulated kinase (ERK) and beta-catenin signaling.	GW 4064	101-107	catenin (cadherin associated protein), beta 1	Mus musculus	270-282
23772048-3	2013	In human hepatocytes, both the endogenous FXR ligand chenodeoxycholic acid and synthetic FXR-specific agonist GW4064 increased ADH1 mRNA, protein, and activity.	GW 4064	110-116	nuclear receptor subfamily 1 group H member 4	Homo sapiens	89-92
23767959-2	2013	We have found that chenodeoxycholic acid and the synthetic FXR (farnesoid X receptor) ligand GW4064 induce the mRNA and protein expression of DGKtheta in the HepG2 cell line and in primary human hepatocytes.	GW 4064	93-99	nuclear receptor subfamily 1 group H member 4	Homo sapiens	59-62
23767959-2	2013	We have found that chenodeoxycholic acid and the synthetic FXR (farnesoid X receptor) ligand GW4064 induce the mRNA and protein expression of DGKtheta in the HepG2 cell line and in primary human hepatocytes.	GW 4064	93-99	nuclear receptor subfamily 1 group H member 4	Homo sapiens	64-84
23767959-7	2013	We also found that GW4064 and PA promote the phosphorylation of mTOR, Akt and FoxO1 (forkhead box O1), and that silencing DGKtheta expression significantly abrogated the ability of GW4046 to promote the phosphorylation of these PA-regulated targets.	GW 4064	19-25	mechanistic target of rapamycin kinase	Homo sapiens	64-68
23767959-7	2013	We also found that GW4064 and PA promote the phosphorylation of mTOR, Akt and FoxO1 (forkhead box O1), and that silencing DGKtheta expression significantly abrogated the ability of GW4046 to promote the phosphorylation of these PA-regulated targets.	GW 4064	19-25	AKT serine/threonine kinase 1	Homo sapiens	70-73
23767959-7	2013	We also found that GW4064 and PA promote the phosphorylation of mTOR, Akt and FoxO1 (forkhead box O1), and that silencing DGKtheta expression significantly abrogated the ability of GW4046 to promote the phosphorylation of these PA-regulated targets.	GW 4064	19-25	forkhead box O1	Homo sapiens	78-83
23767959-7	2013	We also found that GW4064 and PA promote the phosphorylation of mTOR, Akt and FoxO1 (forkhead box O1), and that silencing DGKtheta expression significantly abrogated the ability of GW4046 to promote the phosphorylation of these PA-regulated targets.	GW 4064	19-25	forkhead box O1	Homo sapiens	85-100
23772048-3	2013	In human hepatocytes, both the endogenous FXR ligand chenodeoxycholic acid and synthetic FXR-specific agonist GW4064 increased ADH1 mRNA, protein, and activity.	GW 4064	110-116	alcohol dehydrogenase 1A (class I), alpha polypeptide	Homo sapiens	127-131
23674610-7	2013	PAPSS1/2 knockdown significantly activated farnesoid X receptor (FXR), retinoid-related orphan receptor, and pregnane X receptor responsive reporters, and treatment with the FXR agonist GW4064 [3-(2,6-dichlorophenyl)-4-(3"-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole] increased Sult2a1 promoter activity when the IR0 was intact.	GW 4064	186-192	nuclear receptor subfamily 1, group H, member 4	Mus musculus	174-177
23674610-7	2013	PAPSS1/2 knockdown significantly activated farnesoid X receptor (FXR), retinoid-related orphan receptor, and pregnane X receptor responsive reporters, and treatment with the FXR agonist GW4064 [3-(2,6-dichlorophenyl)-4-(3"-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole] increased Sult2a1 promoter activity when the IR0 was intact.	GW 4064	186-192	sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1	Mus musculus	294-301
23674610-7	2013	PAPSS1/2 knockdown significantly activated farnesoid X receptor (FXR), retinoid-related orphan receptor, and pregnane X receptor responsive reporters, and treatment with the FXR agonist GW4064 [3-(2,6-dichlorophenyl)-4-(3"-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole] increased Sult2a1 promoter activity when the IR0 was intact.	GW 4064	186-192	3'-phosphoadenosine 5'-phosphosulfate synthase 1	Mus musculus	0-6
23371517-0	2013	Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance.	GW 4064	22-28	nuclear receptor subfamily 1, group H, member 4	Mus musculus	10-13
23688559-4	2013	Here we describe the use of the X-ray crystal structure of FXR complexed with the potent small molecule agonist GW4064 to design and synthesize a novel fluorescent, high-affinity probe (DY246) for time resolved fluorescence resonance energy transfer (TR-FRET) assays.	GW 4064	112-118	nuclear receptor subfamily 1 group H member 4	Homo sapiens	59-62
23507574-3	2013	Moreover, we report that chemerin expression and secretion are induced in HepG2 cells and primary hepatocytes from wild-type mice, but not farnesoid X receptor (FXR)-/- mice, in response to the synthetic FXR ligand GW4064.	GW 4064	215-221	retinoic acid receptor responder 2	Homo sapiens	25-33
23507574-4	2013	Hepatic chemerin expression is decreased in FXR-/- mice but up-regulated by GW4064 administration in wild-type mice.	GW 4064	76-82	retinoic acid receptor responder (tazarotene induced) 2	Mus musculus	8-16
23124354-4	2013	Here, we demonstrated that treatment with GW4064, a specific FXR agonist, markedly reduced Leydig tumor growth in vivo by inhibiting proliferation and inducing apoptosis.	GW 4064	42-48	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	61-64
23371517-7	2013	RESULTS: Activation of FXR by GW4064 suppressed weight gain in C57BL/6 mice fed with either HFD or high-fat and high-cholesterol diet.	GW 4064	30-36	nuclear receptor subfamily 1, group H, member 4	Mus musculus	23-26
23371517-11	2013	In addition, activation of FXR by GW4064 avoided diet-induced hyperinsulinemia and hyperglycemia through decreasing the transcript levels of phosphoenolpyruvate carboxykinase (Pepck) and glucose-6-phosphatase (G6pase), two key enzymes in gluconeogenesis.	GW 4064	34-40	nuclear receptor subfamily 1, group H, member 4	Mus musculus	27-30
23371517-11	2013	In addition, activation of FXR by GW4064 avoided diet-induced hyperinsulinemia and hyperglycemia through decreasing the transcript levels of phosphoenolpyruvate carboxykinase (Pepck) and glucose-6-phosphatase (G6pase), two key enzymes in gluconeogenesis.	GW 4064	34-40	phosphoenolpyruvate carboxykinase 1, cytosolic	Mus musculus	141-174
23371517-11	2013	In addition, activation of FXR by GW4064 avoided diet-induced hyperinsulinemia and hyperglycemia through decreasing the transcript levels of phosphoenolpyruvate carboxykinase (Pepck) and glucose-6-phosphatase (G6pase), two key enzymes in gluconeogenesis.	GW 4064	34-40	phosphoenolpyruvate carboxykinase 1, cytosolic	Mus musculus	176-181
23371517-11	2013	In addition, activation of FXR by GW4064 avoided diet-induced hyperinsulinemia and hyperglycemia through decreasing the transcript levels of phosphoenolpyruvate carboxykinase (Pepck) and glucose-6-phosphatase (G6pase), two key enzymes in gluconeogenesis.	GW 4064	34-40	glucose-6-phosphatase, catalytic	Mus musculus	187-208
23371517-11	2013	In addition, activation of FXR by GW4064 avoided diet-induced hyperinsulinemia and hyperglycemia through decreasing the transcript levels of phosphoenolpyruvate carboxykinase (Pepck) and glucose-6-phosphatase (G6pase), two key enzymes in gluconeogenesis.	GW 4064	34-40	glucose-6-phosphatase, catalytic	Mus musculus	210-216
21924881-5	2013	METHODS AND RESULTS: FXR is expressed in neonatal cardiomyocytes and the treatment with FXR agonists, chenodeoxycholic acid (CDCA), and GW4064, increased the mRNA expression of FXR and its canonical target gene, the small heterodimer partner (SHP), as well as proliferator-activated receptor alpha PPARalpha, acyl-CoA oxidase (AOX) and pyruvate dehydrogenase kinase (PDK-4).	GW 4064	136-142	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	21-24
23541942-1	2013	Here we report that bile acid chenodeoxycholic acid (CDCA) and synthetic farnesoid X receptor (FXR) agonist GW4064 robustly induced tumor suppressor N-Myc downstream regulated gene 2 (NDRG2) expression in human hepatoma cells and primary hepatocytes.	GW 4064	108-114	nuclear receptor subfamily 1 group H member 4	Homo sapiens	95-98
23541942-1	2013	Here we report that bile acid chenodeoxycholic acid (CDCA) and synthetic farnesoid X receptor (FXR) agonist GW4064 robustly induced tumor suppressor N-Myc downstream regulated gene 2 (NDRG2) expression in human hepatoma cells and primary hepatocytes.	GW 4064	108-114	NDRG family member 2	Homo sapiens	149-182
23541942-1	2013	Here we report that bile acid chenodeoxycholic acid (CDCA) and synthetic farnesoid X receptor (FXR) agonist GW4064 robustly induced tumor suppressor N-Myc downstream regulated gene 2 (NDRG2) expression in human hepatoma cells and primary hepatocytes.	GW 4064	108-114	NDRG family member 2	Homo sapiens	184-189
23541942-4	2013	Moreover, mice given GW4064 exhibit an increase of Ndrg2 expression in liver and kidney, where both NDRG2 and FXR are enriched.	GW 4064	21-27	N-myc downstream regulated gene 2	Mus musculus	51-56
23541942-4	2013	Moreover, mice given GW4064 exhibit an increase of Ndrg2 expression in liver and kidney, where both NDRG2 and FXR are enriched.	GW 4064	21-27	N-myc downstream regulated gene 2	Mus musculus	100-105
23541942-4	2013	Moreover, mice given GW4064 exhibit an increase of Ndrg2 expression in liver and kidney, where both NDRG2 and FXR are enriched.	GW 4064	21-27	nuclear receptor subfamily 1, group H, member 4	Mus musculus	110-113
23313557-6	2013	In HepG2 cells, GCs induced a decreased expression of FXR and SHP, and inhibited the regulatory effect of GW4064 on FXR-target genes.	GW 4064	106-112	nuclear receptor subfamily 1 group H member 4	Homo sapiens	116-119
23313557-7	2013	In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OSTbeta, and a down-regulation of CYP27A1.	GW 4064	66-72	nuclear receptor subfamily 1 group H member 4	Homo sapiens	57-60
23313557-7	2013	In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OSTbeta, and a down-regulation of CYP27A1.	GW 4064	66-72	retinoid X receptor alpha	Homo sapiens	61-64
23313557-7	2013	In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OSTbeta, and a down-regulation of CYP27A1.	GW 4064	66-72	nuclear receptor subfamily 0 group B member 2	Homo sapiens	97-100
23313557-7	2013	In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OSTbeta, and a down-regulation of CYP27A1.	GW 4064	66-72	solute carrier family 51 subunit beta	Homo sapiens	105-112
23313557-7	2013	In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OSTbeta, and a down-regulation of CYP27A1.	GW 4064	66-72	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	139-146
23313557-10	2013	Moreover, GCs have a synergistic effect on GW4064-induced FXR activation, whereas chenodeoxycholate and GW4064 have an additive effect.	GW 4064	43-49	nuclear receptor subfamily 1 group H member 4	Homo sapiens	58-61
21924881-5	2013	METHODS AND RESULTS: FXR is expressed in neonatal cardiomyocytes and the treatment with FXR agonists, chenodeoxycholic acid (CDCA), and GW4064, increased the mRNA expression of FXR and its canonical target gene, the small heterodimer partner (SHP), as well as proliferator-activated receptor alpha PPARalpha, acyl-CoA oxidase (AOX) and pyruvate dehydrogenase kinase (PDK-4).	GW 4064	136-142	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	88-91
21924881-5	2013	METHODS AND RESULTS: FXR is expressed in neonatal cardiomyocytes and the treatment with FXR agonists, chenodeoxycholic acid (CDCA), and GW4064, increased the mRNA expression of FXR and its canonical target gene, the small heterodimer partner (SHP), as well as proliferator-activated receptor alpha PPARalpha, acyl-CoA oxidase (AOX) and pyruvate dehydrogenase kinase (PDK-4).	GW 4064	136-142	nuclear receptor subfamily 1, group H, member 4	Rattus norvegicus	88-91
21924881-5	2013	METHODS AND RESULTS: FXR is expressed in neonatal cardiomyocytes and the treatment with FXR agonists, chenodeoxycholic acid (CDCA), and GW4064, increased the mRNA expression of FXR and its canonical target gene, the small heterodimer partner (SHP), as well as proliferator-activated receptor alpha PPARalpha, acyl-CoA oxidase (AOX) and pyruvate dehydrogenase kinase (PDK-4).	GW 4064	136-142	nuclear receptor subfamily 0, group B, member 2	Rattus norvegicus	243-246
21924881-5	2013	METHODS AND RESULTS: FXR is expressed in neonatal cardiomyocytes and the treatment with FXR agonists, chenodeoxycholic acid (CDCA), and GW4064, increased the mRNA expression of FXR and its canonical target gene, the small heterodimer partner (SHP), as well as proliferator-activated receptor alpha PPARalpha, acyl-CoA oxidase (AOX) and pyruvate dehydrogenase kinase (PDK-4).	GW 4064	136-142	peroxisome proliferator activated receptor alpha	Rattus norvegicus	298-307
21924881-5	2013	METHODS AND RESULTS: FXR is expressed in neonatal cardiomyocytes and the treatment with FXR agonists, chenodeoxycholic acid (CDCA), and GW4064, increased the mRNA expression of FXR and its canonical target gene, the small heterodimer partner (SHP), as well as proliferator-activated receptor alpha PPARalpha, acyl-CoA oxidase (AOX) and pyruvate dehydrogenase kinase (PDK-4).	GW 4064	136-142	acyl-CoA oxidase 1	Rattus norvegicus	309-325
21924881-5	2013	METHODS AND RESULTS: FXR is expressed in neonatal cardiomyocytes and the treatment with FXR agonists, chenodeoxycholic acid (CDCA), and GW4064, increased the mRNA expression of FXR and its canonical target gene, the small heterodimer partner (SHP), as well as proliferator-activated receptor alpha PPARalpha, acyl-CoA oxidase (AOX) and pyruvate dehydrogenase kinase (PDK-4).	GW 4064	136-142	acyl-CoA oxidase 1	Rattus norvegicus	327-330
21924881-5	2013	METHODS AND RESULTS: FXR is expressed in neonatal cardiomyocytes and the treatment with FXR agonists, chenodeoxycholic acid (CDCA), and GW4064, increased the mRNA expression of FXR and its canonical target gene, the small heterodimer partner (SHP), as well as proliferator-activated receptor alpha PPARalpha, acyl-CoA oxidase (AOX) and pyruvate dehydrogenase kinase (PDK-4).	GW 4064	136-142	pyruvate dehydrogenase kinase 4	Rattus norvegicus	367-372
23101941-0	2012	Unbinding pathways of GW4064 from human farnesoid X receptor as revealed by molecular dynamics simulations.	GW 4064	22-28	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	50-60
23878601-4	2013	Interestingly, activation of the farnesoid X receptor (FXR) through the bile acid ursodeoxycholic acid (UDCA) or synthetic FXR agonists, such as GW4064, can increase DDAH1 expression.	GW 4064	145-151	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	43-53
23878601-4	2013	Interestingly, activation of the farnesoid X receptor (FXR) through the bile acid ursodeoxycholic acid (UDCA) or synthetic FXR agonists, such as GW4064, can increase DDAH1 expression.	GW 4064	145-151	nuclear receptor subfamily 1 group H member 4	Homo sapiens	55-58
23878601-4	2013	Interestingly, activation of the farnesoid X receptor (FXR) through the bile acid ursodeoxycholic acid (UDCA) or synthetic FXR agonists, such as GW4064, can increase DDAH1 expression.	GW 4064	145-151	nuclear receptor subfamily 1 group H member 4	Homo sapiens	123-126
23878601-4	2013	Interestingly, activation of the farnesoid X receptor (FXR) through the bile acid ursodeoxycholic acid (UDCA) or synthetic FXR agonists, such as GW4064, can increase DDAH1 expression.	GW 4064	145-151	dimethylarginine dimethylaminohydrolase 1	Homo sapiens	166-171
23101941-2	2012	GW4064 is a potent and selective FXR agonist and has become a tool compound to probe the physiological functions of FXR.	GW 4064	0-6	nuclear receptor subfamily 1 group H member 4	Homo sapiens	33-36
23101941-2	2012	GW4064 is a potent and selective FXR agonist and has become a tool compound to probe the physiological functions of FXR.	GW 4064	0-6	nuclear receptor subfamily 1 group H member 4	Homo sapiens	116-119
23101941-3	2012	Until now, the mechanism of GW4064 entering and leaving the FXR pocket is still poorly understood.	GW 4064	28-34	nuclear receptor subfamily 1 group H member 4	Homo sapiens	60-63
23101941-4	2012	Here, we report a computational study of GW4064 unbinding pathways from FXR by using several molecular dynamics (MD) simulation techniques.	GW 4064	41-47	nuclear receptor subfamily 1 group H member 4	Homo sapiens	72-75
23101941-5	2012	Based on the crystal structure of FXR in complex with GW4064, conventional MD was first used to refine the binding and check the stability of GW4064 in the FXR pocket.	GW 4064	54-60	nuclear receptor subfamily 1 group H member 4	Homo sapiens	34-37
23101941-5	2012	Based on the crystal structure of FXR in complex with GW4064, conventional MD was first used to refine the binding and check the stability of GW4064 in the FXR pocket.	GW 4064	54-60	nuclear receptor subfamily 1 group H member 4	Homo sapiens	156-159
23101941-5	2012	Based on the crystal structure of FXR in complex with GW4064, conventional MD was first used to refine the binding and check the stability of GW4064 in the FXR pocket.	GW 4064	142-148	nuclear receptor subfamily 1 group H member 4	Homo sapiens	34-37
23101941-5	2012	Based on the crystal structure of FXR in complex with GW4064, conventional MD was first used to refine the binding and check the stability of GW4064 in the FXR pocket.	GW 4064	142-148	nuclear receptor subfamily 1 group H member 4	Homo sapiens	156-159
23101941-6	2012	Random acceleration MD simulations were then performed to explore the possible unbinding pathways of GW4064 from FXR.	GW 4064	101-107	nuclear receptor subfamily 1 group H member 4	Homo sapiens	113-116
22579649-0	2012	Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand.	GW 4064	94-100	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	114-124
22817871-4	2012	In the present study, we for the first time identified that in human hepatoma cell line HepG2 the activation of FXR by the natural agonist chenodeoxycholic acid (CDCA) and the synthetic specific agonist GW4064 upregulated CISH at both transcriptional and translational levels, and inhibited interleukin (IL)6-induced STAT5 activation.	GW 4064	203-209	nuclear receptor subfamily 1 group H member 4	Homo sapiens	112-115
22817871-4	2012	In the present study, we for the first time identified that in human hepatoma cell line HepG2 the activation of FXR by the natural agonist chenodeoxycholic acid (CDCA) and the synthetic specific agonist GW4064 upregulated CISH at both transcriptional and translational levels, and inhibited interleukin (IL)6-induced STAT5 activation.	GW 4064	203-209	cytokine inducible SH2 containing protein	Homo sapiens	222-226
22817871-4	2012	In the present study, we for the first time identified that in human hepatoma cell line HepG2 the activation of FXR by the natural agonist chenodeoxycholic acid (CDCA) and the synthetic specific agonist GW4064 upregulated CISH at both transcriptional and translational levels, and inhibited interleukin (IL)6-induced STAT5 activation.	GW 4064	203-209	signal transducer and activator of transcription 5A	Homo sapiens	317-322
22579649-3	2012	In the present study, we examined the effects of acyclic retinoid (ACR), a synthetic retinoid targeting RXRalpha, plus GW4064, a ligand for FXR, on the growth of human HCC cells.	GW 4064	119-125	nuclear receptor subfamily 1 group H member 4	Homo sapiens	140-143
22579649-4	2012	We found that ACR and GW4064 preferentially inhibited the growth of HLE, HLF, and Huh7 human HCC cells in comparison with Hc normal hepatocytes.	GW 4064	22-28	MIR7-3 host gene	Homo sapiens	82-86
22579649-9	2012	Our results suggest that ACR and GW4064 cooperatively inhibit RXRalpha phosphorylation, modulate the expression of FXR-regulated genes, thus resulting in the induction of apoptosis and the inhibition of growth in HCC cells.	GW 4064	33-39	retinoid X receptor alpha	Homo sapiens	62-70
22579649-9	2012	Our results suggest that ACR and GW4064 cooperatively inhibit RXRalpha phosphorylation, modulate the expression of FXR-regulated genes, thus resulting in the induction of apoptosis and the inhibition of growth in HCC cells.	GW 4064	33-39	nuclear receptor subfamily 1 group H member 4	Homo sapiens	115-118
22643070-0	2012	FXR agonist GW4064 increases plasma glucocorticoid levels in C57BL/6 mice.	GW 4064	12-18	nuclear receptor subfamily 1, group H, member 4	Mus musculus	0-3
22643070-2	2012	FXR agonist GW4064 increased fasting plasma corticosterone levels (+45%; P<0.01) in C57BL/6 mice, indicative of enhanced adrenal steroidogenesis.	GW 4064	12-18	nuclear receptor subfamily 1, group H, member 4	Mus musculus	0-3
22643070-4	2012	Scavenger receptor BI (SR-BI) mRNA and protein expression, respectively, increased 1.9-fold (P<0.01) and 1.5-fold, which suggests a stimulated lipoprotein-associated cholesterol uptake into the adrenals upon GW4064 treatment.	GW 4064	211-217	scavenger receptor class B, member 1	Mus musculus	0-21
22643070-4	2012	Scavenger receptor BI (SR-BI) mRNA and protein expression, respectively, increased 1.9-fold (P<0.01) and 1.5-fold, which suggests a stimulated lipoprotein-associated cholesterol uptake into the adrenals upon GW4064 treatment.	GW 4064	211-217	scavenger receptor class B, member 1	Mus musculus	23-28
22643070-6	2012	In conclusion, we have shown that the FXR agonist GW4064 stimulates plasma corticosterone levels in C57BL/6 mice.	GW 4064	50-56	nuclear receptor subfamily 1, group H, member 4	Mus musculus	38-41
22561792-8	2012	Lithocholic acid (LCA) (10 muM), chenodeoxycholic acid (CDCA) (10 muM), or GW4064 (0.1 muM) treatment increased reporter activity in a construct including the three motifs under FXR-expressing conditions whereas LCA and not CDCA or GW4064 treatment increased the reporter activity under pregnane X receptor (PXR)-expressing conditions.	GW 4064	75-81	nuclear receptor subfamily 1 group H member 4	Homo sapiens	178-181
22561792-8	2012	Lithocholic acid (LCA) (10 muM), chenodeoxycholic acid (CDCA) (10 muM), or GW4064 (0.1 muM) treatment increased reporter activity in a construct including the three motifs under FXR-expressing conditions whereas LCA and not CDCA or GW4064 treatment increased the reporter activity under pregnane X receptor (PXR)-expressing conditions.	GW 4064	75-81	nuclear receptor subfamily 1 group I member 2	Homo sapiens	287-306
22561792-8	2012	Lithocholic acid (LCA) (10 muM), chenodeoxycholic acid (CDCA) (10 muM), or GW4064 (0.1 muM) treatment increased reporter activity in a construct including the three motifs under FXR-expressing conditions whereas LCA and not CDCA or GW4064 treatment increased the reporter activity under pregnane X receptor (PXR)-expressing conditions.	GW 4064	75-81	nuclear receptor subfamily 1 group I member 2	Homo sapiens	308-311